Oligonucleotides conjugated to oleic acid and uses thereof

Abstract

The invention provides oligonucleotide and / or oligonucleotide analogue molecules that are antagonists of a microRNA, preferably antagonists of human microRNAs hsa-miR-23b-3p and hsa-miR-218-5p, that comprise a mixture of phosphorothioate and phosphodiester linkages, and that are conjugated to at least one oleic acid molecule. Inhibiting these microRNAs allows to increase the endogenous levels of the corresponding proteins MBNL1 and / or MBNL2. The present invention further provides compositions comprising said oligonucleotides and / or oligonucleotide analogue molecules and their uses for the treatment and prevention of DM in a subject in need thereof.

Description

[0001] OLIGONUCLEOTIDES CONJUGATED TO OLEIC ACID AND USES

[0002] THEREOF

[0003] TECHNICAL FIELD OF THE INVENTION

[0004] The present invention relates to the field of medicine. More specifically, the invention relates to oligonucleotide antagonists of endogenous microRNAs, particularly hsa-miR-218-5p and hsa-miR-23b-3p, that are conjugated to oleic acid, and their uses.

[0005] BACKGROUND OF THE INVENTION

[0006] Myotonic dystrophy type 1 (DM1) is a rare genetic disease with no current effective treatment. DM1 is associated with a substantial disease burden resulting in impairment across many different patient systems and tissues. Muscle weakness and fatigue constitute the two most common disease manifestations, reported by 93% and 90% of patients, respectively, followed by muscle locking (73%). Other phenotypes include cardiac dysfunctions, cataracts, insulin resistance, and cognitive impairment. DM1 disease is based on CTG repeat expansions occurring in the DM1 protein kinase (DMPK) gene, which are transcribed into pathogenic mRNAs. It is currently well established that CUG expansions bind with high affinity to the Muscleblind-like (MBNL1 , 2, and 3) family of proteins, thereby inhibiting their normal function, but other alterations may contribute to MBNL1 and MBNL2 depletion. In skeletal muscle and brain, MBNL1 and MBNL2, respectively, are preferentially expressed, whereas MBNL3 is expressed primarily during embryonic development and adult tissue regeneration.

[0007] MBNL1 and MBNL2 proteins control alternative splicing and polyadenylation of several transcripts, specifically by causing a shift from foetal to adult patterns, and act antagonistically to CLIGBP Elav-like family member 1 (CELF) proteins in splice regulation, which are found upregulated and mislocated in DM1. Further, it has been shown that there is genetic redundancy between MBNL1 and 2 genes, as the deletion of only one resulted in the upregulation of the other and occupancy of its binding sites in target RNAs (see Lee 2013. Compound loss of muscleblind-like function in myotonic dystrophy. EMBO Mol Med 5:1887- 900.) The depletion of MBNL1 protein function has been shown to be a critical factor in the course of the disease. Indeed, MBNL1 loss of function accounts for more than 80% of missplicing events and nearly 70% of expression defects. MBNL genes and / or MBNL protein upregulation in DM1 mice and patient-derived fibroblasts is well tolerated and rescues several symptoms, such as myotonia and mis-splicing events, as well as the reduction of foci formation, opening the path for the development of therapeutic approaches aimed at increasing the expression of these genes. MBNL1 and MBNL2 depletion also impinge on several other gene expression processes, for example impairing trafficking of membrane- associated mRNAs or miRNA biogenesis. MicroRNAs (also referred herein as “miRNA” or “miRs”) are a class of small non-coding RNAs that play important roles in regulating gene expression, particularly in gene silencing. In human cells, the expression of hsa-miR-23b-3p and hsa-miR-218-5p has been shown to regulate MBNL1 and MBNL2 transcripts directly by luciferase reporter assay (Cerro-Herreros et al. 2018 Nat. Commun. 9, 2482). Silencing of hsa-miR-23b-3p and hsa-miR-218-5p increases Muscleblind-like protein expression and alleviates myotonic dystrophy phenotypes in mammalian models. On the other hand, antimiRs are a class of oligonucleotides that prevents other molecules, such as microRNAs, from binding to a target site on an RNA, particularly in messenger RNA (mRNA) molecules. The use of regular antimiRs as therapeutic molecules has limitations in their development as drug candidates, including a short life span due to degradation in the cellular environment, poor cellular intake from extracellular media, and limited therapeutic window expressed as the ratio of the concentrations at which a compound reaches median toxicity and efficacy (TC50 / EC50) so that the higher the ratio, the better. Thus, methods aimed at increasing antimiRs stability, potency, tissue-specific uptake, and therapeutic window, among other pharmacological parameters, need to be further developed in order to exploit the full potential of antimiRs in inhibiting their target hsa-miR-218-5p and hsa-miR-23b-3p.

[0008] On the one hand, albumin is one of the most abundant proteins in plasma and provides the transport of fatty acids, drugs, ions and other metabolites. Conjugation of the oligonucleotides with fatty acids may increase the albumin binding affinity of the oligonucleotides, enhancing their ability to cross the endothelial barrier and improving their functional uptake into muscles, thereby increasing the oligonucleotide potency in vivo. However, the wide variety of saturated and unsaturated fatty acids that differ in their structure may, in turn, influence protein binding or activity of fatty acid conjugates, leaving unclear what the optimal fatty acid for enhancing oligonucleotide potency is.

[0009] On the other hand, other chemical modifications can be included in the oligonucleotides to increase their pharmacological parameters. Among said modifications, phosphoroth ioate (PS) linkages continue to show promising results as first-generation antisense oligos, although they present important limitations that are still hampering the development of fully modified (full PS) therapeutic oligonucleotides. Said limitations include the toxicity of PS-oligos reported in some studies in mice, rats, monkeys, and humans. In mice and rats, these side effects include thrombocytopenia, the elevation of liver transaminases, hyperplasia of reticuloendothelial cells in various organs, and renal tubular changes (UM Sarmiento, et al. In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice. Antisense Res Dev. 1994 Summer;4(2):99- 107. doi: 10.1089 / ard.1994.4.99. PMID: 7950306; S Agrawal et al. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies. Proceedings of the National Academy of Sciences Mar 1997, 94 (6) 2620-2625; DOI: 10.1073 / pnas.94.6.2620). In monkeys, the side effects observed are activation of complement (Agrawal, Sudhir, et al. "Novel enzymatic and immunological responses to oligonucleotides. "Toxicology letters 82 (1995): 431-434.) and prolongation of activated partial thromboplastin time (aPTT). Because similar side effects have been observed after administration of dextran sulfate, the inference is that these side effects are caused by the polyanionic nature of PS-oligos and are not nucleotide-sequence-specific. Thus, oligonucleotides with reduced toxicity but increased stability need to be developed.

[0010] The present invention overcomes these limitations by providing improved antimiRs conjugated to oleic acid.

[0011] DESCRIPTION OF THE FIGURES

[0012] Figure 1. Evaluation of toxicity and efficacy on DM1 cells. Representation of toxicity (percentage of cell growth inhibition, black) and efficacy (percentage of MBNL1 expression increase, compared to mock-transfected cells, grey) on DM1 myotubes after lipofection with (A) MD23b-2, (B) 5'-23b-Oleic, (C) non-conjugated-23b or (D) 218-D / LNA2 at 5 different concentrations (for MD23b-2, 5'-23b-Oleic and non-conjugated-23b: 10 nM, 50 nM, 200 nM, 1 pM and 5 pM; and for 218-D / LNA2: 0.08 nM, 0.4 nM, 2 nM, 10 nM and 50 nM). The dotted line indicates TC50 and EC50 levels. Each concentration was tested in triplicate. Error bars = standard error of the mean (SEM). The Graphpad’s equation “Bell-shaped dose response” has been used to fit the dose-response curves.

[0013] Figure 2. Functional efficacy assays in HSALRmice 5 days after injection of the indicated treatments. (A) Force / Weight and (B) Myotonia grade were analyzed 5 days after a single injection (Al) of different antimiRs at 3 mg / Kg. The data in A were analyzed by unpaired Student’s t-test compared to HSALRmice treated with PBS (PBS), p values: ns= not significant, *p < 0.05, **p < 0.01 , ***p < 0.001. Data points represent individual mouse values. Error bars = standard error of the mean (SEM).

[0014] Figure 3. miRNA levels on muscle tissues. (A) miR-23b-3p and (B) miR-218-5p expression levels relative to U1 and U6 snRNA endogenous controls were quantified by qRT-PCR on gastrocnemius (gt) and quadriceps (qd) muscles. HSALRmice received an IV injection in the tail vein with either PBS or the different antimiRs, all at the same concentration (3 mg / Kg). Mice were sacrificed 5 days after the injection and the muscles were dissected and processed for RNA extraction. Statistical comparisons were all performed against PBS-treated HSALR values with a Student’s t-test. p values: ns = not significant, *p < 0.05, **p < 0.01 , ***p < 0.001 , ****p<0.0001. Data points represent individual mouse values. Error bars = standard error of the mean (SEM).

[0015] Figure 4. Expression of MbnH and Mbnl2 on skeletal muscles of treated HSALRmice. (A) MbnH and (B) Mbnl2 transcript levels were quantified by qRT-PCR relative to Gapdh endogenous control on gastrocnemius (gt) and quadriceps (qd) muscles; (C) MbnH protein levels relative to endogenous tubulin control using quantitative dot blot. HSALRmice received an IV injection in the tail vein with PBS or the different antimiRs, all at the same dose (3 mg / Kg). Gastrocnemius and quadriceps muscles were dissected 5 days after the injection and the tissues were processed for RNA and protein analysis. Statistical comparisons were all performed against PBS-treated HSALRvalues with a Student’s t-test. p values: ns = not significant, *p < 0.05, **p < 0.01 , ***p < 0.001 , ****p<0.0001. Data points represent individual mouse values. Error bars = standard error of the mean (SEM).

[0016] Figure 5. AntimiRs improved Mbnl-dependent missplicing of transcripts. HSALRmice received an IV injection in the tail vein with PBS or the different antimiRs, all at the same dose (3 mg / Kg). Gastrocnemius and quadriceps muscles were dissected 5 days after the injection and the tissues were processed for RNA extraction. (A) RT-PCR semiquantitative analyses of the splicing of (A) Atp2a1 exon 22, (B) Nfix exon 7, (C) MbnH exon 5, and (D) Clcnl exon 7a in gastrocnemius (gt) and quadriceps (qd) muscles. Exon inclusion levels of healthy control mice (FVB) are also included for comparison. Statistical comparisons were all performed against PBS-treated HSALRvalues with a Student’s t-test. p values: ns = not significant, *p < 0.05, **p < 0.01 , ***p < 0.001 , ****p<0.0001. Data points represent individual mouse values. Error bars = standard error of the mean (SEM).

[0017] Figure 6. Representative agarose gels used for the quantifications summarized in Fig 5 of Atp2a1, Clcnl, Nfix, and MbnH transcripts in gastrocnemius and quadriceps muscles. Effect of treatment with the indicated oligonucleotides against miR-23b-3p (A,B) and miR-218-5p (C,D). Splicing patterns of wild-type mice (FVB) and PBS-treated HSALRmice are also shown for comparison.

[0018] Figure 7. Spider graphs showing the effect of the indicated treatments on several DM1- related molecular or functional phenotypes in HSALRmice. The values represented are the recovery index (Rl), and they measure how close the different values of treated HSALRmice are compared to FVB controls' parameters, represented as 1 (solid black line). Panel (A) summarizes Rl for antimiRs against miR-23b-3p, while (B) focuses on Rl for antimiRs against miR-218-5p. For more representation details, see “Radar charts” in the Materials and Methods section.

[0019] Figure 8. Chemical structure of different linkers used to connect MD23b-2 V2 oligo and Oleic acid. The draw of the entire resulting molecule, except for the oligonucleotide component, was generated with the ChemDraw software.

[0020] Figure 9. Quantification of MBNL1 protein in DM1 cells treated with the indicated concentrations of oligo MD23b-2 V2 conjugated to the oleic acid in 3'using the different linkers drawn in figure 8. Protein levels were quantified by Quantitative dot blot analysis (QDB) and normalized to endogenous GAPDH. The resulting protein levels from DM1 cells treated with transfection reagent only (DM1) were given the value of 1 , and the rest of the data were normalized accordingly. Statistical comparisons shown were all performed against DM1 cells treated with transfection reagent via Student’s t-test. p values: ns = not significant, *p < 0.05, **p < 0.01 , and ***p < 0.001. Error bars = standard error of the mean (SEM).

[0021] Figure 10. A) Chemical structure of MD23b-2 V2 3’01 oligo. The draw of the complete molecule was generated with the ChemDraw software. B) Chemical structure of MD23b-2- PS / PO 3’01 oligo. The draw of the complete molecule was generated with the ChemDraw software C) Chemical structure of 218 MOE Oleic 3’ oligo. The draw of the complete molecule was generated with the ChemDraw software.

[0022] Figure 11. Determination of MD23b-2 V2 3’01 and MD23b-2 V2 (ng / g) in the brain, gastrocnemius, quadriceps, kidney, and liver by ELISA. Statistical comparisons between MD23b-2 V2 3'01 and MD23b-2 V2 for the specified tissues were performed using Student's t- test. Statistical significance was set to p<0.05 (**p<0.01 , ***p<0.001). Error bars = SEM.

[0023] Figure 12: MBNL1 relative levels. Phase I and Phase II. Quantification of MBNL1 levels by Western Blot in protein extracts from brain of the NHP. Comparison of MBNL1 protein levels in brain NHP from the phase I, two weeks after the last administration and phase II, three weeks after the last administration. In the western blots, GAPDH levels were used as internal standard and the data was normalized to the MBNL1 protein levels in PBS-treated NHP (group 2), which were given the value of 1. Data is mean ± SEM.

[0024] Figure 13: Muscle strength levels relative to weight after repeated IV administration of MD23b-2 V2 3’01 (0, 6, 9, 12 and 24 mg / kg) to HSALR mice. A) Muscle strength levels after repeated administration (one every two weeks, for 6 weeks) of MD23b-2 V2 3’01 at 0, 6, 9, 12 and 24 mg / kg in HSALR mice (red bars) have been compared (normalized) to the strength levels in the non-treated (PBS, shown as discontinued horizontal red bar. Strength is shown at days 0, 7, 14, 21 , 28, 35 and 42. Statistical significance was set to p<0.05 (ns: not significant, *p<0.05, **p<0.01 , ***p<0.001). Analysis was made via one-way ANOVA test, followed by Dunnett's test. B) Representation of muscle strength levels versus time after treatment compared to the strength levels on non-treated mice. Values are mean ± SEM. PBS: phosphate buffer saline.

[0025] Figure 14: MBNL1 protein levels at different organs after repeated IV administration of MD23b-2 V23’01 (0, 6, 9, 12 and 24 mg / kg) to HSALR mice. MBNL1 protein levels in muscle (quadriceps, gastrocnemius and diaphragm), kidney, liver, brain and heart, after repeated administration (one every two weeks, for 6 weeks) of MD23B-2 V2 3’OL at 0, 6, 9, 12 and 24 mg / kg to HSALR mice. MBNL1 levels from MD23b-2 V2 3’01 -treated mice (red bars) are compared to the PBS-treated HSALR mice (PBS, grey bar). Statistical analysis was performed by using an Kruskal-Wallis test (a = 0.05), followed by a Dunn's test. Statistical significance was set to p<0.05 (ns: not significant, *p < 0.05, **p < 0.01 , ***p < 0.001 , and ****p < 0.0001). Values are mean ± SEM. PBS: phosphate buffer saline.

[0026] Figure 15: miR-23b relative levels and PSR values after repeated IV administration of MD23b-2 V2 3’01 (0, 6, 9, 12 and 24 mg / kg) to HSALR mice. A) miR-23b relative expression in QD and GT muscles 14 days after last administration of MD23b-2 V2 3’01 at 6, 9, 12 and 24 mg / kg (red bars). miR-23b was quantified relative to U1 and U6 snRNA endogenous controls. Statistical comparisons shown were all performed against normalized PBS values (grey bars, horizontal grey line) for mice treated with MD23b-2 V2 3’01 at doses of 6, 9, 12 and 24 mg / kg (red bars) via one way ANOVA followed by Dunnett's test. Statistical significance was set to p<0.05 (n.s.: not significant, *p < 0.05, **p < 0.01 , ***p < 0.001 , and ****p < 0.0001). B) Graphical representation of overall PSR splicing calculated as the average percentage recovery of the splicing of MBNL1 exon 5, NFIX exon 7, CLCN1 exon 7a, BIN1 exon 11 , CACNA1S exon 29 and ATP2A1 exon 22 in GT and QD muscles in treated HSALR mice. All statistical comparisons were performed against the data obtained in PBS-treated via one-way Anova / Kruskal-Wallis followed by Dunnett's or Dunn's tests, respectively. Statistical significance was set to p<0.05 (n.s.: not significant, *p < 0.05, **p < 0.01 , ***p < 0.001 , and ****p < 0.0001). Values are mean ± SEM. Statistical significance was set to p<0.05. PBS: Phosphate buffer saline; PSR: Percentage splicing recovery; WT: Wild type.

[0027] Figure 16 Quantification of MBNL1 levels in protein extracts from the quadriceps muscles of the rats by Western Blot. Comparison of MBNL1 protein levels in the muscles of rats of the different experimental groups (groups 1 ,2, 3, 4 and 5) from the main phase. In the western blots, GAPDH levels were used as internal standard and the data was normalized to the MBNL1 protein levels in PBS-treated rats (group 1), which were given the value of 1. Data is mean ± SEM. Statistical significance was assessed using Kruskal-Wallis (a = 0.05) following Dunn's test. Statistical significance was set to p<0.05 (ns: not significant, * p<0.05, ** p<0.01 , *** p<0.001 , **** p<0.0001). Error bars = SEM.

[0028] Figure 17: Quantification of MBNL1 levels in protein extracts from the quadriceps muscles of the rats by Western Blot. Comparison of MBNL1 protein levels in the muscles of rats of the different experimental groups (groups 1 , and 5) from the recovery phase. In the western blots, GAPDH levels were used as internal standard and the data was normalized to the MBNL1 protein levels in PBS-treated rats (group 1), which were given the value of 1. Data is mean ± SEM. Statistical significance was assessed using unpaired t test. Statistical significance was set to p<0.05 (ns: not significant, * p<0.05, ** p<0.01 , *** p<0.001 , **** p<0.0001). Error bars = SEM

[0029] Figure 18: Quantification of MBNL1 levels by Western Blot in protein extracts from quadriceps of the minipigs. Comparison of MBNL1 protein levels in the muscles of minipigs of the different experimental groups (groups 1 ,2, 3 and 4) from the main phase animals. In the western blots, GAPDH levels were used as internal standard and the data was normalized to the MBNL1 protein levels in PBS-treated minipigs (group 1), which were given the value of 1. Data is the mean ± SEM. Statistical significance was assessed using Welch's ANOVA test (a = 0.05) following Dunn's test. Statistical significance was set to p<0.05 (ns: not significant, * p<0.05, ** p<0.01 , *** p<0.001 , **** p<0.0001). Error bars = SEM.

[0030] Figure 19: Quantification of MBNL1 levels by Western Blot in protein extracts from quadriceps of the minipigs. Comparison of MBNL1 protein levels in the muscles of minipigs of the different experimental groups (groups 1 , and 4) for the recovery phase animals. In the western blots, GAPDH levels were used as internal standard and the data was normalized to the MBNL1 protein levels in PBS-treated minipigs (group 1), which were given the value of 1. Data is the mean ± SEM. Statistical significance was assessed using unpaired t test. Statistical significance was set to p<0.05 (ns: not significant, * p<0.05, ** p<0.01 , *** p<0.001 , **** p<0.0001). Error bars = SEM.

[0031] Figure 20: A) Test Item 1 (X82108) IV in plasma vs time. B) Test Item 1 (X82108) IV in CSF vs time. C) Test Item 1 (X82108) IT in plasma vs time. D) Test Item 1 (X82108) IT in CSF vs time. E) Test Item 2 (X82102) IT in plasma vs time. F) Test Item 2 (X82102) IT in CSF time.

[0032] G) Test Item 3 (X85204) IT in plasma vs time. H) Test Item 3 (X85204) IT in CSF vs time.

[0033] Figure 21. Quantification of antimiR-23b oligonucleotides following a single intravenous administration (24 mg / kg) in FVB mice. (A-F) Concentrations of naked, oleic-conjugated, and palmitic-conjugated antimiR-23b oligonucleotides (5' or 3'). (A) Oligonucleotide concentrations in cerebrospinal fluid (CSF) at 0.5 h, quantified by hybridization ElectroChemiLuminescence ImmunoAssay (hybECLIA). (B) Oligonucleotide concentrations in brain at 0.5 h, determined by Enzyme-Linked OligoSorbent Assay (ELOSA). (C) Summary tables of pairwise statistical comparisons for CSF and brain measurements at 0.5 h, including adjusted p-values. (D) Oligonucleotide concentrations in plasma at 0.5 h, quantified by hybECLIA. (E) Oligonucleotide concentrations in skeletal muscle at 0.5 h, determined by ELOSA. (F) Summary tables of pairwise statistical comparisons for plasma and skeletal muscle measurements at 0.5 h, including adjusted p-values . (G-J) Concentrations of naked vs. 3'-oleic antimiR-23b at 14 days post-administration. (G) CSF; (H) Brain; (I) Plasma; (J) Skeletal muscle. Results are presented as mean ± SEM; ns = not significant, # p<0.1 , **p < 0.01 , ****p < 0.0001.

[0034] Figure 22. Pharmacokinetics of antimiR-23b after intravenous administration (24 mg / kg) in FVB mice. (A) CSF and (B) plasma concentrations in ng / ml of the oleic-conjugated oligonucleotide (X82108), the palmitic-conjugated oligonucleotide (X85204), and the naked variant (X82102) were quantified using hybridization ElectroChemiLuminescence ImmunoAssay (hybECLIA). Samples were collected from 0.5 hours to 30 days post-injection. Data are shown as mean ± SEM.

[0035] Figure 23. Pharmacokinetics of antimiR-23b after intrathecal administration in CD-1 mice (0.4 mg / animal). (A) CSF concentrations and (B) brain levels of oleic-, naked-, and palmitoyl-conjugated oligonucleotides. Quantification was performed by hybECLIA for CSF and ELOSA for brain tissue. The oleic conjugate displayed higher exposure and longer persistence in both CSF and brain compared with naked and palmitoyl conjugates. Data are shown as mean ± SEM.

[0036] Figure 24. Brain distribution of oleic acid-conjugated oligonucleotides after intrathecal (IT) and intravenous (IV) administration. Representative fluorescence in situ hybridization (FISH) images obtained 24 h post-dose show compound localization (green) and nuclei (blue). IT delivery led to predominant localization in superficial regions such as cortex and brainstem, with lower concentration into central brain areas. Although both oligonucleotides reach brain areas, IV delivery produced a broader and more homogeneous distribution, reaching both superficial and deeper regions, including central brain areas.

[0037] Figure 25. Transcriptional silencing of CD36 and FATP4. Relative expression of CD36 and FATP4 by RT-qPCR in transdifferentiated myotubes after treatment with specific siRNAs. Data are shown as mean ± SEM. *p < 0.05, **p < 0.01 , ***p < 0.001 , **p < 0.0001.

[0038] Figure 26. Analysis of cellular uptake of Cy3-labeled oligonucleotides after CD36 and FATP4 inhibition. (A) Effects of CD36 inhibition with siCD36 and SSO and FATP4 inhibition with siFATP4 on the intracellular uptake of the oleic acid-conjugated oligonucleotide (OL), expressed as integrated fluorescence density relative to cells treated with the unconjugated oligonucleotide (NC) in myotubes. Data are shown as mean ± SEM. Statistical differences relative to the corresponding NC are indicated below with asterisks (*p < 0.05, **p < 0.01 , *p < 0.001). Differences relative to the CNT group are indicated above with hash symbols (#p < 0.05). (B) Representative microscopy images of cells treated with NC or OL (red, Cy3-labeled) in untreated myotubes (CNT) or after treatment with siCD36. Nuclei were stained with NucBlue (blue).

[0039] Figure 27. CD36 silencing after 24 h in differentiated myotubes. (A) Quantification of CD36 protein levels normalized to GAPDH in differentiated control myotubes (CNT) and siCD36- transfected cells by Western blot. (B) Representative Western blot showing CD36 (~75 kDa) and GAPDH (~37 kDa) as loading control.

[0040] Figure 28. Validation of CD36 expression in CHO-K1 cells. (A) Relative CD36 protein levels in human myotubes and CHO-K1 cells quantified by Western blot. (B) Representative Western blot of CD36 in myotubes and CHO-K1. (C) Relative CD36 protein levels in CHO-K1 versus CHO-CD36 cells. (D) Representative Western blot of CD36 in CHO-K1 and CHO-CD36. GAPDH was used as loading control. Data are shown as mean ± SEM. *p < 0.05, **p < 0.01 , ***p < 0.001 , ****p < 0.0001.

[0041] Figure 29. Effect of CD36 expression on intracellular uptake of lipid-conjugated oligonucleotides in CHO-K1 cells. (A) Fluorescence intensity (RFU) in CHO-K1 and CHO- CD36 cells treated with, oleic acid-conjugated (OL), or palmitic acid-conjugated (PAL) oligonucleotides relative to CHO-K1. Data are shown as mean ± SEM. *p < 0.05, **p < 0.01 , ***p < 0.001 , ****p < 0.0001 ; ordinary one-way ANOVA. (B) Representative fluorescence microscopy images of CHO-K1 and CHO-CD36 cells treated with OL or PAL. Cy3-labeled oligonucleotides are shown in red and nuclei in blue (NucBlue).

[0042] Figure 30. CD36 protein expression in different brain regions. (A) Protein expression of CD36 in cortex (CX), brainstem (BS), cerebellum (CB) and rest of brain (RB). The results shown are the mean of the intensity of the normalized volume (Norm. Vol. (Int)) of each group.

[0043] (B) Representative Western blot of CD36 in CX, BS, CB and RB. GAPDH was used as loading control. Data are shown as mean ± SEM (n=3). Statistical comparisons are indicated as **p < 0.01.

[0044] Figure 31. Quantification of X82108 in different brain regions 24 hours after intravenous administration. The brain regions studied are cortex (CX), brainstem (BS), cerebellum (CB) and rest of brain (RB). Data are shown as mean ± SEM (n=3). Statistical comparisons are indicated as ns = not significant.

[0045] Figure 32. Relative Malatl expression in cortex, cerebellum, and rest of brain seven days after intravenous administration of MALAT1 -targeting ASOs. Shown are vehicle (- ), non-conjugated ASO (NK), and oleic-acid-conjugated ASO (OL). ASO-Naked shows no reduction relative to vehicle, whereas ASO-Oleic produces a decrease in Malatl expression in all regions, with the lowest relative levels observed in the cerebellum. Data are mean ± SEM; statistical comparisons are indicated as *p < 0.05, **p < 0.01 , ns = not significant.

[0046] Figure 33. MALAT1 knockdown following IT administration of ASO-MALAT1-OL in rats.

[0047] Relative MALAT1 mRNA levels were measured in the cortex and midbrain at 4 hours and 7 days after a single IT injection of naked ASO-MALAT 1 or oleic-acid-conjugated ASO-MALAT 1 (ASO-MALAT1-OL). Data are normalized to the naked ASO at each time point and are shown as mean ± SEM (n=2).

[0048] BRIEF DESCRIPTION OF THE INVENTION

[0049] In one aspect, the present invention relates to an oligonucleotide molecule, or a mixture of two or more of said molecules, wherein said oligonucleotide molecule comprises between 10 to 30 nucleotides in length, wherein said oligonucleotide molecule comprises at least two nucleotides chemically linked by a phosphoroth ioate linkage, and wherein said oligonucleotide molecule is conjugated at its 3' and / or 5' ends to at least one oleic acid molecule. Preferably, wherein the molecule is an antagonist of a microRNA, more preferably wherein the microRNA is the human hsa-miR-23b-3p or the human hsa-miR-218-5p. In an embodiment, the oligonucleotide molecule according to the first aspect comprises between 15 to 30 nucleotides in length, comprises at least two nucleotides linked by a phosphodiester linkage, wherein the number of nucleotides that are chemically linked by a phosphorothioate linkage is greater than the number of nucleotides that are chemically linked by a phosphodiester linkage.

[0050] In an embodiment, the oligonucleotide molecule according to the first aspect comprises between 15 to 30 nucleotides in length, and wherein said oligonucleotide molecule also comprises a fragment composed of a succession of at least 15 consecutive nitrogen bases of nucleotides that are identical in at least 80% to the sequence of a region present in SEQ ID NO: 1 (antimiR-218-5p) or 2 (antimiR-23b-3p), or SEQ ID NO: 52-110.

[0051] In an embodiment, the oligonucleotide molecule according to the first aspect comprises between 15 to 30 nucleotides in length, and wherein said oligonucleotide molecule also comprises a fragment composed of a succession of at least 15 consecutive nitrogen bases of nucleotides that are identical to the sequence of a region present in SEQ ID NO: 1 (antimiR- 218-5p) or 2 (antimiR-23b-3p).

[0052] In an embodiment, the oligonucleotide molecule according to the first aspect comprises at least one chemical modification, wherein the chemical modification is selected from the group of: i) 2'-O-methyl (2'OMe), ii) 2'-O-Methoxyethyl (2' MOE), and / or iii) an extra bridge connecting the 2' oxygen and 4' carbon (LN A).

[0053] In an embodiment, the oligonucleotide molecule according to the first aspect comprises between 15 to 30 nucleotides in length, and wherein said oligonucleotide molecule also comprises a fragment composed of a succession of at least 15 consecutive nitrogen bases of nucleotide that are identical in at least 80% to the sequence of a region present in SEQ ID NOs: 3, 4, 5, 22, 23, 24, 49, 50 or 51 (antagonists of hsa-miR-23b) or SEQ ID NOs: 7, 8, 9, 14, 25, 26, 27, or 28 (antagonists of hsa-miR-218-5p).

[0054] In an embodiment, the oligonucleotide molecule according to the first aspect comprises between 15 to 30 nucleotides in length, wherein the nucleotide sequence of said oligonucleotide consists of SEQ ID NOs: 3, 4, 5, 22, 23, 24, 49, 50 or 51 (antagonists of hsa- miR-23b) or SEQ ID NOs: 7, 8, 9, 14, 25, 26, 27, or 28 (antagonists of hsa-miR-218-5p). In another aspect, the present invention relates to composition, preferably a pharmaceutical composition, comprising at least an oligonucleotide molecule as defined in the first aspect or any of its embodiments, or a mixture of two or more of them, optionally further comprising a carrier and / or one or more pharmaceutically acceptable excipients.

[0055] In another aspect, the present invention relates to composition as defined in the second aspect or any of its embodiment, for use in therapy.

[0056] In another aspect, the present invention relates to composition as defined in the second aspect or any of its embodiment, for use in targeting muscular cells in a subject in need thereof.

[0057] In another aspect, the present invention relates to composition as defined in the second aspect or any of its embodiment, for use in the prevention or treatment of muscular diseases or in the prevention or treatment of RNAopathies.

[0058] Preferably, the disease is myotonic dystrophy, more preferably myotonic dystrophy is of type 1.

[0059] DESCRIPTION OF THE INVENTION

[0060] GENERAL DEFINITIONS

[0061] It must be noted that, as used herein, the singular forms "a", "an", and "the", include plural references unless the context clearly indicates otherwise. Further, unless otherwise indicated, the term "at least" preceding a series of elements is to be understood to refer to every element in the series. Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the present invention.

[0062] If the term "about" as used in connection with a numerical value throughout the specification and the claims denotes an interval of accuracy, familiar and acceptable to a person skilled in the art. For instance, the term “about” means the indicated value ± 1% of its value, or the term “about” means the indicated value ± 2% of its value, or the term “about” means the indicated value ± 5% of its value, the term “about” means the indicated value ± 10% of its value, or the term “about” means the indicated value ± 20% of its value, or the term “about” means the indicated value ± 30% of its value. Preferably, the term “about” means exactly the indicated value (± 0%).

[0063] As used herein, the conjunctive term "and / or" between multiple recited elements is understood as encompassing both individual and combined options. For instance, where two elements are conjoined by "and / or", a first option refers to the applicability of the first element without the second. A second option refers to the applicability of the second element without the first. A third option refers to the applicability of the first and second elements together. Any one of these options is understood to fall within the meaning, and therefore satisfy the requirement of the term "and / or" as used herein. Concurrent applicability of more than one of the options is also understood to fall within the meaning, and therefore satisfy the requirement of the term "and / or."

[0064] Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integer or step. When used herein, the term "comprising" can be substituted with the term "containing" or "including" or sometimes when used herein with the term "having". Any of the aforementioned terms (comprising, containing, including, having), whenever used herein in the context of an aspect or embodiment of the present invention may be substituted with the term "consisting of", though less preferred.

[0065] When used herein, "consisting of" excludes any element, step, or ingredient not specified in the claim element. When used herein, "consisting essentially of” does not exclude materials or steps that do not materially affect the basic and novel characteristics of the claim.

[0066] As used herein, names referring to murine genes are typed italicized with an uppercase letter followed by all lowercase letters. Murine protein designations follow the same rules as murine gene symbols, but are not italicized. When referring to human genes or proteins, uppercase letters are always used, being italicized in the case of the gene. Nevertheless, a skilled person will be able to infer the precise nature of the biomolecule (protein, gene, transcript) and species from the technical context of the description.

[0067] By “oligonucleotide,” as referred herein is meant any short segment of DNA, RNA, or DNA / RNA, including both natural and synthetic nucleotides. As used in this invention, the term "oligonucleotide molecules" includes both oligonucleotides as such, as well as the "oligonucleotide analogues". "Oligonucleotide analogues" are the molecules derived therefrom that incorporate some chemical modification in at least one of the nucleotide units that form them, either in the phosphate group, the pentose or one of the nitrogenous bases; the modifications consisting in the addition of non-nucleotide groups at the 5' and / or 3' ends are also included as well as phosphorodiamidate morpholino oligomers, peptide nucleic acids (PNAs; mimics of DNA in which the deoxyribose phosphate backbone is replaced by a pseudopeptide polymer to which the nucleobases are linked), and the like. By extension, for the purposes of this invention and as used herein, the terms "oligonucleotide molecule" and "oligonucleotide analogue" or “oligonucleotide analogue molecule” also include sponges of microRNAs or microRNA sponges, as it can be considered that the main constituent of the same are tandem repeats of oligonucleotides, characterized in that each of these oligonucleotides are in themselves or contain a binding site of a microRNA of interest. For the sake of clarity, it is mentioned that the oligonucleotide sequences disclosed herein and numbered as “SEQ ID NO”, comprise a nucleobase sequence together with chemical modifications and / or fatty acid conjugation, if any. For example, SEQ ID NO 3 refers to the nucleobase sequence “ATCCCTGGCAATGTGA”, together with the LNA, phosphoroth ioate linkages, and 5-Methyl-2'-O-Methyl cytidine, modifications, among others. Thus, this sequence is represented herein as SEQ ID NO 3: AbsTbs(5Mc)s(5Mc)sCmTbGmsgsCms- AbAmTbGbTmsGbsAb(NHC6)(OleicAcid).

[0068] By “antagonist oligonucleotide” is referred herein as an oligonucleotide that is able to block or inhibit the natural function of a molecule, in this case, a microRNA. Thus, the antagonist oligonucleotides of the present invention are inhibitor molecules that avoid the activation, stability or function of the antimi R to which they bind. In the context of the present invention, “antagonist” is synonymous of “inhibitor” and can thus be used interchangeably. For example, an “antagonist oligonucleotide of hsa-miR-23b-3p” refers to an oligonucleotide molecule that inhibits the function of the hsa-miR-23b-3p.

[0069] "Percentage of sequence identity" for polynucleotides and polypeptides is determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions (i.e. , gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the same nucleobase or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity. Optimal alignment of sequences for comparison may be conducted by computerized implementations of known algorithms (BLAST in the resources of the National Center for Biotechnology Information, CLUSTAL in the resources of the European Bioinformatics Institute, GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, Wis.), or by inspection. It should be noted that the “percentage of identity” as used herein is decided in the context of a local alignment, i.e., it is based on the alignment of regions of local similarity between nucleobase sequences, contrary to a global alignment, which aims to align two sequences across their entire span. Thus, in the context of the present invention, percentage identity is calculated preferably only based on the local alignment comparison algorithm.

[0070] Often, especially in the case of antimiRs, chemical modifications are incorporated to the corresponding nucleotide units, which mainly affect the ribose moiety and / or phosphate, modifications that are difficult to depict in the usual representations of nucleotide sequences, in which the nucleotide present in a given position is identified by the abbreviation of the nitrogenous base that is part of it. Therefore, in the present invention, there are compared molecules of microRNA antagonists that refer to the percentage of identity between the sequences of the nitrogenous bases or nucleobases of the nucleotide or nucleotide analogue units present in these units, as this is what indicates whether two molecules or sequence fragments are designed from the same original basic nucleotide sequence, independently of the different chemical modifications that may have been included in the nucleotides in each case.

[0071] As used in this specification, it is understood that two chains of nucleotide molecules are 100% complementary when the nucleotide or nucleotide analogue sequence of one of them, read in the 5'-3' sense, is the sequence of nucleotides or nucleotide analogues that present the nitrogenous bases which pair with the nitrogenous bases of nucleotides or nucleotide analogues of the other sequence, read in the 3'-5' sense. That is to say, the sequence 5'- UAGC-3' would be complementary to the sequences 3'-AUCG-5' and 3'-ATCG-5', which would be, respectively, sequences 5'-GCUA-3' and 5'-GCTA-3' read in the 5'-3' sense. In an embodiment, it is preferred that the antagonist molecule comprises in its sequence a fragment that is identical to the complementary sequence to that of the seed region of the microRNA to be antagonized, at least with regard to the complementarity of the nitrogenous bases.

[0072] As used herein, “antimiRs” refer to oligonucleotides, preferably oligoribonucleotides, that are complementary to a microRNA, preferably a mature microRNA, that is their target and they bind to with great affinity inhibiting it. Therefore, antimiRs refer to oligonucleotides, usually chemically modified with respect to the corresponding oligomer composed only of nucleotide units, and that are complementary and thus inhibitors of a target microRNA. In the particular case of the present invention, the antimiRs described herein are preferably at least partially complementary to human microRNAs hsa-miR-23b-3p or hsa-miR-218-5p. As used herein, “microRNA sponges” are usually designed so that they inhibit microRNAs with a complementary heptameric or octameric fragment (seed region), such that a single sponge construct can be used to block a whole family of microRNAs sharing the same motif, although they may also contain the entire target sequence for a specific microRNA or only a miRNA- specific region, devoid of the seed region, to make it specific.

[0073] The expressions "pharmaceutically acceptable" or "pharmacologically acceptable" refer to molecular entities and compositions that do not produce any adverse, allergic or other reactions when administered to an animal or human being. As used herein, "pharmaceutically acceptable vehicle" includes solvents, buffers, solutions, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption retarding agents, fatty acids such as oleic acid, and similar acceptable agents for use in formulation pharmaceuticals, such as pharmaceutical products suitable for administration to human beings.

[0074] “Preventing”, “to prevent”, or “prevention”, include without limitation, decreasing, reducing or ameliorating the risk of a symptom, disorder, condition, or disease, and protecting an animal from a symptom, disorder, condition, or disease. A prevention may be applied or administered prophylactically.

[0075] “Treating”, “to treat”, or “treatment”, include without limitation, restraining, slowing, stopping, reducing, ameliorating, or reversing the progression or severity of an existing symptom, clinical sign, disorder, condition, or disease. A treatment may be applied or administered therapeutically.

[0076] By “TC50” or “half-maximal inhibitory concentration” is referred herein as the concentration of an inhibitor administered to test organism or test cell lines that produces toxic effects in 50 percent of a population of exposed organisms or cell lines in a given time period.

[0077] By “EC50” or “half-maximal effective concentration” is referred herein as the concentration of an antagonist or inhibitor required to obtain a response halfway between the baseline and maximum in a given time period. That is, EC50 is the concentration required to obtain a 50% of the effect caused by the treatment.

[0078] By “Emax” is referred herein as the maximum response achievable from an applied or dosed agent, in this case, an antagonist molecule. Emax is measured as the maximum fold change of the target protein, e.g. MBNL1 protein, obtained after transfection with a specific antimiR- 23b-3p or antimiR-218-5p compared to the mock (transfected with vehicle or non-transfected). The “Tindex” or “therapeutic index / ratio” is a quantitative measurement of the relative safety of a drug. In the present invention, the Tindex is defined as the ratio between the amount of a therapeutic agent that causes 50% toxicity (TC50) and the amount that causes 50% of the therapeutic effect (EC50), multiplied by the maximum response achievable:

[0079] Tindex= (TC50 / EC50)*Emax

[0080] The term "3 ' end", as used herein, designates the end of a nucleotide strand that has the hydroxyl group of the third carbon in the sugar-ring at its terminus. The term "5' end", as used herein, designates the end of a nucleotide strand that has the fifth carbon in the sugar-ring at its terminus.

[0081] DETAILED DESCRIPTION

[0082] As stated above, improved oligonucleotides comprising chemical modifications resulting in less toxicity but increased therapeutic effect need to be developed. Thus, two main objectives were covered by the present invention. On the one hand, it was an objective of the present invention to evaluate what is the best fatty acid to be conjugated to the oligonucleotide, and to design oligonucleotides that have the maximum allowed amount of PS linkages that provide the beneficial effect to the molecule but without being too toxic for administration in vivo. On the other hand, the present invention also provides specific microRNA inhibitors, particularly oligonucleotide molecules or analogues thereof, aimed at correcting the insufficient function of MBNL (Muscleblind-like) proteins, partially originating from overexpression of hsa-miR-23b-3p and hsa-miR-218-5p in patients with myotonic dystrophy (DM), preferably myotonic dystrophy 1 (DM1).

[0083] First, the inventors tested in vitro the effects of conjugating previously published antagomiR- 23b and antagomiR-218 oligonucleotides (Cerro-Herreros et al. 2018 Nat. Commun. 9, 2482) with different hydrophobic moieties, (including lipids and fatty acids) (Table 1) in terms of toxicity, efficacy (levels of MBNL1 protein) and therapeutic index (Tindex). The antagomiR sequences used in this study contained all 2'OME modified nucleotides and a mix of phosphorothioate (PS) linkages and phosphodiester (PO) linkages. Surprisingly, it was found that, for both the antagomiR-23b and antagomiR-218 oligonucleotides, the conjugation with oleic acid produced the most important improvement of the Tindex.

[0084] Next, inventors tested the ability of oleic acid to act as a carrier, and the experiment shown in Fig. 11 and Example 9 demonstrated that oleic acid is an excellent carrier or vehicle to deliver oligonucleotides to tissues such as muscle and central nervous system (CNS). In fact, Example 19 shows that oleic acid is an excellent carrier of vehicle to deliver the oligonucleotides to the cerebrospinal fluid (CSF). Further, Figures 12-13 and Example 10 demonstrate that the vehiculization of the oligonucleotide molecule by the oleic acid does not only occur in an animal model with DM1 phenotype, but also in healthy animals (in this case, monkeys). These results open the path for therapeutic uses of oleic acid as a carrier when conjugated to oligonucleotide molecules, especially in the context of diseases affecting muscle and / or CNS or CSF, which were two of the main tissued where the oleic acid enhanced the delivery of the oligonucleotide.

[0085] DM1 is a neuromuscular disease that affects muscle tissue, but also central nervous system. Hence, the inventors screened for the antimiR sequence with the best Tindex in DM1 cells among a pool of antimiRs with lengths ranging between 15 and 22 nucleotides, including nucleotides carrying different chemical modifications such as LNA, 2'OME and 2'MOE. The best performing antagonist of human hsa-miR-23b-3p in this study was MD23b-2, and the oligo with the best Tindex for an antagonist of human hsa-miR-218-5p was 218-D / LNA2 (see Tables, 2 and 3, Figure 1). Modified versions of each of these two molecules were combined with oleic acid, and the resulting molecules were tested in a murine model of DM1 (HSALRmice) and in DM1 cells (only for a modified version of MD23-b2). The results of these tests revealed that the conjugation of oleic acid to an oligonucleotide that comprises a mixture of PS / PO increases the therapeutic effect of said oligonucleotide (see Table 4, Table 5 and Table 6). Overall, the results obtained in the present study led the authors to conclude that the best fatty acid to be conjugated to the oligonucleotide molecule to improve the levels of MBNL1 in DM1 cells and a mouse model of the disease is oleic acid, and that this conjugation improves the therapeutic index of the oligonucleotide when a mixture of PS / PO linkages is present in the molecule.

[0086] In view of these results, in a first aspect, the present invention relates to an oligonucleotide and / or oligonucleotide analogue molecule, or a mixture of two or more of said molecules, wherein the oligonucleotide and / or oligonucleotide analogue molecule is conjugated to at least one oleic acid molecule at the 3' and / or 5' ends of said oligonucleotide and / or oligonucleotide analogue molecule. Preferably, the oligonucleotide and / or oligonucleotide analogue is an antagonist of a microRNA. Preferably, the oligonucleotide and / or oligonucleotide analogue is an antagonist of the microRNA selected from the group consisting of human hsa-miR-23b-3p or the human hsa-miR-218-5p. In the context of the present invention, “conjugation” or “conjugated to the 3’ and / or 5’ end of an oligonucleotide molecule or analogue thereof” is referred herein to the addition of at least one oleic acid molecule to the 5’ and / or 3’ end of the oligonucleotide and / or analogue thereof. The conjugation can be performed directly, such as by covalently linking the at least one oleic acid molecule to the 5’ and / or 3’ end of the oligonucleotide and / or analogue thereof, or by means of a spacer molecule, as will be explained in detail below. Because the oligonucleotide is conjugated to oleic acid, the compound formed by both elements (oligonucleotide and oleic acid) may also be referred to as a conjugate.

[0087] The microRNAs hsa-miR-23b-3p and hsa-miR-218-5p are repressors of the expression of MBNL genes, among other gene transcripts, and thus it is their repressive capacity that will be diminished by the presence of its antagonists. In the context of the present invention, inhibitors, silencers or blockers are compounds that are capable of producing a decrease in the endogenous activity of said hsa-miR-23b-3p and hsa-miR-218-5p, and thus these three terms have been included under the denomination of "antagonist". While, strictly speaking, the term "silencing" could be interpreted as the absolute annulment of such activity, since the difference between such annulment or a non-absolute decrease in repressive activity may depend on the concentration of the compound used, it will be sufficient for a compound to result in a decrease in the repressive activity of a microRNA to be considered an inhibitor, silencer, blocker or, in short, an antagonist thereof. In addition, taking into account the knowledge about the possibility of inhibiting microRNA function by targeting the mature microRNA, the precursor microRNA (pre-microRNA or pre-miRNA) or the primary microRNA (pri-microRNA or pri-miRNA), a compound could be considered a microRNA inhibitor, silencer, blocker or antagonist according to the present invention if it targets the mature microRNA, but also if it targets the precursor microRNA or the primary microRNA transcript, provided that it is capable of producing a decrease in the endogenous activity of said microRNA. Therefore, as used herein, the four terms (inhibitors, silencers, blockers or antagonists) are used as synonyms in this specification.

[0088] With regard to the nucleotide sequence of the antagonists of the present invention, it is important to note that there should be sufficient complementarity with the endogenous molecules to which they must bind. Said endogenous molecule is preferably a microRNA molecule, more preferably the hsa-miR-23b-3p or hsa-miR-218-5p molecules. Human hsa- miR-218-5p and hsa-miR-23b-3p differ in the sequence of nucleotides which must be taken into account for the design of the sequence of antagonists and their microRNA binding site. The “microRNA binding site” is the nucleotide sequence comprised in the antagonist that is complementary or partially complementary to at least a portion of its target microRNA. Preferably, the microRNA binding sites of the antagonists defined herein are complementary or partially complementary to at least a portion of hsa-miR-23b-3p or hsa-miR-218-5p. The sequence of the binding site can be a perfect match, meaning that it has perfect complementarity to the microRNA. Alternatively, the sequence can be partially complementary, meaning that one or more mismatches may occur when the microRNA is base-paired to the binding site of the antagonist. Importantly, if the antagonist is partially complementary to the target microRNAs (preferably hsa-miR-23b-3p or hsa-miR-218-5p) its binding site preferably contains perfect or near-perfect complementarity (90%, 91 % 92%, 93%, 94%, 95%, 96%, , 97%, 98%, 99% or preferably 100% complementary) to the seed region of the target microRNAs (preferably hsa-miR-23b-3p or hsa-miR-218-5p). The “seed region” of a microRNA normally comprises or consists of nucleotide 2 to nucleotide 7 from the 5' end of the microRNA.

[0089] Thus, in the design of the antimiRs of the present invention, the sequence of the mature versions of the target microRNAs and their seed region can be considered. We show below the sequences of their mature versions, wherein the seed region of each of them is represented in bold, and their access code (Mimat) in the miRbase database (www.mirbase.org):

[0090] Hsa (homo sapiens)-miR-218-5p (MIMAT0000275): 5’- UUGUGCUUGAUCUAACCAUGU -3’ (SEQ ID NO: 10); Seed region: UGUGCU (SEQ ID NO: 12) hsa-miR-23b-3p (MIMAT0000418): 5’-AUCACAUUGCCAGGGAUUACCAC-3’ (SEQ ID NO: 11); Seed region: UCACAU (SEQ ID NO: 13)

[0091] In an embodiment, the oligonucleotide and / or oligonucleotide analogues molecules are inhibitors, blockers or antagonists of the types known as antimiRs and microRNA sponges. Preferably, the oligonucleotide and / or analogue thereof, according to the first aspect or any of its embodiments, is an antimiR, more preferably an antimiR of hsa-miR-218-5p or hsa-miR- 23b-3p.

[0092] In an embodiment, the oligonucleotide and / or analogue thereof is at least 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25 nucleotides in length. In an embodiment, the oligonucleotide and / or analogue thereof is between 10-50 nucleotides in length, more preferably between 10-30 or 15-25 nucleotides in length. Preferably, the oligonucleotide molecule and / or analogue thereof is an antimiR whose sequence comprises, consists, or consists essentially of a fragment composed of a succession of at least 7, 8, 9, 10, 11 , 12, 13, 14, 15, or 16 consecutive nitrogen bases of nucleotide or nucleotide analogue units that are identical in at least 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5%, or 100% to the complementary sequence of a region present in SEQ ID NOs: 10 (hsa-miR-218-5p) or 11 (hsa-miR-23b-3p). More preferably, the sequence of the nitrogen bases of the nucleotide or nucleotide analogue units comprised in the oligonucleotide molecule and / or analogue thereof is identical in at least 60%, 70%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5%, or 100% to the complementary sequence of SEQ ID NOs: 10 (hsa-miR-218-5p) or 11 (hsa-miR-23b-3p).

[0093] In an embodiment, the antagonist is an antimiR and its sequence comprises a fragment composed of a succession of at least 5-8 nucleotide or nucleotide analogue units wherein the sequence of the nitrogenous bases of said nucleotide or nucleotide analogue units is identical in at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% to the complementary sequence of the seed region of the hsa-miR-23b-3p as set forth in SEQ ID NO: 13. Preferably, said antimiR comprises a fragment composed of a succession of at least 5-8 nucleotide or nucleotide analogue units that are 100% complementary to the seed region as set forth in SEQ ID NO: 13. In an embodiment, the antagonist is an antimiR whose sequence comprises a first fragment and a second fragment, wherein the first fragment is composed of a succession of at least 5-8 nucleotide or nucleotide analogue units wherein the sequence of the nitrogenous bases of said first fragment is identical in at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% to the complementary sequence of the seed region of the hsa-miR-23b-3p as set forth in SEQ ID NO: 13, and wherein the second fragment is adjacent to the first fragment (i.e., it is located upstream and / or downstream of the first fragment) and it is composed of a succession of at least 7, 8, 9, 10, 11 , 12, 13, 14, 15, or 16 consecutive nitrogen bases of nucleotide or nucleotide analogue units that are identical in at least 60%, 70%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5%, or 100% to the complementary sequence of a region present in SEQ ID NOs: 11. By “adjacent” is referred herein as immediately next to the first fragment, i.e., without any nucleotide in between the first and the second fragments. In some alternative embodiments, the second fragment is located 6, 7, 8, 9, 10, or 11 nucleotides upstream and / or downstream of the first fragment. More preferably, the second fragment is located 1 , 2, 3, 4, or 5 nucleotides upstream and / or downstream of the first fragment.

[0094] In an embodiment, the antagonist is an antimiR and its sequence comprises a fragment composed of a succession of at least 5-8 nucleotide or nucleotide analogue units wherein the sequence of the nitrogenous bases of said nucleotide or nucleotide analogue units is identical in at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% to the complementary sequence of the seed region of the hsa-miR-218-5p as set forth in SEQ ID NO: 12. Preferably, said antimiR comprises a fragment composed of a succession of at least 5-8 nucleotide or nucleotide analogue units that are 100% complementary to the seed region as set forth in SEQ ID NO: 12. In an embodiment, the antagonist is an antimiR whose sequence comprises a first fragment and a second fragment, wherein the first fragment is composed of a succession of at least 5-8 nucleotide or nucleotide analogue units wherein the sequence of the nitrogenous bases of said first fragment is identical in at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% to the complementary sequence of the seed region of the hsa-miR-218-5p as set forth in SEQ ID NO: 12, and wherein the second fragment is adjacent to the first fragment (i.e., it is located upstream and / or downstream of the first fragment) and it is composed of a succession of at least 7, 8, 9, 10, 11 , 12, 13, 14, 15, or 16 consecutive nitrogen bases of nucleotide or nucleotide analogue units that are identical in at least 60%, 70%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5%, or 100% to the complementary sequence of a region present in SEQ ID NOs: 10. By “adjacent” is referred herein as immediately followed to the first fragment, i.e., without any nucleotide in between the first and the second fragments. In some alternative embodiments, the second fragment is located 6, 7, 8, 9, 10, or 11 nucleotides upstream and / or downstream of the first fragment. More preferably, the second fragment is located 1 , 2, 3, 4, or 5 nucleotides upstream and / or downstream of the first fragment.

[0095] Also comprised within the concept of oligonucleotide and / or oligonucleotide analogue molecules useful for the purpose of the present invention and comprised within its scope are those microRNA inhibitors, blockers or antagonists that act on pri-microRNAs or pre- microRNAs, usually altering microRNAs biogenesis and having a negative effect on microRNAs activity, mainly due to a decrease of the available active microRNA. In animal cells, immature pri-miRNAs are processed into pre-miRNAs by the Microprocessor complex in the nucleus, and are then transported into the cytoplasm to undergo further processing into mature miRNAs. It thus must be understood that targeting the pri-microRNA and / or the pre-microRNA of hsa-miR-23b-3p or hsa-miR-218-5p and altering their biogenesis so that the levels of said microRNAs are decreased should also result in a decrease of their activity. Therefore, for the purpose of the present invention, an antagonist of hsa-miR-23b-3p or an antagonist of hsa- miR-218-5p must be understood to comprise not only those molecules capable of acting the mature forms, but also those molecules capable of acting on the pri-microRNA or the pre- microRNA and decreasing the levels of the mature forms of hsa-miR-23b-3p or hsa-miR-218- 5p. In order to design them, it must be taken into account that:

[0096] - The primary microRNA (pri-microRNA) of hsa-miR-23b-3p is the transcripts of gene AOPEP (ENSG00000148120; ch r9: 97488983-97849441).

[0097] - The microRNA precursor (pre-microRNA) of hsa-miR-23b-3p corresponds to genomic positions hg19 chr9:97847490-97847586 [+] and to the sequence:

[0098] CUCAGGUGCUCUGGCUGCUUGGGUUCCUGGCAUGCUGAUUUGUGACUUAAG AUUAAAAUCACAUUGCCAGGGAUUACCACGCAACCACGACCUUGGC (SEQ ID NO: 19). As this sequence is longer than hsa-miR-23b-3p, it is possible to design an antagonist specific to the pre-microRNA.

[0099] - hsa-miR-218-5p has two genomic positions encoding for it and two precursor pre- microRNAs, Pre-hsa-mir-218-1 (chr4:20529898-20530007):

[0100] GUGAUAAUGUAGCGAGAUUUUCUGUUGUGCUUGAUCUAACCAUGUGGUUGCG AGGUAUGAGUAAAACAUGGUUCCGUCAAGCACCAUGGAACGUCACGCAGCUU UCUACA (SEQ ID NO: 20), and Pre-mir-218-2 (chr5:1681951 SI- 168195260): GACCAGUCGCUGCGGGGCUUUCCUUUGUGCUUGAUCUAACCAUGUGGUGGAA CGAUGGAAACGGAACAUGGUUCUGUCAAGCACCGCGGAAAGCACCGUGCUCU CCLIGCA (SEQ ID NO: 21). Both precursors could be used for the design of antagonists.

[0101] - Pre-hsa-mir-218-1 derives from intramolecular hairpin structures located inside the transcripts of gene SLIT2 (ENSG00000145147: chr4:20254883-20621284) while hsa- miR-218-5p-2 derives from the gene SLIT3 (ENSG00000184347, chr5: 168088745- 168728133 for hsa-miR-218-5p-2), which can be regarded, respectively, as their pri- miRNAs. No other mature microRNAs are part of the same cluster. Then, in the case of hsa-miR-218-5p, both the pre-miRNAs or the pri-miRNAs could be envisaged as targets of antagonists to reduce the mature miRNA and increase MBNL protein levels.

[0102] As shown in the examples below, particularly in Table 1 and Table 4, the authors of the present invention developed and optimized several antimiRs against hsa-miR-23b-3p and hsa-miR- 218-5p, whose Tindex was greatly improved with the addition of oleic acid. Among them, the specific sequence of the antimiRs comprising the SEQ ID NOs: 1 (antagonist of the human hsa-miR-218-5p) and SEQ ID NO: 2 (antagonist of the human hsa-miR-23b-3p) are specially mentioned due to their optimal characteristic and efficiency in DM1 cells, as shown in the Example section.

[0103] Further, functional equivalents of SEQ ID NO: 1 or 2 are also contemplated herein, where specific changes in particular nucleobases would not significantly destabilize the molecule and thus, its therapeutic effect would be maintained. Said functional equivalent sequences are set forth in SEQ ID NO: 52-79 (functional equivalents of the antimiR-23b-3p of SEQ ID NO: 2), and SEQ ID NO: 80-110 (functional equivalents of the antimiR-218-5p of SEQ ID NO: 1). By “functional equivalents” is referred herein to other oligonucleotides that differ in their nucleobase sequence from that of SEQ ID NO: 1 or 2, but which perform the same function and provide the same utility or technical effect as SEQ ID NO: 1 or 2. Thus, in an embodiment, the oligonucleotide molecule and / or analogue thereof is an antagonist of the human hsa-miR-218-5p and it comprises, consists, or consists essentially of a fragment composed of a succession of at least 7, 8, 9, 10, 11 , 12, 13, 14, 15, or 16 consecutive nitrogen bases of nucleotide or nucleotide analogue units that are identical in at least 50%, 60%, 70%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% to the sequence of a region present in SEQ ID NO: 1 (TTAGATCAAGCACAA) or SEQ ID NO: 80-110. Preferably, the full length sequence of the nitrogen bases of the nucleotide or nucleotide analogue units comprised in the oligonucleotide molecule and / or analogue thereof is identical in at least 60%, 70%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5%, or 100% to the full length sequence of the nitrogenous bases of the oligonucleotide in SEQ ID NO: 1 or SEQ ID NO: 80-110.

[0104] In a further embodiment, the oligonucleotide molecule and / or analogue thereof is an antagonist of the human hsa-miR-23b-3p and it comprises, consists, or consists essentially of a fragment composed of a succession of at least 7, 8, 9, 10, 11 , 12, 13, 14, 15, or 16 consecutive nitrogen bases of nucleotide or nucleotide analogue units that are identical in at least 50%, 60%, 70%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% to the sequence of a region present in SEQ ID NO: 2 (ATCCCTGGCAATGTGA) or SEQ ID NO: 52-79. Preferably, the full length sequence of the nitrogen bases of the nucleotide or nucleotide analogue units comprised in the oligonucleotide molecule and / or analogue thereof is identical in at least 60%, 70%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5%, or 100% to the full length sequence of the nitrogenous bases of the oligonucleotide in SEQ ID NO: 2 or SEQ ID NO: 52-79.

[0105] It is noted that, in the oligonucleotide molecule and / or analogue thereof according to the present invention, each uracil and thymine base within the full length of the oligonucleotide molecule and / or analogue, preferably each uracil and thymine base in the seed region, can be optionally replaced, respectively, by a thymine or uracil base. This applies for all the “T” nucleobases comprised in all the oligonucleotides disclosed herein, except for SEQ ID NO: 52-110, where at certain positions, a “II” instead of “T” is preferred. In said certain positions, a II, rather than a T, is thus included.

[0106] Likewise, each guanosine base within the full length of the oligonucleotide molecule and / or analogue, preferably each guanosine in the seed region, can be optionally replaced, respectively, by a hypoxanthine base. This applies for all the oligonucleotides disclosed herein. In an embodiment, the oligonucleotide and / or oligonucleotide analogue that is an antagonist human hsa-miR-23b-3p or the human hsa-miR-218-5p is capable of increasing the endogenous levels of MBNL proteins, preferably MBNL1 and / or MBNL2 proteins. Preferably, the oligonucleotide and / or oligonucleotide analogue is identical in at least 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5%, or 100% to the sequence of a region present in SEQ ID NO: 1 (antimiR-218-5p) or 2 (antimiR-23b-3p), or SEQ ID NO: 52-110, and is capable of increasing the endogenous levels of MBNL proteins, preferably MBNL1 and / or MBNL2 proteins. Preferably, the increase in the endogenous levels of MBNL proteins is a statistically significant increase in comparison to untreated cells or untreated tissues, wherein preferably the statistical comparison is performed using a Student’s t-test, see e.g., Fig. 4. Most preferably, the increase, preferably statistically significant increase, in the endogenous levels of MBNL proteins is of at least 1.2-, 1.3-, 1.4-, or 1 .5-fold change in treated cells of muscular tissues (more preferably quadriceps and gastrocnemius) with respect to untreated cells of muscular tissues. Preferably, the increase in endogenous levels of MBNL proteins in treated cells or tissues is of at least 15%, 20%, 30%, 40%, 50% or more when compared to untreated cells or tissues. By “untreated cell or tissue” is referred herein to one or more cells or tissues, including whole animals such as mice, that are healthy or present a DM 1 phenotype, and that have not been treated with the oligonucleotide and / or oligonucleotide analogue of the first aspect or any of its embodiments. Preferably, the untreated cell is a muscular cells and the untreated tissue is muscular tissue.

[0107] The antimiRs of the present invention, including those as defined in SEQ ID NO: 1 or 2, can be further optimized in order to improve their in vivo stability and efficacy. To do so, several modifications in their chemical architecture have been described (for a review, see Mckenzie et al., Recent progress in non-native nucleic acid modifications. Chem. Soc. Rev., 2021 ,50, 5126-5164). These modifications can be made in the pentose (in the preferred embodiment in which the oligonucleotide is an oligoribonucleotide, the modification would be in the ribose), in the internucleotide linkage, or in the nucleobase, or in a combination thereof. When the oligonucleotides or oligoribonucleotides of the present invention are chemically modified, they are considered in the context of the present invention as oligonucleotide analogues or oligoribonucleotide analogues, respectively. In an embodiment, the antimiR is an oligonucleotide analogue and it comprises at least six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen or sixteen chemical modifications along the whole molecule. In an embodiment, the antimiR is an oligoribonucleotide analogue that comprises all its nucleotides chemically modified. Modifications in the internucleotide linkage It is considered included in the possible modifications that give rise to the oligonucleotides analogues of the present invention the modifications that give rise to phosphorothioate linkages, which are modifications that affect phosphate groups that are part of the "skeleton" of the polynucleotide chain, giving rise to the introduction of a sulphur atom in substitution of an oxygen atom of the phosphate group that is not acting as a bridge between nucleotides; these modifications cause the linkages between nucleotides to be resistant to degradation by nucleases, in addition to other desirable pharmacological properties, so they are commonly inserted between the last 3-5 nucleotides at the 5' or 3' ends of oligonucleotides to inhibit degradation by exonucleases, increasing their stability.

[0108] In a preferred embodiment, at least one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or more than fifteen of the nucleotides comprised in the oligonucleotide or oligonucleotide analogue molecule according to the first aspect or any of its embodiments are chemically linked by a phosphorothioate linkage. Preferably, the oligonucleotide and / or oligonucleotide analogue according to the first aspect or any of its embodiments comprises between 10 to 30 nucleotides in length and comprises at least two nucleotides chemically linked by a phosphorothioate linkage, wherein said oligonucleotide and / or oligonucleotide analogue is conjugated at its 3' and / or 5' ends to at least one oleic acid molecule. In an even more preferred embodiment, the oligonucleotide or oligonucleotide analogue molecule comprises a mixture of PS and phosphodiester (PO) linkages, wherein at least two nucleotides of said molecule are chemically linked by a phosphorothioate linkage and at least two nucleotides of said molecule are linked by a phosphodiester linkage. In a further preferred embodiment, the number of nucleotides that are chemically linked by a phosphorothioate (PS) linkage is greater than the number of nucleotides that are chemically linked by a phosphodiester linkage. In an embodiment, the oligonucleotide molecule and / or analogue thereof is between 13-17 nucleotides long, and comprises at least 7, 8, 9, or 10 nucleotides that are chemically linked by a phosphorothioate (PS) linkage. In an embodiment, the ratio of PS:PO in the oligonucleotide molecule and / or analogue thereof is 1.2:1 , 1.5:1 , 1.7:1 , 2:1 , 2.2:1 , 2.5:1 , 2.7:1 , 3:1. Preferably, the ratio PS: PS in the oligonucleotide molecule and / or analogue thereof is between 1.2:1 and 2.7:1 , more preferably 1.5:1 or 2.5:1. By “ratio PS:PO” is referred herein as the number of PS linkages per PO linkage. For instance, when an oligonucleotide molecule consists of 15 nucleotides and has 10 PS linkages and 4 POs linkages (see, e.g., SEQ ID NO: 7), it is said that said molecule has a ratio PS:PO of 2.5:1. In an embodiment, more than 50%, 55%, preferably 60%, 70% or 75% of the linkages between the nucleotides are PS linkages. In an embodiment, all the nucleotides comprised in the oligonucleotide or oligonucleotide analogue molecule are chemically linked by a phosphorothioate linkage. As stated above, preferably, the oligonucleotide or oligonucleotide analogue molecule is an antagonist of a microRNA (i.e., an antimiR).

[0109] Modifications in the pentose, preferably in the ribose: The most widely used sugar modifications are those that are located in the OH group at the 2' position. Among them, the most important ones in the context of the present invention are 2'fluoro (2’F: introduction of a fluorine atom at the ribose 2’ position), 2'-O-methoxyethyl (MOE), or 2'0-methyl (OMe) modifications. Thus, in an embodiment, the oligonucleotide or oligonucleotide analogue molecule, preferably the antimiR, according to the present invention is chemically modified to comprise at least one pentose with one of the following modifications: 2'fluoro (2’F: introduction of a fluorine atom at the ribose 2’ position), 2'-O-methoxyethyl (MOE), and / or 2'0-methyl (OMe). In an embodiment, all the nucleotides in the oligonucleotide molecule are 2'OME modified nucleotides.

[0110] Another modification that can be performed in the oligonucleotide or oligonucleotide analogue molecule, preferably the antimiR, of the present invention is the formation of Bicyclic 2'-4' modifications. There are a variety of ribose derivatives that lock the carbohydrate ring into the 3'-encfo conformation by the formation of bicyclic structures with a bridge between the 2' oxygen and the 4' position. In an embodiment, the formation of a bridge between the 2' oxygen and the 4' carbon locks the ribose in the 3' endo conformation, leading to a modification called locked nucleic acids, or LNA. The introduction of LNAs modifications highly increases the stability of the antimiR-target miRNA hybrids making them significantly more thermodynamically stable and resistant to degradation, which especially happens when said modifications are placed at the ends of the molecule. In an embodiment, the first nucleotide starting from the 3' region comprises an LNA modification. In another embodiment, each of the two first oligonucleotides starting from the 5' region comprises an LNA modification. More modifications of bicyclic nucleotides include bridged nucleic acids, ethyl-bridged (ENAs), constrained ethyl (cEt) nucleic acids, bicyclic (bicyclo-DNA) and tricyclic (Tricyclo-DNA)s structures and Conformationally Restricted Nucleotides (CRN) with a varying affinity for target sequences.

[0111] More modifications include the so-called PMOs (nucleic acids where ribose has been substituted by a morpholino group). By “morpholino” is understood as bases attached to a backbone of methylenemorpholine rings linked through phosphorodiamidate groups. Another backbone modifications are the so-called PNAs ("Peptide Nucleic Acid1: peptide nucleic acid in which the ribose-phosphate group is replaced by an amino acid moiety so that the skeleton of the nucleotide analogue is a structure of repeat units of N-(2-aminoethyl)-glycine linked by peptide linkages).

[0112] In an embodiment, an oligonucleotide or oligonucleotide analogue molecule, preferably the antimiR, according to the present invention, is chemically modified to comprise at least one pentose of the nucleotides forming the antimiR comprises morpholino nucleic acids (PMOs) or peptide nucleic acids (PNAs).

[0113] Modifications in the nucleobase: Because of its frequent use, also included among the chemical modifications that give rise to the oligonucleotides, preferably oligoribonucleotide analogues of the invention, preferably the antimiR, is the 5 methylation of the nitrogenous base cytosine (C), which decreases the detection of the oligonucleotide analogue by the immune system. Thus, in an embodiment, at least one, two, three, four, five, or more than five of the nucleotides comprised in the oligonucleotide and / or oligonucleotide analogue molecule, preferably the antimiR, according to the first aspect or any of its embodiments comprises a methylated cytosine. In a preferred embodiment, all the cytosines in the oligonucleotide or oligonucleotide analogue molecule, preferably the antimiR, according to the first aspect or any of its embodiments, are methylated.

[0114] Another possible modification is 2,6 diaminopurine that is able to form base pairs with thymidine or uridine with an extra H-bond (3 H-bonds instead of 2 present in the natural A:T base pairs). Thus, in an embodiment, at least one, two, three, four, five, or more than five of the nucleotides comprised in the oligonucleotide and / or oligonucleotide analogue molecule according to the first aspect or any of its embodiments comprises a 2,6 diaminopurine.

[0115] As can be deduced from the definition of "oligonucleotide molecules" and that of "oligonucleotide analogues", also included within the definition of oligonucleotide analogues are hybrid molecules, in which some units present modifications and others do not, as well as hybrids between analogues of nucleic acids and peptides or, even, hybrid molecules in which some of the nucleotide units are nucleotides (or analogues thereof) and others are deoxynucleotides (nucleotides in which the sugar is deoxyribose), as well as analogues of the latter, i.e. RNA-DNA hybrids and analogues thereof. Other chemical modifications are possible and known, which are also comprised within the possible modifications that give rise to oligonucleotide analogues. With regard to the possible chemical modifications included in the oligonucleotide and / or oligonucleotide analogue molecule, the term will be applied especially in the case of one or more of the usual modifications known to those skilled in the art of molecular biology, in terms of basic research and, in particular, in the search for therapeutic applications of these molecules. Information on such modifications can be found in the general common knowledge.

[0116] Modifications of the oligonucleotide and / or oligonucleotide analogue molecule with other nonnucleotide molecules.

[0117] As stated above, the first aspect of the present invention provides an oligonucleotide and / or oligonucleotide analogue molecule that is preferably an antimiR, more preferably an antagonist of the human hsa-miR-23b-3p or of the human hsa-miR-218-5p, or a mixture of two or more of said molecules, wherein the oligonucleotide and / or oligonucleotide analogue molecule is conjugated to at least one oleic acid molecule at the 3' and / or 5' ends of said oligonucleotide and / or oligonucleotide analogue molecule. Thus, all the oligonucleotides included in the present invention are conjugated to at least one oleic acid molecule at their 3’ and / or 5’.

[0118] In some embodiments, other non-nucleotide molecules, such as organic compounds, can also be conjugated at the 3' and / or 5' end of the oligonucleotide and / or oligonucleotide analogue molecule. Said conjugation can be a direct conjugation or by means of a spacer molecule. By “spacer molecule” is referred herein to any molecule or molecules that connect, on the one hand, the oligonucleotide or oligonucleotide analogue and, on the other hand, the non- nucleotide molecule, preferably the oleic acid. The spacer molecule or molecules can be coupled at the 3' or 5' end of the oligonucleotide or oligonucleotide analogue. Preferably, the spacer molecule is covalently bound to said oligonucleotide and to the oleic acid. Preferably, the spacer molecule(s) are bound on one end via a bond between a terminal carbon on the spacer to an oxygen group in the 3’terminal phosphate of the oligonucleotide and on the other end by a bond between the terminal nitrogen group on the linker which forms an amide bond with the carboxy group of oleic acid, e.g. as depicted in Figure 8.

[0119] In a preferred embodiment, the spacer molecule is selected from the group consisting of 3- aminopropyl (NHC3), 5-aminopentyl (NHC5), 6-aminohexyl (NHC6), threoninol or a derivative thereof. In other embodiments, the spacer molecule or molecules may comprise a Thiol- Modifier C6 S-S (C6SSC6). In a further embodiment, the spacer may comprise a Thiol- Modifier C6 S-S (C6SSC6) directly bound to the oligonucleotide, and followed by a 3- aminopropyl (NHC3), 6-aminohexyl (NHC6), threoninol or a derivative thereof (see Fig. 8). In some embodiments, the oligonucleotide may be provided as a prodrug and may comprise a spacer molecule comprising or consisting of a self-immolative group. By “self-immolative” group is referred herein to a molecule that will spontaneous and irreversibly disassembly from the molecule to which it is conjugated, in this case the oligonucleotide. In an embodiment, the self-immolative group is a disulfide linkage that will be reduced inside the cells by naturally occurring thiols such as glutathione, resulting in the release of the oligonucleotide.

[0120] The spacer may be an aliphatic linear or branched hydrocarbon chain, cyclohexyl phenyl and other aromatic spacers, as well as polar spacers based on one or several units of ethylene glycol, glycerol, amino acid, peptide, or carbohydrates. In some cases, the oleyl derivative can be covalently linked to the amino groups by an amide linkage or directly to the nucleobases with an amine linkage as well as to the phosphate linkage as oleyl phosphate.

[0121] Preferably, the oleic acid is conjugated to the oligonucleotide at its 3' end. More preferably, the oleic acid is conjugated by means of a spacer molecule, preferably NHC6, threoninol or NHC3, as shown in Fig. 8. Please note that the addition of the spacer molecule as a connector between the oligonucleotide and the oleic acid is not mandatory, see, e.g., SEQ ID NO: 51 wherein the oleic acid is conjugated at the 5' end of the oligonucleotide and / or oligonucleotide analogue molecule by means of direct conjugation.

[0122] Preferably, all of the oligonucleotides molecules disclosed in the present invention are conjugated to at least one oleic acid molecule at their 3’ and / or 5’ ends, wherein the oligonucleotides molecules further comprise at least two nucleotides chemically linked by a phosphorothioate linkage. Preferably, the oligonucleotides molecules further comprise at least two nucleotides chemically linked by a phosphorothioate linkage and at least two nucleotides of said molecule are linked by a phosphodiester linkage. More preferably, the number of nucleotides that are chemically linked by a phosphorothioate (PS) linkage is greater than the number of nucleotides that are chemically linked by a phosphodiester (PO) linkage.

[0123] Different means known in the art can be used to prepare the oligonucleotides of the present invention. In particular, the oligonucleotides may be synthesized by solid-phase or liquid-phase methods. The oligonucleotide functionalized with the spacer molecule as well as the oleyloligonucleotide conjugate may be prepared using solid-phase oligonucleotide synthesis protocols. In this methodology, a solid support such as controlled pore glass (CPG) is functionalized with the first nucleotide in the 3’-end of the oligonucleotide sequence and the oligonucleotide is usually synthesized in the 3’ to 5’ direction. The introduction of a spacer molecule at the 5’ position is performed by using a phosphoramidite derivative of the spacer molecule that will introduce the spacer molecule through a phosphate linkage to the 5’-position of the oligonucleotide. The introduction of the spacer molecule at the 3’ position requires the preparation of a solid support functionalized with a linker molecule, which is a molecule used to bind the nucleotide to the support. Examples of linker molecules are labile compounds such as phthalimido or succinyl linkers. Of note, while the spacer is conjugated to the oligonucleotide molecule and remains conjugated thereto, the linker is a temporary conjugation that aims the immobilization of the oligonucleotide when it is being synthesized using solid-phase methods. In the case of liquid-phase preparation method, instead of the type of linker defined for the solid-phase method, a protecting group may be used, such as benzoyl or acetyl.

[0124] Among all the oligonucleotides disclosed in the context of the present invention, the following embodiments, including the modifications and combination of modifications, are considered preferred:

[0125] In an embodiment, the oligonucleotide and / or oligonucleotide analogue molecule according to the first aspect or any of its embodiments comprises between 10 to 30 nucleotides in length and is an antimiR-type oligonucleotide analogue, wherein at least two nucleotides of said molecule are chemically linked by a phosphorothioate linkage and at least two nucleotides of said molecule are linked by a phosphodiester linkage, preferably wherein the number of nucleotides that are chemically linked by a phosphorothioate linkage is greater than the number of nucleotides that are chemically linked by a phosphodiester linkage, and wherein: a. the sequence of the nitrogenous bases of the monomeric units of nucleotides or nucleotide analogues is at least 85%, 90%, 93%, 95%, 98%, or 100% complementary to the endogenous molecules to which they must bind (preferably, a microRNA molecule, more preferably the hsa-miR-23b-3p of SEQ ID NO: 11 or hsa-miR-218-5p of SEQ ID NO: 10), and b. it is conjugated at the 5'-end and / or at the 3'-end with at least one oleic acid molecule, preferably by means of a spacer molecule.

[0126] In an embodiment, the oligonucleotide and / or oligonucleotide analogue molecule according to the first aspect or any of its embodiments comprises between 10 to 30 nucleotides in length and is an antimiR-type oligonucleotide analogue, wherein at least two nucleotides of said molecule are chemically linked by a phosphorothioate linkage and at least two nucleotides of said molecule are linked by a phosphodiester linkage, preferably wherein the number of nucleotides that are chemically linked by a phosphorothioate linkage is greater than the number of nucleotides that are chemically linked by a phosphodiester linkage, and wherein: a. the sequence of the oligonucleotide comprises a first fragment and a second fragment, wherein the first fragment is composed of a succession of at least 5-8 nucleotide or nucleotide analogue units that is identical in at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% to the complementary sequence of the seed region of the hsa-miR-23b-3p as set forth in SEQ ID NO: 13, and wherein the second fragment is adjacent to the first fragment (i.e., it is located upstream and / or downstream of the first fragment) and it is composed of a succession of at least 7, 8, 9, 10, 11 , 12, 13, 14, 15, or 16 consecutive nitrogen bases of nucleotide or nucleotide analogue units that are identical in at least 60%, 70%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5%, or 100% to the complementary sequence of a region present in SEQ ID NOs: 11 , and b. it is conjugated at the 5'-end and / or at the 3'-end with at least one oleic acid molecule, preferably by means of a spacer molecule.

[0127] In an embodiment, the oligonucleotide and / or oligonucleotide analogue molecule according to the first aspect or any of its embodiments comprises between 10 to 30 nucleotides in length and is an antimiR-type oligonucleotide analogue, wherein at least two nucleotides of said molecule are chemically linked by a phosphorothioate linkage and at least two nucleotides of said molecule are linked by a phosphodiester linkage, preferably wherein the number of nucleotides that are chemically linked by a phosphorothioate linkage is greater than the number of nucleotides that are chemically linked by a phosphodiester linkage, and wherein: a. the sequence of the oligonucleotide comprises a first fragment and a second fragment, wherein the first fragment is composed of a succession of at least 5-8 nucleotide or nucleotide analogue units that is identical in at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% to the complementary sequence of the seed region of the hsa-miR-218-5p as set forth in SEQ ID NO: 12, and wherein the second fragment is adjacent to the first fragment (i.e., it is located upstream and / or downstream of the first fragment) and it is composed of a succession of at least 7, 8, 9, 10, 11 , 12, 13, 14, 15, or 16 consecutive nitrogen bases of nucleotide or nucleotide analogue units that are identical in at least 60%, 70%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5%, or 100% to the complementary sequence of a region present in SEQ ID NO: 10, and b. it is conjugated at the 5'-end and / or at the 3'-end with at least one oleic acid molecule, preferably by means of a spacer molecule. In an embodiment, the oligonucleotide and / or oligonucleotide analogue molecule according to the first aspect or any of its embodiments comprises between 10 to 30 nucleotides in length, wherein: a. at least two nucleotides of said molecule are chemically linked by a phosphorothioate linkage and at least two nucleotides of said molecule are linked by a phosphodiester linkage, preferably wherein the number of nucleotides that are chemically linked by a phosphorothioate linkage is greater than the number of nucleotides that are chemically linked by a phosphodiester linkage, b. its sequence comprises, consists, or consists essentially of a fragment composed of a succession of at least ?, 8, 9, 10, 11 , 12, 13, 14, 15, or 16 consecutive nitrogen bases of nucleotide or nucleotide analogue units that are identical in at least 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% to the sequence of a region present in SEQ ID NO: 1 or 2 or SEQ ID NO: 52-110, and c. it is conjugated at the 5'-end and / or at the 3'-end with at least one oleic acid molecule, preferably by means of a spacer molecule.

[0128] In an embodiment, the oligonucleotide and / or oligonucleotide analogue molecule according to the first aspect or any of its embodiments comprises between 10 to 30 nucleotides in length and is an antimiR-type oligonucleotide analogue wherein at least two nucleotides of said molecule are chemically linked by a phosphorothioate linkage and at least two nucleotides of said molecule are linked by a phosphodiester linkage, preferably wherein the number of nucleotides that are chemically linked by a phosphorothioate linkage is greater than the number of nucleotides that are chemically linked by a phosphodiester linkage, and wherein: a. at least one of the monomeric units is a nucleotide analogue that presents one or more chemical modifications in the pentose moiety, preferably in the ribose, in the internucleotide linkage, in the nitrogenous base, or in all of them, b. the sequence of the nitrogenous bases of the monomeric units of nucleotides or nucleotide analogues is at least 85%, 90%, 93%, 95%, 98%, or 100% identical to the sequence of nitrogenous bases of the monomeric units of nucleotides of the oligonucleotide SEQ ID NO: 1 or of the oligonucleotide SEQ ID NO: 2, or of their functional equivalents SEQ ID NO: 52-110, and that, c. it is conjugated at the 5'-end and / or at the 3'-end with at least one oleic acid molecule, preferably by means of a spacer molecule.

[0129] In a preferred embodiment, at least one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or more than fifteen of the nucleotides comprised in the oligonucleotide or oligonucleotide analogue molecule according to the first aspect or any of its embodiments comprise at least one modification selected from the group comprising or consisting of: locked nucleic acids, 2'-methoxy, 2'-O- methoxyethyl-, 2’fluoro, BNA, PMO, PNA, CRN, 2,6 diaminopurine, methylated cytosine and / or any combination thereof.

[0130] In a preferred embodiment, the oligonucleotide and / or oligonucleotide analogue molecule comprises between 10 to 30 nucleotides in length and is an antagonist of the human hsa-miR- 23b-3p or hsa-miR-218-5p comprises at least two nucleotides that are chemically linked by a phosphorothioate linkage and at least two nucleotides that are chemically linked by a phosphodiester linkage, wherein preferably the number of nucleotides that are chemically linked by a phosphorothioate linkage is greater than the number of nucleotides that are chemically linked by a phosphodiester linkage, and wherein said oligonucleotide is conjugated to at least one oleic acid molecule, wherein said one oleic acid molecule is conjugated at the 3' and / or 5' ends of said oligonucleotide and / or analogue thereof. Preferably, said oligonucleotide and / or oligonucleotide analogue that is conjugated to at least one molecule of oleic acid at its 3' and / or 5' ends and that comprises more PS linkages than PO linkages comprises, consists, or consists essentially of a fragment composed of a succession of at least 15 consecutive nitrogen bases of nucleotide or nucleotide analogue units that are identical in at least 50%, 60%, 70%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% of the sequence to a region present in SEQ ID NO: 1 (antimiR-218-5p) or SEQ ID NO: 2 (antimiR-23b-3p), or any of their functional equivalents of SEQ ID NO: 52-110.

[0131] In a preferred embodiment, at least three, four, five, six, seven, eight, or more than eight of the nucleotides comprised in the oligonucleotide and / or oligonucleotide analogue molecule are chemically modified, wherein said chemical modification is selected from the group of i) 2'-O- methyl (2'OMe), ii) 2'-O-M ethoxyethyl (2' MOE), and / or iii) an extra bridge connecting the 2' oxygen and 4' carbon (LNA), and / or any combination thereof. In a further embodiment, the nucleotides comprised in oligonucleotide analogue molecule are chemically modified so as to include an extra bridge connecting the 2' oxygen and 4' carbon (LNA) of at least the nucleotides located at the 3' and 5' ends of the oligonucleotide. More preferably, the LNA modification is introduced in at least the last 4th, 3rd, preferably 2nd, or last nucleotide(s) located at the 3' and 5' ends of the oligonucleotide. Also, preferably, at least one of the nucleotides comprised in the oligonucleotide and / or oligonucleotide analogue molecule is 2,6 diaminopurine and / or at least a methylated cytosine.

[0132] In a further embodiment, the oligonucleotide molecule and / or analogue thereof is an antagonist of the human hsa-miR-23b-3p and it comprises, consists, or consists essentially of a fragment composed of a succession of at least 7, 8, 9, 10, 11 , 12, 13, 14, 15, or 16 consecutive nitrogen bases of nucleotide or nucleotide analogue units that are identical in at least 50%, 60%, 70%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% to the sequence of a region present in SEQ ID NO: 3 or SEQ ID NO: 22 (MD23b-2 V2 3' Ol), wherein said oligonucleotide molecule and / or analogue thereof comprises at least an oleic acid conjugated at the 3' end. Preferably, the full-length sequence of the nitrogen bases of the nucleotide or nucleotide analogue units comprised in the oligonucleotide molecule and / or analogue thereof is identical in at least 60%, 70%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5%, or 100% to the full-length sequence of the nitrogenous bases of the oligonucleotide in SEQ ID NO: 3 or SEQ ID NO: 22 (MD23b-2 V2 3'01), wherein said oligonucleotide molecule and / or analogue thereof comprises at least an oleic acid conjugated at the 3' end. In an embodiment, the oligonucleotide consists of SEQ ID NO: 3 or SEQ ID NO:

[0133] 22.

[0134] In a further embodiment, the oligonucleotide molecule and / or analogue thereof is an antagonist of the human hsa-miR-23b-3p and it comprises, consists, or consists essentially of a fragment composed of a succession of at least 7, 8, 9, 10, 11 , 12, 13, 14, 15, or 16 consecutive nitrogen bases of nucleotide or nucleotide analogue units that are identical in at least 50%, 60%, 70%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% to the sequence of a region present in SEQ ID NO: 4 or SEQ ID NO: 23 (MD23b-2 PS / PO 3' Ol), wherein said oligonucleotide molecule and / or analogue thereof comprises at least an oleic acid conjugated at the 3' end. Preferably, the full length sequence of the nitrogen bases of the nucleotide or nucleotide analogue units comprised in the oligonucleotide molecule and / or analogue thereof is identical in at least 60%, 70%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5%, or 100% to the full length sequence of the nitrogenous bases of the oligonucleotide in SEQ ID NO: 4 or SEQ ID NO: 23 (MD23b-2 PS / PO 3' Ol), wherein said oligonucleotide molecule and / or analogue thereof comprises at least an oleic acid conjugated at the 3' end. In an embodiment, the oligonucleotide consists of SEQ ID NO: 4 or SEQ ID NO:

[0135] 23.

[0136] In a further embodiment, the oligonucleotide molecule and / or analogue thereof is an antagonist of the human hsa-miR-23b-3p and it comprises, consists, or consists essentially of a fragment composed of a succession of at least 7, 8, 9, 10, 11 , 12, 13, 14, 15, or 16 consecutive nitrogen bases of nucleotide or nucleotide analogue units that are identical in at least 50%, 60%, 70%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% to the sequence of a region present in SEQ ID NO: 5 or SEQ ID NO: 24 or SEQ ID NO: 51 (MD23b-2 PS / PO 5' Ol), wherein said oligonucleotide molecule and / or analogue thereof comprises at least an oleic acid conjugated at the 5' end. Preferably, the full length sequence of the nitrogen bases of the nucleotide or nucleotide analogue units comprised in the oligonucleotide molecule and / or analogue thereof is identical in at least 60%, 70%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5%, or 100% to the full length sequence of the nitrogenous bases of the oligonucleotide in SEQ ID NO: 5 or SEQ ID NO: 24 or SEQ ID NO: 51 (MD23b-2 PS / PO 5' Ol), wherein said oligonucleotide molecule and / or analogue thereof comprises at least an oleic acid conjugated at its 5' end. In an embodiment, the oligonucleotide consists of SEQ ID NO: 5 or SEQ ID NO: 24 or SEQ ID NO: 51.

[0137] In a further embodiment, the oligonucleotide molecule and / or analogue thereof is an antagonist of the human hsa-miR-23b-3p and it comprises, consists, or consists essentially of a fragment composed of a succession of at least 7, 8, 9, 10, 11 , 12, 13, 14, 15, or 16 consecutive nitrogen bases of nucleotide or nucleotide analogue units that are identical in at least 50%, 60%, 70%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% to the sequence of a region present in SEQ ID NO: 49 or SEQ ID NO: 50 (MD23b-2 V2 3' Ol with C6SSC6), wherein said oligonucleotide molecule and / or analogue thereof comprises at least an oleic acid conjugated at the 3' end. Preferably, the full length sequence of the nitrogen bases of the nucleotide or nucleotide analogue units comprised in the oligonucleotide molecule and / or analogue thereof is identical in at least 60%, 70%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5%, or 100% to the full length sequence of the nitrogenous bases of the oligonucleotide in SEQ ID NO: 49 or SEQ ID NO: 50 (MD23b-2 V2 3' Ol with C6SSC6), wherein said oligonucleotide molecule and / or analogue thereof comprises at least an oleic acid conjugated at its 5' end. In an embodiment, the oligonucleotide consists of SEQ ID NO: 49 or SEQ ID NO: 50 (MD23b-2 V2 3' Ol with C6SSC6).

[0138] In a further embodiment, the oligonucleotide molecule and / or analogue thereof is an antagonist of the human hsa-miR-218-5p and it comprises, consists, or consists essentially of a fragment composed of a succession of at least 7, 8, 9, 10, 11 , 12, 13, 14, 15, or 16 consecutive nitrogen bases of nucleotide or nucleotide analogue units that are identical in at least 50%, 60%, 70%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% to the sequence of a region present in SEQ ID NO: 7 or SEQ ID NO: 25 (hsa-miR-218-5p MOE Oleic 3'), wherein said oligonucleotide molecule and / or analogue thereof comprises at least an oleic acid conjugated at the 3' end. Preferably, the full length sequence of the nitrogen bases of the nucleotide or nucleotide analogue units comprised in the oligonucleotide molecule and / or analogue thereof is identical in at least 60%, 70%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5%, or 100% to the full length sequence of the nitrogenous bases of the oligonucleotide in SEQ ID NO: 7 or SEQ ID NO: 25 (hsa-miR-218-5p MOE Oleic 3'), wherein said oligonucleotide molecule and / or analogue thereof comprises at least an oleic acid conjugated at the 3' end. In an embodiment, the oligonucleotide consists of SEQ ID NO: 7 or SEQ ID NO: 25.

[0139] In a further embodiment, the oligonucleotide molecule and / or analogue thereof is an antagonist of the human hsa-miR-218-5p and it comprises, consists, or consists essentially of a fragment composed of a succession of at least 7, 8, 9, 10, 11 , 12, 13, 14, 15, or 16 consecutive nitrogen bases of nucleotide or nucleotide analogue units that are identical in at least 50%, 60%, 70%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% to the sequence of a region present in SEQ ID NO: 8 or SEQ ID NO: 26 (hsa-miR-218-5p MOE DD Oleic 3'), wherein said oligonucleotide molecule and / or analogue thereof comprises at least an oleic acid conjugated at the 3' end. Preferably, the full length sequence of the nitrogen bases of the nucleotide or nucleotide analogue units comprised in the oligonucleotide molecule and / or analogue thereof is identical in at least 60%, 70%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5%, or 100% to the full length sequence of the nitrogenous bases of the oligonucleotide in SEQ ID NO: 8 or SEQ ID NO: 26 (hsa-miR-218-5p MOE DD Oleic 3'), wherein said oligonucleotide molecule and / or analogue thereof comprises at least an oleic acid conjugated at the 3' end. In an embodiment, the oligonucleotide consists of SEQ ID NO: 8 or SEQ ID NO: 26.

[0140] In a further embodiment, the oligonucleotide molecule and / or analogue thereof is an antagonist of the human hsa-miR-218-5p and it comprises, consists, or consists essentially of a fragment composed of a succession of at least 7, 8, 9, 10, 11 , 12, 13, 14, 15, or 16 consecutive nitrogen bases of nucleotide or nucleotide analogue units that are identical in at least 50%, 60%, 70%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% to the sequence of a region present in SEQ ID NO: 9 or SEQ ID NO: 27 (hsa-miR-218-5p OME / MOE Oleic 3'), wherein said oligonucleotide molecule and / or analogue thereof comprises at least an oleic acid conjugated at the 3' end. Preferably, the full length sequence of the nitrogen bases of the nucleotide or nucleotide analogue units comprised in the oligonucleotide molecule and / or analogue thereof is identical in at least 60%, 70%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5%, or 100% to the full length sequence of the nitrogenous bases of the oligonucleotide in SEQ ID NO: 9 or SEQ ID NO: 27 (hsa-miR-218-5p OME / MOE Oleic 3'), wherein said oligonucleotide molecule and / or analogue thereof comprises at least an oleic acid conjugated at the 3' end. In an embodiment, the oligonucleotide consists of SEQ ID NO: 9 or SEQ ID NO: 27.

[0141] In a further embodiment, the oligonucleotide molecule and / or analogue thereof is an antagonist of the human hsa-miR-218-5p and it comprises, consists, or consists essentially of a fragment composed of a succession of at least 7, 8, 9, 10, 11 , 12, 13, 14, 15, or 16 consecutive nitrogen bases of nucleotide or nucleotide analogue units that are identical in at least 50%, 60%, 70%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% to the sequence of a region present in SEQ ID NO: 14 or SEQ ID NO: 28 (hsa-miR-218-5p OME / MOE Oleic 3'2), wherein said oligonucleotide molecule and / or analogue thereof comprises at least an oleic acid conjugated at the 3' end. Preferably, the full length sequence of the nitrogen bases of the nucleotide or nucleotide analogue units comprised in the oligonucleotide molecule and / or analogue thereof is identical in at least 60%, 70%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5%, or 100% to the full length sequence of the nitrogenous bases of the oligonucleotide in SEQ ID NO: 14 or SEQ ID NO: 28 (hsa-miR-218- 5p OME / MOE Oleic 3'2), wherein said oligonucleotide molecule and / or analogue thereof comprises at least an oleic acid conjugated at the 3' end. In an embodiment, the oligonucleotide consists of SEQ ID NO: 14 or SEQ ID NO: 28.

[0142] Preferably, the oligonucleotide molecule and / or analogue thereof of the first aspect comprises, or consists of SEQ ID NOs SEQ ID NOs: 3, 4, 5, 22, 23, 24, 49, 50 or 51 (antagonists of hsa- miR-23b) or SEQ ID NOs: 7, 8, 9, 14, 25, 26, 27, or 28 (antagonists of hsa-miR-218-5p), or a sequence that has 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NOs: 3, 4, 5, 22, 23, 24, 49, 50, 51 , 7, 8, 9, 14, 25, 26, 27, or 28.

[0143] Preferably, the oligonucleotide and / or oligonucleotide analogue is identical in at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5%, or 100% to any of SEQ ID NOs: 3, 4, 5, 22, 23, 24, 49, 50, 51 , 7, 8, 9, 14, 25, 26, 27, or 28, preferably to SEQ ID NOs: 3, 4, 7, 22, 23 or 25, and is capable of increasing, preferably statistically increasing, the endogenous levels of MBNL proteins, preferably MBNL1 and / or MBNL2 proteins in comparison to untreated cells or tissue. Most preferably, the oligonucleotide molecule and / or analogue thereof of the first aspect consists of SEQ ID NOs: 3, 4, 5, 22, 23, 24, 49, 50, 51 , 7, 8, 9, 14, 25, 26, 27, or 28. It is noted that, in the context of the present invention, when a oligonucleotide molecule and / or analogue thereof is said to specifically consists of a specific SEQ ID NO, it is understood that said oligonucleotide molecule and / or analogue thereof also consists of the chemical modifications, spacer molecule, and oleic acid conjugation as set forth in said SEQ ID NO. For instance, when an oligonucleotide molecule and / or analogue thereof consists of SEQ ID NO: 3, 4, or 7, it is interpreted that said oligonucleotide molecule and / or analogue thereof consists of the nucleotide sequence defined in SEQ ID NOs 3, 4, or 7, and the chemical modifications, spacer, and oleic acid conjugation defined in said SEQ ID NOs: 3, 4 or 7. The detailed description of the chemical modifications included in each SEQ ID NOs is included in section “Sequence Listing”.

[0144] Additionally, also comprised within the present invention are compounds such as oligonucleotide molecules and / or analogues thereof in the form of a prodrug, i.e. , in a form or nature that is not fully active but that will be converted or metabolized within the body upon administration to give rise to the fully pharmacologically active oligonucleotides molecules and / or analogues thereof described herein.

[0145] The cellular expression of the microRNA to be inhibited should also be considered. According to miRGator v3.0 (miRGator v3.0: a microRNA portal for deep sequencing, expression profiling and mRNA targeting. Sooyoung Cho et al., Nucleic Acids Research, Volume 41 , Issue D1 , 1 January 2013, Pages D252-D257, https: / / doi.org / 10.1093 / nar / gks1168), hsa-miR-218-5p is expressed in: adipose tissue, brain, central nervous system, kidney, heart, liver and biliary system, lung, pharynx, nasopharynx, nose, placenta, spleen, stem cells, testicle, uterus and joints. hsa-miR-23b-3p, on the other hand, is expressed in: the central nervous system, gastrointestinal tract, adipose tissue, breast, bladder, heart, keratinocytes, kidney, liver and biliary system, lung, lymphoid cells, nose, pharynx, placenta, prostate, skin, spleen, stem cells, testicle, thyroid gland and uterus. Thus, a possible embodiment of the invention considered is an oligonucleotide and / or oligonucleotide analogue molecule that is preferably an antimiR, more preferably an antagonist of hsa-miR-218-5p or hsa-miR-23b-3p, or a mixture of two or more of said molecules, and that the target miRNA is expressed at least in one or more organs selected from the group of the brain, cerebellum, hippocampus or other organs of the central nervous system, skeletal muscle, heart, adipose tissue, kidney, liver and biliary system, lung, pharynx, nasopharynx, nose, placenta, spleen, testicle, uterus, gastrointestinal tract, breast, bladder, prostate, skin, keratinocytes and lymphoid cells or in one or more cells of a primary culture from one of those organs or of an established cell line derived from one of those organs (including induced pluripotent stem cells, known by the acronym IPSCs) or stem cells from one of these organs. The choice of the specific microRNA to be antagonized, in particular, the choice specifically between the human hsa-miR-218-5p or the human hsa-miR-23b-3pp, will also determine the range of tissues where the antagonistic effect can be exerted.

[0146] Examples 2-6 show that 3mg / kg in HSALR mice is an effective dose capable of increasing MBNL1 protein levels. Next, the authors of the present invention aimed at finding the optimal dose for administration in humans. First, different doses were tested in several animal models: Example 11 shows that a dose of 6mg / kg in HSALR mice was also an effective dose (when administer every two weeks for a 6 week period) to achieve an overexpression of MBNL1 protein in several tissues such as muscle, heart and brain. Further, Example 12 shows that in Wistar Rats, a dose of 16 mg / kg was the maximum dose with no adverse effects (NOAEL), and Example 15 shows that in minipigs, a dose of 22.5 mg / kg was the maximum dose with no adverse effects (NOAEL). Example 16 was performed to confirm that all doses tested have a therapeutic effect in increasing MBNL1 protein levels, and the results from the quantification showed that all the treated groups had an increased MBNL protein levels two weeks after the last MD23B-2 V2 3’OL intravenous administration. The increased MBNL1 levels was still present at the end of the recovery period (10 weeks after the last administration). Example 14 confirms that the oligonucleotide administered was capable of increasing MBNL1 levels in hindlimb quadriceps muscles. Importantly, the increase in MBNL1 levels was still present at the end of the recovery period (10 weeks after the last administration).

[0147] Secondly, studies to provide information regarding the safety of the dose were carried out: Example 13 provides information regarding the safety of the dose tested, since it shows that the main biological parameters in central nervous, cardiovascular and respiratory system in minipigs and Wistar rats were not affected by the administration of the oligonucleotide of the present invention at 2.5 mg / kg, 7.5 mg / kg and 22.5 mg / kg (in minipigs) or 8 mg / kg, 16 mg / kg or 40 mg / kg (in rats).

[0148] Third, the doses were converted to humans. Preferably, the dose conversion is performed following the Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers (Center for Drug Evaluation and Research, FDA. July 2005 Pharmacology and Toxicology), also available in https: / / www.fda.gov / media / 72309 / download. In allometric scaling, dose data from nonclinical studies in one or more animal species are used to predict human drug exposure for a range of drug doses. This is a rapid method that can inform dosing decisions or determine if it is worthwhile to progress a particular therapeutic compound. Preferably, in the context of the present invention, the dose in the animal model is converted to a human dose by applying an allometric factor (FA) as follows:

[0149] For instance, a dose of 6mg / kg of a certain oligonucleotide as tested in HSALR mice corresponds to a dose of 0.49 mg / kg in humans (6 mg / kg divided by 12.3), which means that an average human of 70kg would need to receive a dose of 34.14 mg (0.49 mg / kg multiplied by 70) of said oligonucleotide. Of note, a safety factor may be preferably applied to provide a margin of safety for protection of human subjects receiving the initial clinical dose. This safety factor allows for variability in extrapolating from animal toxicity studies to studies in humans resulting from: (1) uncertainties due to enhanced sensitivity to pharmacologic activity in humans versus animals; (2) difficulties in detecting certain toxicities in animals (e.g., headache, myalgias, mental disturbances); (3) differences in receptor densities or affinities; (4) unexpected toxicities; and (5) interspecies differences in ADME of the therapeutic. These differences can be accommodated by lowering the human starting dose from the human equivalent dose (HED) of the selected species NOAEL. The default safety factor that should normally be used is 10. A safety factor lower than 10 can be applied for calculation of the starting dose for the First-in-human study, as was done with other antisense oligonucleotides without any adverse clinical consequences.

[0150] In view of the above results, in an embodiment, the oligonucleotide and / or oligonucleotide analogue is formulated to be administrated in a human subject. Of course, the oligonucleotide and / or oligonucleotide analogue is administrated together with the oleic acid, as the oleic acid its conjugated to the oligonucleotide, and the oleic-acid-conjugated oligonucleotide is formulated to be administrated in a human subject. Preferably, the oligonucleotide and / or oligonucleotide analogue is formulated to be administrated to a human at a dose of between 10 mg to 1125 mg per dose per person, preferably between 10 mg and 300 mg, more preferably between 15 mg and 290 mg, even more preferably between 18 mg and 288 mg, most preferably between 33 mg and 144 mg per dose per person and wherein, preferably, the oligonucleotide and / or oligonucleotide analogue is administered intravenously. Preferably, the oligonucleotide and / or oligonucleotide analogue is formulated to be administrated to a human, preferably intravenously, at a dose of about 10 to about 1125 mg per dose per person, preferably about 10 to about 300 mg, more preferably about 15 to about 290 mg, even more preferably about 18 to about 288 mg, most preferably about 34 to about 144 mg per dose per person. Preferably, the dose in humans is selected from the list consisting of 18 mg, 36 mg, 72 mg, 144 mg, 288 mg and 576 mg per dose per person, wherein the administration is preferably via intravenous route. Most preferably, the dose in humans is selected from the list consisting of 36 mg, 72 mg and 144 mg per dose per person, wherein the administration is preferably via intravenous route. In an embodiment, the dose in humans is 188 mg per dose per person, or less than 188 mg, wherein the administration is preferably via intravenous route. In an embodiment, the dose in humans is 18 mg per dose per person, or more than 18 mg, wherein the administration is preferably via intravenous route. In an embodiment, the dose in humans is 36 mg or about 36 mg per dose per person wherein the administration is preferably via intravenous route. In an embodiment, the dose in humans is 10 mg or about 10 mg per dose per person wherein the administration is preferably via intravenous route. In an embodiment, the dose in humans is 64 mg or about 64 mg per dose per person wherein the administration is preferably via intravenous route.

[0151] In an embodiment, the oligonucleotide and / or oligonucleotide analogue is formulated to be administrated to a human at a dose of between 0.142 mg to 16.07 mg per kg of body weight (mg / kg), preferably between 0.142 mg / kg and 4.285 mg / kg, more preferably between 0.214 mg / kg and 4.142 mg / kg, even more preferably between 0.257 mg / kg and 4.114 mg / kg, most preferably between 0.4878 mg / kg and 2.057 mg / kg, and wherein, preferably, the oligonucleotide and / or oligonucleotide analogue is administered intravenously. Preferably, the oligonucleotide and / or oligonucleotide analogue is formulated to be administrated to a human, preferably intravenously, at a dose of about 0.142 mg to about 16.07 mg per kg of body weight (mg / kg), preferably about 0.142 mg / kg to about 4.285 mg / kg, more preferably about 0.214 mg / kg to about 4.142 mg / kg, even more preferably about 0.257 mg / kg to about 4.114 mg / kg, most preferably about 0.4878 mg / kg to about 2.057 mg / kg. Preferably, the dose in humans is selected from the list consisting of 0.257 mg / kg, 0.514 mg / kg, 1.028 mg / kg, 2.057 mg / kg, 4.114 mg / kg and 8.228 mg / kg, wherein the administration is preferably via intravenous route. Most preferably, the dose in humans is selected from the list consisting of 0.514 mg / kg, 1.028 mg / kg and 2.057 mg / kg, wherein the administration is preferably via intravenous route.

[0152] In an embodiment, the dose in humans is 2.68 mg / kg, or less than 2.68 mg / kg, wherein the administration is preferably via intravenous route. In an embodiment, the dose in humans is 0.257 mg / kg or more than 0.257 mg / kg, wherein the administration is preferably via intravenous route. In an embodiment, the dose in humans is 0.51 mg / kg or about 0.51 mg / kg, wherein the administration is preferably via intravenous route. In an embodiment, the dose in humans is 0.14 mg / kg or about 0.14 mg / kg per dose per person wherein the administration is preferably via intravenous route. In an embodiment, the dose in humans is 0.91 mg / kg or about 0.91 mg / kg per dose per person wherein the administration is preferably via intravenous route.

[0153] In an embodiment, the oligonucleotide and / or oligonucleotide analogue is formulated to be administrated to a human at a dose of between 0.142 mg per kg of body weight per day of administration (mg / kg / day of administration) and 16,07 mg / kg / day of administration, preferably between 0.142 mg / kg / day of administration and 4.285 mg / kg / day of administration, more preferably between 0.214 mg / kg / day of administration and 4.142 mg / kg / day of administration, even more preferably between 0.257 mg / kg / day of administration and 4.114 mg / kg / day of administration, most preferably between 0. 4878 mg / kg / day of administration and 2.057 mg / kg / day of administration, and wherein, preferably, the oligonucleotide and / or oligonucleotide analogue is administered intravenously. Preferably, the dose in humans is selected from the list consisting of 0.257 mg / kg / day, 0.514 mg / kg / day, 1.028 mg / kg / day, 2.057 mg / kg / day, 4.114 mg / kg / day and 8.228 mg / kg / day of administration, wherein the administration is preferably via intravenous route. Most preferably, the dose in humans is selected from the list consisting of 0.514 mg / kg / day, 1.028 mg / kg / day and 2.057 mg / kg / day of administration, wherein the administration is preferably via intravenous route.

[0154] In an embodiment, the dose in humans is 2.68 mg / kg / day, or less than 2.68 mg / kg / day, wherein the administration is preferably via intravenous route. In an embodiment, the dose in humans is 0.257 mg / kg / day or more than 0.257 mg / kg / day, wherein the administration is preferably via intravenous route. In an embodiment, the dose in humans is 0.51 mg / kg / day or about 0.51 mg / kg / day, wherein the administration is preferably via intravenous route. In an embodiment, the dose in humans is 0.14 mg / kg / day or about 0.14 mg / kg / day wherein the administration is preferably via intravenous route. In an embodiment, the dose in humans is 0.91 mg / kg / day or about 0.91 mg / kg / day herein the administration is preferably via intravenous route.

[0155] With regard to the intrathecal administration, Examples 19 -20 show that this route of administration provides a more sustained presence of the oligonucleotide (which is the active ingredient) in CNS, particularly CSF, and that therapeutic dose by intrathecal route will be between 22.75 to 196.46 mg, considering a safety factor of 10x, or between 22.5 to 392.92 mg if we consider a safety factor of 5x. Table 37 shows the preferred HED in humans based on efficacy dose therefore after a safety factor of 1X and the highest dose based on toxicity after applying a safety factor of 10x.

[0156] In view of the above results, the oligonucleotide and / or oligonucleotide analogue is formulated to be administrated to a human at a dose of between 10 to 400 mg per dose per person, or 10 mg to 230 mg per dose per person, preferably between 15 mg and 210 mg, more preferably between 18 mg and 200 mg, even more preferably between 22 mg and 200 mg, most preferably between 22.75 mg and 196.46 mg per dose per person or between 45.50 mg and 181.51 mg per dose per person and wherein, preferably, the oligonucleotide and / or oligonucleotide analogue is administered intrathecally. Preferably, the oligonucleotide and / or oligonucleotide analogue is formulated to be administrated to a human, preferably intrathecally, at a dose of about 10 to about 230 mg per dose per person, preferably about 15 to about 210 mg, more preferably about 18 to about 200 mg, even more preferably about 22 to about 200 mg, most preferably about 22.75 to about 196.46 mg per dose per person or between 45.50 mg and 181.51 mg per dose per person. In an embodiment, the dose in humans is between 22.5 and 392.92 mg per dose per person, wherein the administration is preferably via intrathecal route.

[0157] Preferably, the dose in humans is selected from the list consisting of 10 mg, 15 mg, 18 mg, 20 mg, 22 mg, 22.75 mg, 45.50 mg, 181.51 mg, 196.46 and 200 mg per dose per person, wherein the administration is preferably via intrathecal route. Most preferably, the dose in humans is selected from the list consisting of 22.75 mg, 45.50 mg, 181.51 mg and 196.46 mg per dose per person, wherein the administration is preferably via intrathecal route.

[0158] In an embodiment, the dose in humans is 200 mg per dose per person, or less than 200 mg, wherein the administration is preferably via intrathecal route. In an embodiment, the dose in humans is 18 mg per dose per person, or more than 18 mg, wherein the administration is preferably via intrathecal route. In an embodiment, the dose in humans is 36 mg or about 36 mg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the dose in humans is 10 mg or about 10 mg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the dose in humans is 64 mg or about 64 mg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the dose in humans is 22.75 mg or about 22.75 mg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the dose in humans is 45.50 mg or about 45.50 mg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the dose in humans is 181.51 mg or about 181.51 mg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the dose in humans is 196.46 mg or about 196.46 mg per dose per person wherein the administration is preferably via intrathecal route.

[0159] In an embodiment, the oligonucleotide and / or oligonucleotide analogue is formulated to be administrated to a human at a dose of between 0.14 and 5.71 mg per kg of body weight (mg / kg), or between 0.142 mg to 3. 28 mg / kg, preferably between 0.214 mg / kg and 3 mg / kg, more preferably between 0.25 mg / kg and 2.85 mg / kg, even more preferably between 0.31 mg / kg and 2.85 mg / kg, most preferably between 0.325 mg / kg and 2.808 mg / kg or between 0.65 mg / kg and 2.59 mg / kg and wherein, preferably, the oligonucleotide and / or oligonucleotide analogue is administered intrathecally. Preferably, the oligonucleotide and / or oligonucleotide analogue is formulated to be administrated to a human, preferably intrathecally, at a dose of about 0.142 mg to about 3.28 mg per kg of body weight (mg / kg), preferably about 0.214 mg / kg to about 3 mg / kg, more preferably about 0.25 mg / kg to about 2.85 mg / kg, even more preferably about 0.31 mg / kg to about 2.85 mg / kg, most preferably about 0.325 mg / kg to about 2.8087 mg / kg or about 0.65 mg / kg to about 2.59 mg / kg. In an embodiment, the dose in humans is between 0.32 mg / kg / and 5.91 mg / kg, wherein the administration is preferably via intrathecal route.

[0160] Preferably, the dose in humans is selected from the list consisting of 0.14 mg / kg, 0.21 mg / kg, 0.25 mg / kg, 0.28 mg / kg, 0.31 mg / kg, 0.32 mg / kg, 0.65 mg / kg, 2.59 mg / kg, 2.80 mg / kg and 2.85 mg / kg, wherein the administration is preferably via intrathecal route. Most preferably, the dose in humans is selected from the list consisting of 0.32 mg / kg, 0.65 mg / kg, 2.59 mg / kg and 2.80 mg / kg, wherein the administration is preferably via intrathecal route.

[0161] In an embodiment, the dose in humans is 2.85 mg / kg, or less than 2.85 mg / kg, wherein the administration is preferably via intrathecal route. In an embodiment, the dose in humans is 0.325 mg / kg or more than 0.325mg / kg, wherein the administration is preferably via intrathecal route. In an embodiment, the dose in humans is 0.65 mg / kg or more than 0.65mg / kg, wherein the administration is preferably via intrathecal route. In an embodiment, the dose in humans is 0.514 mg / kg or about 0.514 mg / kg, wherein the administration is preferably via intrathecal route. In an embodiment, the dose in humans is 0.14 mg / kg or about 0.14 mg / kg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the dose in humans is 0.91 mg / kg or about 0.91 mg / kg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the dose in humans is 0.32 mg / kg or about 0.32 mg / kg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the dose in humans is 0.65 mg / kg or about 0.65 mg / kg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the dose in humans is 2.59 mg / kg or about 2.59 mg / kg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the dose in humans is 2.80 mg / kg or about 2.80 mg / kg per dose per person wherein the administration is preferably via intrathecal route.

[0162] In an embodiment, the oligonucleotide and / or oligonucleotide analogue is formulated to be administrated to a human at a dose of between 0.14 and 5.71 mg per kg of body weight per day of administration (mg / kg / day), or 0.142 mg / kg / day of administration and 3.28 mg / kg / day of administration, preferably between 0.214 mg / kg / day of administration and 3 mg / kg / day of administration, more preferably between 0.25 mg / kg / day of administration and 2.85 mg / kg / day of administration, even more preferably between 0.31 mg / kg / day of administration and 2.85 mg / kg / day of administration, most preferably between 0.325 mg / kg / day of administration and 2.808 mg / kg / day of administration or between 0.65 mg / kg / day and 2.59 mg / kg / day of administration, and wherein, preferably, the oligonucleotide and / or oligonucleotide analogue is administered intrathecally. In an embodiment, the dose in humans is between 0.32 mg / kg / day and 5.91 mg / kg / day, wherein the administration is preferably via intrathecal route.

[0163] Preferably, the dose in humans is selected from the list consisting of 0.14 mg / kg / day, 0.21 mg / kg / day, 0.25 mg / kg / day, 0.28 mg / kg / day, 0.31 mg / kg / day, 0.32 mg / kg / day, 0.65 mg / kg / day, 2.59 mg / kg / day, 2.80 mg / kg / day and 2.85 mg / kg / day, wherein the administration is preferably via intrathecal route. Most preferably, the dose in humans is selected from the list consisting of 0.32 mg / kg / day, 0.65 mg / kg / day, 2.59 mg / kg / day and 2.80 mg / kg / day , wherein the administration is preferably via intrathecal route.

[0164] In an embodiment, the dose in humans is 2.85 mg / kg / day, or less than 2.85 mg / kg / day, wherein the administration is preferably via intrathecal route. In an embodiment, the dose in humans is 0.325 mg / kg / day or more than 0.325 mg / kg / day, wherein the administration is preferably via intrathecal route. In an embodiment, the dose in humans is 0.65 mg / kg / day or more than 0.56 mg / kg / day, wherein the administration is preferably via intrathecal route. In an embodiment, the dose in humans is 0.514 mg / kg / day or about 0.514 mg / kg / day, wherein the administration is preferably via intrathecal route. In an embodiment, the dose in humans is 0.14 mg / kg / day or about 0.14 mg / kg / day wherein the administration is preferably via intrathecal route. In an embodiment, the dose in humans is 0.91 mg / kg / day or about 0.91 mg / kg / day herein the administration is preferably via intrathecal route. In an embodiment, the dose in humans is 0.32 mg / kg / day or about 0.32 mg / kg / day per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the dose in humans is 0.65 mg / kg / day or about 0.65 mg / kg / day per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the dose in humans is 2.59 mg / kg / day or about 2.59 mg / kg / day per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the dose in humans is 2.80 mg / kg / day or about 2.80 mg / kg / day per dose per person wherein the administration is preferably via intrathecal route.

[0165] Administration of a dose can be accomplished by a single administration, such as by bolus injection, or in several administrations over a period of time, or by continuous infusion over an appropriate period of time. Preferably, the dose is administrated in a single administration step, preferably intravenously or intrathecally. Preferably, the dose is administered once every 2 weeks, once a month, or once every eight weeks. Preferably, the administration of the dose is every two weeks or every month.

[0166] In a second aspect, the present invention relates to a composition, preferably a pharmaceutical composition, comprising at least an oligonucleotide as defined in the first aspect or any of its embodiments, or a mixture of two or more of them, optionally further comprising a carrier and / or one or more pharmaceutically acceptable excipients. Preferably, the composition comprises an antimiR as defined in the first aspect or any of its embodiments, more preferably an antagonist of the human hsa-miR-218-5p or the human hsa-miR-23b-3p. In an embodiment, the compositions that comprise one of these anti-microRNAs or their mixtures, as well as any other anti-microRNA directed against the human hsa-miR-218-5p or the human hsa-miR-23b-3p or mixtures thereof, or in general any oligonucleotide and / or oligonucleotide analogue molecule that is an inhibitor of one of these microRNAs or of another microRNA that down-regulates the expression of the human gene MBNL1 and / or MBNL2, including compositions which also comprise a pharmaceutically acceptable carrier and / or excipient.

[0167] In one possible embodiment, the pharmaceutical composition comprises an effective dose of an inhibitor or antagonist, preferably an antimiR, more preferably an antagonist of the human hsa-miR-218-5p or of the human hsa-miR-23b-3pp or a mixture thereof, as defined in the first aspect or any of its embodiments. Preferably, the inhibitor / antagonist of the human hsa-miR- 218-5p present in the composition is the antimiR type inhibitor used in the examples of this invention represented by SEQ ID NO: 1 or its functional equivalents of SEQ ID NO: 80-110; and the inhibitor / antagonist of the human hsa-miR-23b-3p present in the composition is the antimiR type inhibitor represented by SEQ ID NO: 2 or its functional equivalents of SEQ ID NO: 52-79, where the inhibitor is conjugated at its 3' and / or 5' ends to at least one oleic acid molecule. More preferably, the inhibitor(s) / antagonist(s) comprised in the composition will be present at a concentration that allows the administration of a therapeutically effective dose.

[0168] An "effective dose" or "therapeutically effective dose" is a sufficient amount to achieve a beneficial or desired clinical outcome. An effective dose of an inhibitor / antagonist of a microRNA, according to previous results obtained with molecules directed against other microRNAs, can be from about 0.5 mg / kg to about 100 mg / kg in mice, preferably from about 1.5 mg / kg to 100 mg / kg in mice or from about 0.75 mg / kg to 50 mg / kg in rats. However, the precise determination of what would be considered an effective dose in humans can be based on individual factors for each patient, including size, age, and the nature of the inhibitor or antagonist (for example, if it is an expression construct, an antimiR or oligonucleotide analogue, etc).

[0169] In an embodiment, therapeutically effective dose of the oligonucleotide and / or analogue in humans is a dose of between 10 mg to 1125 mg per dose per person, preferably between 10 mg and 300 mg, more preferably between 15 mg and 290 mg, even more preferably between 18 mg and 288 mg, most preferably between 33 mg and 144 mg per dose per person. Preferably, therapeutically effective dose of the oligonucleotide and / or analogue thereof for humas is a dose of about 10 to about 1125 mg per dose per person, preferably about 10 to about 300 mg, more preferably about 15 to about 290 mg, even more preferably about 18 to about 288 mg, most preferably about 34 to about 144 mg per dose per person. Preferably, the therapeutically effective dose of the oligonucleotide and / or analogue in humans is selected from the list consisting of 18 mg, 36 mg, 72 mg, 144 mg, 288 mg and 576 mg per dose per person. Most preferably, the therapeutically effective dose of the oligonucleotide and / or analogue in humans is selected from the list consisting of 36mg, 72mg and 144 mg per dose per person. Also preferably, the therapeutically effective dose of the oligonucleotide and / or analogue in humans is selected from the list consisting of 10, 36, or 68 mg per dose per person. Prefrably, the doses disclosed in this paragraph are administrated intravenously in a human.

[0170] In an embodiment, therapeutically effective dose of the oligonucleotide and / or analogue in humans is a dose of between 10 to 400 mg per dose per person, or 10 mg to 230 mg per dose per person, preferably between 15 mg and 210 mg, more preferably between 18 mg and 200 mg, even more preferably between 22 mg and 200 mg, most preferably between 22.75 mg and 196.46 mg per dose per person or between 45.50 mg and 181.51 mg per dose per person. Preferably, therapeutically effective dose of the oligonucleotide and / or analogue thereof for humans is a dose of about 10 to about 230 mg per dose per person, preferably about 15 to about 210 mg, more preferably about 18 to about 200 mg, even more preferably about 22 to about 200 mg, most preferably about 22.75 to about 196.46 mg per dose per person or between 45.50 mg and 181.51 mg per dose per person. Preferably, the therapeutically effective dose of the oligonucleotide and / or analogue in humans is selected from the list consisting of 10 mg, 15 mg, 18 mg, 20 mg, 22 mg, 22.75 mg, 45.50 mg, 181.51 mg, 196.46 and 200 mg per dose per person. In an embodiment, the dose in humans is between 22.5 and 392.92 mg per dose per person. Also preferably, the therapeutically effective dose of the oligonucleotide and / or analogue in humans is selected from the list consisting of 10, 36, or 68 mg per dose per person. Most preferably, the therapeutically effective dose of the oligonucleotide and / or analogue in humans is selected from the list consisting of 22.75, 45.50, 181.51 and 196.46 per dose per person. Most preferably, the therapeutically effective dose of the oligonucleotide and / or analogue in humans is selected between 45.50 mg and 181.51 mg per dose per person. Prefrably, the doses disclosed in this paragraph are administrated intrathecally in a human.

[0171] In an embodiment, the therapeutically effective dose of the oligonucleotide and / or analogue thereof for humas is a dose of between 0.142 mg to 16.07 mg per kg of body weight (mg / kg), preferably between 0.142 mg / kg and 4.285 mg / kg, preferably between 0.214 mg / kg and 4.142 mg / kg, more preferably between 0.257 mg / kg and 4.114 mg / kg, most preferably between 0. 4878 mg / kg and 2.057 mg / kg of the oligonucleotide and / or analogue thereof. Preferably the therapeutically effective dose of the oligonucleotide and / or analogue thereof for humas is a dose of about 0.142 mg to about 16,07 mg per kg of body weight (mg / kg), preferably about 0.142 mg / kg to about 4.285 mg / kg, more preferably about 0.214 mg / kg to about 4.142 mg / kg, even more preferably about 0.257 mg / kg to about 4.114 mg / kg, most preferably about 0.4878 mg / kg to about 2.057 mg / kg. Most preferably, the therapeutically effective dose in humans is selected from the list consisting of 0.257 mg / kg, 0.514 mg / kg, 1.028 mg / kg, 2.057 mg / kg, 4.114 mg / kg and 8.228 mg / kg. Most preferably, the therapeutically effective dose in humans is selected from the list consisting of 0.514 mg / kg, 1.028 mg / kg and 2.057 mg / kg. Also preferably, the therapeutically effective dose of the oligonucleotide and / or analogue in humans is selected from the list consisting of 0.14, 0.51 , or 0.91 mg / kg. Prefrably, the doses disclosed in this paragraph are administrated intravenously a human.

[0172] In an embodiment, the therapeutically effective dose of the oligonucleotide and / or analogue thereof for humas is a dose of between 0.14 and 5.71 mg per kg of body weight (mg / kg), or 0.142 mg to 3.28 mg / kg, preferably between 0.214 mg / kg and 3 mg / kg, preferably between 0.25 mg / kg and 2.85 mg / kg, more preferably between 0.31 mg / kg and 2.85 mg / kg, most preferably between 0.325 mg / kg and 2.808 mg / kg or between 0.65 mg / kg and 2.59 mg / kg of the oligonucleotide and / or analogue thereof. In an embodiment, the dose in humans is between 0.32 mg / kg and 5.91 mg / kg. Preferably the therapeutically effective dose of the oligonucleotide and / or analogue thereof for humas is a dose of about 0.14 to about 5.71 mg per kg of body weight (mg / kg), or about 0.142 mg to about 3.28 mg / kg, preferably about 0.214 mg / kg to about 3mg / kg, more preferably about 0.25 mg / kg to about 2.85 mg / kg, even more preferably about 0.31 mg / kg to about 2.85 mg / kg, most preferably about 0.325 mg / kg to about 2.808 mg / kg or about 0.65 mg / kg to about 2.59 mg / kg. Most preferably, the therapeutically effective dose in humans is selected from the list consisting of 0.14 mg / kg, 0.21 mg / kg, 0.25 mg / kg, 0.28 mg / kg, 0.31 mg / kg, 0.32 mg / kg, 0.65 mg / kg, 2.59 mg / kg, 2.80 mg / kg and 2.85 mg / kg. Most preferably, the therapeutically effective dose in humans is selected from the list consisting of 0.32 mg / kg, 0.65 mg / kg, 2.59 mg / kg and 2.80 mg / kg. Also preferably, the therapeutically effective dose of the oligonucleotide and / or analogue in humans is selected from the list consisting of 0.14, 0.51 , or 0.91 mg / kg. Preferably, the doses disclosed in this paragraph are administrated intrathecally in a human.

[0173] In an embodiment, the therapeutically effective dose of the oligonucleotide and / or analogue thereof for humans is a dose of between 0.142 mg per kg of body weight per day of administration (mg / kg / day) and 16.07 mg / kg / day, preferably between 0.142 mg / kg / day and 4.285 mg / kg / day, preferably between 0.214 mg / kg / day and 4.142 mg / kg / day, more preferably between 0.257 mg / kg / day and 4.114 mg / kg / day, most preferably between 0. 4878 mg / kg / day and 2.057 mg / kg / day of the oligonucleotide and / or analogue thereof. Most preferably, the therapeutically effective dose of the oligonucleotide and / or analogue in humans is selected from the list consisting of 0.257 mg / kg / day, 0.514 mg / kg / day, 1.028 mg / kg / day, 2.057 mg / kg / day, 4.114 mg / kg / day and 8.228 mg / kg / day of administration. Most preferably, the therapeutically effective dose of the oligonucleotide and / or analogue in humans is selected from the list consisting of 0.514 mg / kg / day, 1.028 mg / kg and 2.057 mg / kg / day. Also preferably, the therapeutically effective dose of the oligonucleotide and / or analogue in humans is selected from the list consisting of 0.14, 0.51 , or 0.91 mg / kg / day. Prefrably, the doses disclosed in this paragraph are administrated intravenously in a human.

[0174] In an embodiment, the therapeutically effective dose of the oligonucleotide and / or analogue thereof for humas is a dose of between 0.14 and 5.71 mg per kg of body weight per day of administration (mg / kg / day), or between 0.142 mg to 3.28 mg / kg / day, preferably between 0.214 mg / kg / day and 3 mg / kg / day, preferably between 0.25 mg / kg / day and 2.85 mg / kg / day, more preferably between 0.31 mg / kg / day and 2.85 mg / kg / day, most preferably between 0.325 mg / kg / day and 2.808 mg / kg / day or between 0.65 mg / kg / day and 2.59 mg / kg / day of the oligonucleotide and / or analogue thereof. Preferably the therapeutically effective dose of the oligonucleotide and / or analogue thereof for humas is a dose of about 0.142 mg to about 3.28 mg per kg of body weight per day (mg / kg / day), preferably about 0.214 mg / kg / day to about 3mg / kg / day, more preferably about 0.25 mg / kg / day to about 2.85 mg / kg / day, even more preferably about 0.31 mg / kg / day to about 2.85 mg / kg / day, most preferably about 0.325 mg / kg / day to about 2.808 mg / kg / day or about 0.65 mg / kg / day to about 2.59 mg / kg / day. In an embodiment, the dose in humans is between 0.32 mg / kg / day and 5.91 mg / kg / day. Most preferably, the therapeutically effective dose in humans is selected from the list consisting of 0.14 mg / kg / day, 0.21 mg / kg / day, 0.25 mg / kg / day, 0.28 mg / kg / day, 0.31 mg / kg / day, 0.32 mg / kg / day, 0.65 mg / kg / day, 2.59 mg / kg / day, 2.80 mg / kg / day and 2.85 mg / kg / day. Most preferably, the therapeutically effective dose in humans is selected from the list consisting of 0.32 mg / kg / day, 0.65 mg / kg / day, 2.59 mg / kg / day and 2.80 mg / kg / day. Also preferably, the therapeutically effective dose of the oligonucleotide and / or analogue in humans is selected from the list consisting of 0.14, 0.51 , or 0.91 mg / kg / day. Prefrably, the doses disclosed in this paragraph are administrated intrathecally in a human.

[0175] Administration of the therapeutically effective dose can be accomplished by a single administration, such as by bolus injection, or in several administrations over a period of time, or by continuous infusion over an appropriate period of time. Preferably, the therapeutically effective dose is administrated in a single administration step, preferably intravenously or intrathecally. Preferably, the therapeutically effective dose of the oligonucleotide and / or analogue thereof is administered intravenously, preferably in a bolus injection, or intrathecally. Preferably, the dose is administered once every 2 weeks, once a month, or once every eight weeks. Preferably, the administration of the dose is every two weeks or every month.

[0176] Preferably, the administration of the therapeutically effective dose is every two weeks, or every three or four weeks, or every eight weeks. Preferably, the administration of the therapeutically effective dose is every two weeks or every month.

[0177] For its clinical application, the compositions according to the uses of this invention, will then be considered pharmaceutical compositions of this invention, and they can be prepared in an appropriate form for the desired application. It may be necessary or convenient to administer multiple doses to the subject during a particular treatment period, administering doses daily, weekly, monthly, every two months, every three months or every six months. In certain embodiments, the subject receives an initial dose at the beginning, which is larger than one or more subsequent doses or maintenance doses. In certain embodiments, the subject receives doses periodically or chronically, especially in the case of treatment of chronic diseases, such as DM1.

[0178] Colloidal dispersion systems, such as macromolecule complexes, nanocapsules, micro-spheres, pearls and lipid-based systems that include oil-in-water emulsions, micelles, mixed micelles, other oligonucleotide-based delivery vehicles, and liposomes, can be used as administration vehicles of the inhibitors / antagonists of this invention, with which the pharmaceutical composition of the invention is formed. Another possibility is to prepare the pharmaceutical compositions of the invention using appropriate salts and buffers to make the administration vehicles stable and to assist in the capture by the target cells. The compositions of this invention can be aqueous compositions that comprise an effective amount of the administration vehicle and which comprise either the oligonucleotide molecules of the invention, independently or forming liposomes or other complexes, or expression vectors thereof, dissolved or dispersed in a pharmaceutically acceptable carrier or aqueous medium.

[0179] Additional active ingredients may also be incorporated into the compositions, provided that they do not inactivate the molecules of this invention or their expression vectors.

[0180] The solutions of the active compounds as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary storage and use conditions, these preparations generally contain a preservative to prevent the growth of microorganisms. The oligonucleotides can also be prepared in a solution of phosphate-buffered saline and sodium chloride. For example, the oligonucleotides can be prepared in phosphate-buffered saline at a pH of between 6.5 and 8, preferably at a pH of about 6.8 - 7 and sodium chloride at a concentration of about 150 mM.

[0181] The compositions of this invention can usually be formulated in a neutral or salt form. Pharmaceutically acceptable salts include, for example, acid addition salts (formed with free amino groups of the protein) derived from inorganic acids (e.g., hydrochloric or phosphoric acids), or organic acids (e.g. acetic, oxalic, tartaric, mandelic acids), and the like. Salts formed with free carboxyl groups of the protein can also be derived from inorganic bases (for example, sodium, potassium, ammonium, calcium, or ferric hydroxides) or organic bases (e.g. isopropylamine, trimethylamine, histidine, procaine, and the like).

[0182] In a third aspect, the present invention provides an oligonucleotide as defined in the first aspect or any of its embodiment, or a composition, preferably a pharmaceutical composition, as defined in the second aspect or any of its embodiments for use in therapy. Preferably, the oleic acid conjugated to the oligonucleotide molecule and / or analogue thereof acts as a vehicle to deliver said oligonucleotide molecule and / or analogue thereof to relevant tissues, such as muscle, CSF and / or CNS. Thus, the oligonucleotide molecule or analogue thereof according to the first aspect and conjugated at its 3' and / or 5' ends to at least one oleic acid molecule may be for use in a method of treatment by therapy in a human subject in need thereof, wherein said oligonucleotide molecule and / or analogue thereof is an active ingredient of said treatment by therapy, and wherein said oleic acid molecule is used as a pharmaceutically acceptable vehicle or carrier of said oligonucleotide molecule and / or analogue thereof. The term “active ingredient” is used in the present invention to refer the substance which is pharmaceutically active and responsible of the therapeutic effect. In the case of antagonists of antimiRs, the active ingredient is the molecule, preferably the oligonucleotide molecule, that targets the endogenous miR. Most preferably, the term “active ingredient” is used herein to refer to the oligonucleotide molecule and / or analogue thereof defined in the first aspect of the present invention, or in any of its embodiments. Included are also the dosages disclosed above, for use in therapy, preferably in the treatment of muscular, CSF, of CNS diseases.

[0183] In a fourth aspect, the present invention provides an oligonucleotide as defined in the first aspect or any of its embodiment, or a composition, preferably a pharmaceutical composition, as defined in the second aspect or any of its embodiments for use in the prevention or treatment of muscular and / or nervous system diseases, preferably central nervous system or muscular diseases involving weakness and wasting away of muscle tissue, particularly involving loss of muscular strength, increasing disability, and deformity, and / or preferably nervous system diseases that involve structural and / or functional changes in the brain and / or other tissues of the CNS, such as in the CSF. Preferably, muscular diseases are muscular dystrophy diseases. Preferably, the muscular dystrophy diseases are selected from the group consisting of Becker muscular dystrophy, congenital muscular dystrophy, Duchenne muscular dystrophy, Distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, Facioscapulohumeral muscular dystrophy, Limb-Girdle muscular dystrophy, Myotonic dystrophy, and Oculopharyngeal muscular dystrophy. Preferably, the muscular disease is myotonic dystrophy, preferably of type 1 and / or 2. Preferably, the use according to the fourth aspect includes the use of the at least one oleic acid molecule as a vehicle when conjugated to an oligonucleotide molecule and / or analogue thereof to deliver said oligonucleotide molecule and / or analogue thereof to the relevant tissue, such as muscle, CSF and / or to CNS.

[0184] In an alternative fourth aspect, the present invention provides an oligonucleotide as defined in the first aspect or any of its embodiment, or a composition, preferably a pharmaceutical composition, as defined in the second aspect or any of its embodiments for use in the prevention or treatment of diseases characterized by insufficient amount or function of MBNL genes and / or proteins in a subject in need thereof. Preferably, said use includes the use of the at least one oleic acid molecule as a vehicle when conjugated to an oligonucleotide molecule and / or analogue thereof to deliver said oligonucleotide molecule and / or analogue thereof to the relevant tissue, such as muscle, CSF and / or to CNS. By “insufficient amount or function of MBNL genes and / or proteins” is referred herein to statistically significant lower amounts or function of MBNL genes and / or proteins in comparison to a healthy subject. In a further alternative fourth aspect, the present invention provides an oligonucleotide as defined in the first aspect or any of its embodiment, or a composition, preferably a pharmaceutical composition, as defined in the second aspect or any of its embodiments for use in targeting muscular, CSF and / or CNS cells in a subject in need thereof, preferably muscular cells in a subject suffering from DM or DM1. By “targeting muscular, CSF, and / or CNS cells” is referred herein as increasing the insufficient amounts of MBNL proteins and / or genes in said cells or tissues. CNS cells include preferably neurons, but also glial cells (astrocytes, oligodendrocytes, ependymal cells, and microglia), choroid plexus cells, cells related to blood vessels and coverings. Muscular cells include smooth, preferably skeletal, and cardiac cells. Preferably, the increase is a statistically significant increase, preferably in comparison to a control cell or an untreated cell.

[0185] In a further alternative fourth aspect, the present invention provides an oligonucleotide as defined in the first aspect or any of its embodiment, or a composition, preferably a pharmaceutical composition, as defined in the second aspect or any of its embodiments for use in the prevention or treatment of diseases characterized by the expression of toxic RNAs (also called RNAopathies or RNA-mediated / RNA-dominant diseases). Preferably, said use includes the use of the at least one oleic acid molecule as a vehicle when conjugated to an oligonucleotide molecule and / or analogue thereof to deliver said oligonucleotide molecule and / or analogue thereof to the relevant tissue, such as muscle, CSF and / or to CNS. Said diseases are usually characterized by the expansion of unstable microsatellite repeats caused by unusual mutation mechanisms, wherein the expression of the expansions of a repetitive element create a sink for RNA-binding proteins by increasing the mass of target RNA per nucleus and also by increasing the avidity of RNA-protein interaction due to a high local concentration of binding sites in each mutant transcript, among other mechanisms. Preferably, the RNAopathies or RNA-mediated / RNA-dominant diseases are neuromuscular or neurodegenerative diseases, more preferably selected from the group consisting of DM type 1 (ORPHA:273) or type 2 (ORPHA:606); Fragile X-Associated Tremor / Ataxia Syndrome (ORPHA:93256; FXTAS); C9ORF72 Amyotrophic Lateral Sclerosis and / or Frontotemporal Dementia(ORPHA:275872; ALS / FTD); Spinocerebellar Ataxias (SCAs) or benign adult familial myoclonic epilepsy (BAFME).

[0186] In a further alternative fourth aspect, the present invention provides an oligonucleotide as defined in the first aspect or any of its embodiment, or a composition, preferably a pharmaceutical composition, as defined in the second aspect or any of its embodiments for use in the prevention or treatment of diseases characterized by an excess in the amount or function of miR-23b-3p and / or miR-218-5p. By “excessive amount or function of miR-23b-3p and / or miR-218-5p” is referred herein to statistically significant higher amounts or function of miR-23b-3p and / or miR-218-5p in comparison to those in a healthy subject. Preferably, the disease characterized by an excess in the amount or function of miR-23b-3p and / or miR-218- 5p is myotonic dystrophy, preferably of type 1 and / or 2. Preferably, said use includes the use of the at least one oleic acid molecule as a vehicle when conjugated to an oligonucleotide molecule and / or analogue thereof to deliver said oligonucleotide molecule and / or analogue thereof to the relevant tissue, such as muscle, CSF and / or to CNS.

[0187] As shown in Examples 22-24, CD36 is the key transporter of oleic-conjugated oligonucleotides, acting as a central mediator for intravenous delivery of said compound to the target tissue, especially to deep-brain regions, such as hindbrain regions, particularly cerebellum. Consequently, the data represented in Examples 22-24 provide plausibility for the prevention or treatment of diseases characterized by the presence of tissues where high concentration of CD36 is present, as the oligonucleotide of the invention will be specifically delivered to said tissue, thanks to its conjugation to oleic acid.

[0188] Hence, in a further alternative fourth aspect, the present invention provides an oligonucleotide as defined in the first aspect or any of its embodiments, or a composition, preferably a pharmaceutical composition, as defined in the second aspect or any of its embodiments, for use in the prevention or treatment of diseases characterized by CD36 overexpression. As used herein, the term “CD36 overexpression” or “high concentration of CD36” refers to an increased level of CD36 protein and / or mRNA expression in a cell or population of cells as compared to a control or a reference value.

[0189] In an embodiment, CD36 overexpression is determined using any of various analytical methods. Such methods include, for example, flow cytometry, in which an increase in median fluorescence intensity (MFI) for CD36 can be observed; immunohistochemistry (IHC) or immunocytochemistry (ICC), which allow detection of an increase in staining intensity or in the proportion of CD36+cells; western blotting or ELISA assays for quantifying CD36 protein levels; or by measuring the levels of CD36 protein in the CFS of a subject. Alternatively, the overexpression may be assessed at the nucleic acid level by quantitative PCR (qPCR) or digital PCR targeting CD36-encoding sequences, or by RNA sequencing or other transcriptom ic techniques.

[0190] In an embodiment, the CD36 overexpression is at least a 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold or greater increase in CD36 mRNA levels, as determined by preferably qPCR. In an embodiment, the CD36 overexpression is at least a 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold or greater increase in CD36 protein levels, as determined by preferably Western blot or ELISA.

[0191] In some embodiments, the CD36 overexpression is a statistically significant overexpression. As used herein, “statistically significant” or “significant” is referred as the determination by an analyst that the results in the data are not explainable by chance alone as determined using appropriate statistical analyses (e.g., t-test, ANOVA, or equivalent), based on biological or technical replicates. Statistical hypothesis testing is the method by which the skilled person makes this determination. This test provides a p-value, which is the probability of observing results as extreme as those in the data, assuming the results are truly due to chance alone. A p-value of 0.1 or lower (preferably 0.05, 0.01 , 0.001 or lower) is considered herein to be statistically significant. As used herein, the term “control” refers to any reference against which CD36 expression levels are compared, including but not limited to: (i) a corresponding non-diseased cell or cell population; (ii) a population of cells isolated from a healthy subject or subjects; (iii) a pre- established or standardized threshold value; (iv) a historical or literature-derived value; (v) an in vitro reference sample; (vi) a cell or cell population obtained from the same subject at a baseline or pre-disease time point; or (vii) a cell or cell population that has not been exposed to a disease-inducing agent.

[0192] In an embodiment, the disease characterized by having CD36 overexpression is selected from the list consisting of (see Example 24): Spinal cord injury, Stroke, Epilepsy, Alzheimer’s disease, Demyelinating central nervous system disorders, Prion disease, and Germinal matrix hemorrhage.

[0193] Further, as shown in Figure 24, the therapeutic oligonucleotide reaches deep-brain regions, particularly the hindbrain, when conjugated to oleic acid and administrated intravenously. Figures 30 and 31 demonstrate that the therapeutic oligonucleotide reaches cerebellum, where high concentration of CD36 is found.

[0194] Hence, in a further alternative fourth aspect, the present invention provides an oligonucleotide as defined in the first aspect or any of its embodiments, or a composition, preferably a pharmaceutical composition, as defined in the second aspect or any of its embodiments, for use in the prevention or treatment of a deep-brain disorder. “Deep-brain disorder” encompasses a diverse group of neurological conditions in which the main pathological involvement occurs in subcortical structures such as the basal ganglia, thalamus, subthalamic nucleus, globus pallidus, substantia nigra, cerebellum and brainstem nuclei. These regions are essential for motor control, sensorimotor integration, arousal, and cognitive-emotional regulation, and their dysfunction leads to characteristic clinical syndromes.

[0195] The most representative category is the group of basal ganglia movement disorders, including:

[0196] • Parkinson’s disease (PD) and atypical parkinsonian syndromes such as multiple system atrophy (MSA-P) and progressive supranuclear palsy (PSP);

[0197] • Huntington’s disease (HD), characterized by degeneration of the striatum;

[0198] • Dystonias, both isolated and combined, including genetic forms (e.g., TOR1A, THAP1 , GNAL);

[0199] • Wilson’s disease, with copper accumulation preferentially damaging basal ganglia;

[0200] • Essential tremor and myoclonus-dystonia, involving cerebello-thalamic and pallidal circuits. Deep-brain involvement is also central in several metabolic and genetic conditions, such as pantothenate kinase-associated neurodegeneration (PKAN), PLA2G6-associated neurodegeneration, Leigh syndrome, biotin-thiamine-responsive basal ganglia disease (SLC19A3 deficiencies), and mitochondrial disorders affecting thalamic and brainstem nuclei. In addition, thalamic and brainstem degenerative disorders — including spinocerebellar ataxias with brainstem involvement, multiple system atrophy (MSA-C / MSA-P), and progressive supranuclear palsy (PSP) — form a related group with shared patterns of selective subcortical vulnerability.

[0201] Collectively, these conditions represent a wide and expanding spectrum of diseases in which deep brain structures constitute the primary and defining site of pathology, emphasizing the clinical and therapeutic relevance of targeting subcortical neural circuits.

[0202] In an embodiment, the disorder is a hindbrain disorder. “Hindbrain disorder,” as used herein, refers to any impairment or abnormality in the structural, physiological, biochemical, or functional state of the hindbrain, particularly of the pons, the medulla oblongata, and the cerebellum. Thus, preferably, the hindbrain disorder is a disorder affecting the pons, medulla oblongata, and the cerebellum, also called herein a “pons disorder”, a “medulla oblongata disorder” or a “cerebellum disorder”, respectively.

[0203] In an embodiment, the cerebellum disorder is selected from the list consisting of autosomal dominant spinocerebellar ataxias (SCAs), such as SCA1 , SCA2, SCA3 / Machado-Joseph disease, SCA6, SCA7, SCA8, SCA10, SCA12, and SCA17, as well as newly recognized repeat-expansion disorders such as SCA27B (GAA expansion in FGF14) and SCA4 (GGC expansion in ZFHX3), CANVAS syndrome, Friedreich ataxia, ataxia with vitamin E deficiency, ataxia-telangiectasia, AOA1 / AOA2, ARSACS, and several mitochondrial ataxias caused by defects in genes such as POLG. Preferably, the cerebellum disorder is selected from the list consisting of cerebellar ataxia, Friedreich ataxia, ataxia with vitamin E deficiency, ataxiatelangiectasia, AOA1 / AOA2, or ARSACS.

[0204] In an embodiment, the pons disorder is selected from the list consisting of Marie-Foix Syndrome, Foville Syndrome, Locked-in Syndrome, Ventral Pontine Syndrome, and Facial Colliculus Syndrome.

[0205] In an embodiment, the medulla oblongata disorder is selected from the list consisting of Wallenberg Syndrome, Dejerine Syndrome, and Babinski-Nageotte Syndrome. In a further alternative fourth aspect, the present invention provides an oligonucleotide as defined in the first aspect or any of its embodiments, or a composition, preferably a pharmaceutical composition, as defined in the second aspect or any of its embodiments, for use in the prevention or treatment of diseases characterized by high fatty acid metabolic demand. “High fatty acid metabolic demand” refers to a condition in which affected cells, tissues, or organ systems exhibit an abnormally elevated requirement for fatty acids as a primary metabolic substrate. Tissues affected by these diseases require highly demand on fatty acids, and are thus hypervascularized, thereby having high concentration of CD36.

[0206] Preferably, the disease characterized by high fatty acid metabolic demand is cancer.

[0207] Preferably, the uses of the oligonucleotide of the invention, conjugated to oleic acid in its 5’ or 3’ end, to treat or prevent any of the diseases described above, involves an intravenous administration.

[0208] Preferably, the oligonucleotide or oligonucleotide analogue molecule as defined in the first aspect or any of its embodiments, alone or comprised in the pharmaceutical composition, for use according to the third or fourth aspects is an inhibitor of the human hsa-miR-218-5p or of the human hsa-miR-23b-3p with SEQ ID NO: 1 or 2, respectively, or a sequence with at least 50%, 60%, 70%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 1 or 2. Preferably, the oligonucleotide or oligonucleotide analogue molecule as defined in the first aspect or any of its embodiments, alone or comprised in the pharmaceutical composition, for use according to the third or fourth aspects is an inhibitor of the human hsa-miR-218-5p or of the human hsa-miR-23b-3p with SEQ ID NO: 80-110 or 52-79, respectively, or a sequence with at least 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 80-110 or 52-79.

[0209] More preferably, the oligonucleotide or oligonucleotide analogue molecule as defined in the first aspect or any of its embodiments for use according to the third or fourth aspects is an antagonist comprising or consisting of SEQ ID NO: 3, 4, or 5 (antimiRs against hsa-miR-23b- 3p) or SEQ ID NO: 7, 8, 9 or 14 (antimiRs against hsa-miR-218-5p), or a sequence with at least 50%, 60%, 70%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 3, 4, or 5 (antimiRs against hsa-miR-23b-3p) or with SEQ ID NO: 7, 8, 9 or 14 (antimiRs against hsa-miR-218-5p). More preferably, the oligonucleotide or oligonucleotide analogue molecule as defined in the first aspect or any of its embodiments for use according to the third or fourth aspects is an antagonist comprising or consisting of SEQ ID NO: 22, 23, 24, 49, 50 or 51 (antimiRs against hsa-miR-23b-3p) or SEQ ID NO: 25, 26, 27 or 28 (antimiRs against hsa-miR-218-5p), or a sequence with at least 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 3, 4, or 5 (antimiRs against hsa-miR-23b-3p) or with SEQ ID NO: 7, 8, 9 or 14 (antimiRs against hsa-miR-218-5p). As mentioned above in the first aspect, the oligonucleotides or analogues thereof for use according to the third and fourth aspects also comprise at least one oleic acid molecule conjugated at their 3' and / or 5' ends.

[0210] In an embodiment of the fourth aspect, the treatment is a palliative treatment of one or more symptoms of myotonic dystrophy type 1 and / or type 2, or a palliative treatment of one or more of the muscular disorders that are part of the symptoms of myotonic dystrophy type 1 and / or type 2. In a preferred embodiment of the fourth aspect, the treatment is for chronic myotonic dystrophy type 1 and / or type 2. In a preferred embodiment, the treatment is a therapeutic treatment. Preferably, said use includes the use of the at least one oleic acid molecule as a vehicle when conjugated to an oligonucleotide molecule and / or analogue thereof to deliver said oligonucleotide molecule and / or analogue thereof to the relevant tissue, such as muscle, CSF and / or to CNS.

[0211] In an embodiment of the third and fourth aspects, the subject in need thereof is a mammal, preferably a human being, more preferably a human suffering from DM, preferably DM1.

[0212] The administration of the antagonist through a possible expression vector thereof allows to direct the expression to a tissue or group of specific tissues according to the tropism of the base vector itself and / or by choosing control elements that give rise to the expression of the coding sequence linked to them only in specific tissues. In addition, some specific dosage forms may favour greater access to one or other organs. Thus, also a possible embodiment, combinable with any other, of the third and fourth aspects of the present invention more directly referring to the therapeutic application thereof, could be defined as: use of one of the oligonucleotide and / or oligonucleotide analogue molecules of the invention, a mixture of two or more of them, or a composition comprising at least one of said molecules, for the manufacture of a medicinal product for the treatment of myotonic dystrophy type 1 by inhibition or antagonism of the action of a human hsa-miR-218-5p or hsa-miR-23b-3p in at least one or more organs selected from the group of the brain, cerebellum, hippocampus, or other central nervous system organs, skeletal muscle, heart, adipose tissue, kidney, liver and biliary system, lung, pharynx, nasopharynx, nose, placenta, spleen, testicle, uterus, gastrointestinal tract, breast, bladder, prostate, skin, keratinocytes and lymphoid cells or stem cells from one or more of these organs. Other organs that can also be targeted by the oligonucleotides of the present invention are selected from the group of the brain, cerebellum, hippocampus or another organ of the central nervous system, skeletal muscle, heart, adipose tissue, kidney, liver and biliary system, lung, pharynx, nasopharynx, nose, placenta, spleen, testicle and uterus, gastrointestinal tract, breast, bladder, prostate, skin, keratinocytes and lymphoid cells or stem cells from one or more of these organs, or combinations thereof, as desired or appropriate.

[0213] Given the stability of the antimiRs, direct administration to mammals, preferably human beings, can be considered, for example via subcutaneous or systemic routes, preferably intravenously or intrathecal, for example dissolved or suspended in a pharmaceutically acceptable carrier, such as water or an aqueous solution such as saline or phosphate buffer, or intraarticular delivery. The composition in which they are administered may contain pharmaceutically acceptable excipients.

[0214] The active compositions of this invention can be administered by any of the common routes, provided that the target tissue is available through that route. This includes oral, nasal, intrathecal, or buccal routes and, preferably, the administration may be via an intradermal, transdermal, subcutaneous, intramuscular, intraperitoneal, or intravenous route. As previously commented, it is common for compositions comprising antimiRs to be formulated for intravenous or subcutaneous administration. However, since oleic acid enhances the delivery of the oligonucleotide molecule and / or analogue thereof to muscle, CSF and / or CNS cells when the administration is intravenous (see Examples 9, 10 and 19), it is a preferred embodiment that the administration is intravenous, intraarterial, intrathecal or subcutaneous. Further, it is also preferably that said intravenous, intrathecal, intraarterial or subcutaneous administration is a chronic administration, which means that it is carried out periodically (during the entire life of the patient in need thereof).

[0215] After formulation, the solutions are preferably administered in a form that is compatible with the dosage formulation and in such a quantity that it is therapeutically effective. Formulations can be easily administered in a variety of dosage forms such as injectable solutions, drug release capsules, and the like.

[0216] In an embodiment of the third and any of the fourth aspects, the oligonucleotides and / or analogues thereof are used to treat a human in need thereof. Preferably, the use comprises administering the oligonucleotide as defined in the first aspect or any of its embodiment, or a composition, preferably a pharmaceutical composition, as defined in the second aspect or any of its embodiments at a dose of between 10 mg to 1125 mg per dose per person, preferably between 10 mg and 300 mg, more preferably between 15 mg and 290 mg, even more preferably between 18 mg and 288 mg, most preferably between 36 mg and 144 mg per dose per person and wherein, preferably, the oligonucleotide and / or oligonucleotide analogue is administered intravenously. Preferably, the use comprises administering the oligonucleotide as defined in the first aspect or any of its embodiment, or a composition, preferably a pharmaceutical composition, as defined in the second aspect or any of its embodiments at a dose of about 10 to about 1125 mg per dose per person, preferably about 10 to about 300 mg, more preferably about 15 to about 290 mg, even more preferably about 18 to about 288 mg, most preferably about 34 to about 144 mg per dose per person. Preferably, the use involves administering to a human, preferably intravenously, the oligonucleotide and / or analogue thereof or of the composition at a dose selected from the list consisting of 18 mg, 36 mg, 72 mg, 144 mg, 288 mg and 576 mg per dose per person. Most preferably, the use involves administering to a human, preferably intravenously, the oligonucleotide and / or analogue thereof or the composition at a dose selected from the list consisting of 36 mg, 72 mg and 144 mg per dose per person.

[0217] In an embodiment, the dose used in humans is 188 mg per dose per person, or less than 188 mg, wherein the administration is preferably via intravenous route. In an embodiment, the dose used in humans is 18 mg per dose per person, or more than 18 mg, wherein the administration is preferably via intravenous route. In an embodiment, the dose used in humans is 36 mg or about 36 mg per dose per person wherein the administration is preferably via intravenous route. In an embodiment, the dose used in humans is 10 mg or about 10 mg per dose per person wherein the administration is preferably via intravenous route. In an embodiment, the dose used in humans is 64 mg or about 64 mg per dose per person wherein the administration is preferably via intravenous route.

[0218] Preferably, the use comprises administering the oligonucleotide as defined in the first aspect or any of its embodiment, or a composition, preferably a pharmaceutical composition, as defined in the second aspect or any of its embodiments at a dose of between 10 to 400 mg per dose per person, or 10 mg to 230 mg per dose per person, preferably between 15 mg and 210 mg, more preferably between 18 mg and 200 mg, even more preferably between 22 mg and 200 mg, most preferably between 22.75 mg and 196.46 mg per dose per person or between 45.50 mg and 181.51 mg per dose per person and wherein, preferably, the oligonucleotide and / or oligonucleotide analogue is administered intrathecally. In an embodiment, the dose in humans is between 22.5 and 392.92 mg per dose per person, wherein the administration is preferably via intrathecal route. Preferably, the oligonucleotide and / or oligonucleotide analogue is formulated to be administrated to a human, preferably intrathecally, at a dose of about 10 to about 230 mg per dose per person, preferably about 15 to about 210 mg, more preferably about 18 to about 200 mg, even more preferably about 22 to about 200 mg, most preferably about 22.75 to about 196.46 mg per dose per person or between 45.50 mg and 181.51 mg per dose per person. Preferably, the dose in humans is selected from the list consisting of 10 mg, 15 mg, 18 mg, 20 mg, 22 mg, 22.75, 45.50, 181.51 or 192 mg per dose per person, wherein the administration is preferably via intrathecal route. Most preferably, the dose in humans is selected from the list consisting of 230 mg, 210 mg and 200 mg per dose per person, wherein the administration is preferably via intrathecal route.

[0219] In an embodiment, the dose used in humans is 200 mg per dose per person, or less than 200 mg, wherein the administration is preferably via intrathecal route. In an embodiment, the dose used in humans is 18 mg per dose per person, or more than 18 mg, wherein the administration is preferably via intrathecal route. In an embodiment, the dose used in humans is 36 mg or about 36 mg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the dose used in humans is 10 mg or about 10 mg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the dose used in humans is 64 mg or about 64 mg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the dose used in humans is 22.75 mg or about 22.75 mg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the dose used in humans is 45.50 mg or about 45.50 mg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the dose used in humans is 181.51 mg or about 181.51 mg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the dose used in humans is 196.46 mg or about 196.46 mg per dose per person wherein the administration is preferably via intrathecal route.

[0220] Preferably, the use comprises administering the oligonucleotide as defined in the first aspect or any of its embodiment, or a composition, preferably a pharmaceutical composition, as defined in the second aspect or any of its embodiments at a dose of between 0.142 mg per kg of body weight (mg / kg) to 16.07 mg / kg, preferably between 0.142 mg / kg and 4.285 mg / kg, more preferably between 0.214 mg / kg and 4.142 mg / kg, even more preferably between 0.257 mg / kg and 4.114 mg / kg, most preferably between 0. 4878 mg / kg and 2.057 mg / kg, and wherein, preferably, the oligonucleotide and / or oligonucleotide analogue or the composition is administered intravenously. Preferably, the use comprises administering the oligonucleotide as defined in the first aspect or any of its embodiment, or a composition, preferably a pharmaceutical composition, as defined in the second aspect or any of its embodiments at a dose of about 0.142 mg to about 16,07 mg per kg of body weight (mg / kg), preferably about 0.142 mg / kg to about 4.285 mg / kg, more preferably about 0.214 mg / kg to about 4.142 mg / kg, even more preferably about 0.257 mg / kg to about 4.114 mg / kg, most preferably about 0.4878 mg / kg to about 2.057 mg / kg. Preferably, the use involves administering to a human, preferably intravenously, the oligonucleotide and / or analogue thereof at a dose selected from the list consisting of 0.257 mg / kg, 0.514 mg / kg, 1.028 mg / kg, 2.057 mg / kg, 4.114 mg / kg and 8.228 mg / kg. Preferably, the use involves administering to a human, preferably intravenously, the oligonucleotide and / or analogue thereof a dose selected from the list consisting of 0.514 mg / kg, 1.028 mg / kg and 2.057 mg / kg.

[0221] In an embodiment, the dose used in humans is 2.68 mg / kg, or less than 2.68 mg / kg, wherein the administration is preferably via intravenous route. In an embodiment, the dose used in humans is 0.257 mg / kg or more than 0.257 mg / kg, wherein the administration is preferably via intravenous route. In an embodiment, the dose used in humans is 0.51 mg / kg or about 0.51 mg / kg, wherein the administration is preferably via intravenous route. In an embodiment, the dose used in humans is 0.14 mg / kg or about 0.14 mg / kg per dose per person wherein the administration is preferably via intravenous route. In an embodiment, the dose used in humans is 0.91 mg / kg or about 0.91 mg / kg per dose per person wherein the administration is preferably via intravenous route.

[0222] Preferably, the use comprises administering the oligonucleotide as defined in the first aspect or any of its embodiment, or a composition, preferably a pharmaceutical composition, as defined in the second aspect or any of its embodiments at a dose of between 0.14 and 5.71 mg per kg of body weight (mg / kg), or between 0.142 mg to 3.28 mg / kg, preferably between 0.214 mg / kg and 3 mg / kg, more preferably between 0.25 mg / kg and 2.85 mg / kg, even more preferably between 0.31 mg / kg and 2.85 mg / kg, most preferably between 0.325 mg / kg and 2.808 mg / kg or between 0.65 mg / kg and 2.59 mg / kg, and wherein, preferably, the oligonucleotide and / or oligonucleotide analogue is administered intrathecally. Preferably, the oligonucleotide and / or oligonucleotide analogue is formulated to be administrated to a human, preferably intrathecally, at a dose of about 0.142 mg to about 3.28 mg per kg of body weight (mg / kg), preferably about 0.214 mg / kg to about 3 mg / kg, more preferably about 0.25 mg / kg to about 2.85 mg / kg, even more preferably about 0.31 mg / kg to about 2.85 mg / kg, most preferably about 0.325 mg / kg to about 2.808 mg / kg or about 0.65 mg / kg to about 2.59 mg / kg. In an embodiment, the dose in humans is between 0.32 mg / kg and 5.91 mg / kg, wherein the administration is preferably via intrathecal route. Preferably, the dose in humans is selected from the list consisting of 0.142, 0.214, 0.25, 0.28, 0.31 , 0.325 and 0.65, 2.59, 2.80 and 2.85 mg / kg, wherein the administration is preferably via intrathecal route. Most preferably, the dose in humans is selected from the list consisting of 0.32, 0.65, 2.59 and 2.80 mg / kg, wherein the administration is preferably via intrathecal route.

[0223] In an embodiment, the dose used in humans is 2.85 mg / kg, or less than 2.85 mg / kg, wherein the administration is preferably via intrathecal route. In an embodiment, the dose used in humans is 0.325 mg / kg or more than 0.325mg / kg, wherein the administration is preferably via intrathecal route. In an embodiment, the dose used in humans is 0.65 mg / kg or more than 0.65 mg / kg, wherein the administration is preferably via intrathecal route. In an embodiment, the dose used in humans is 0.514 mg / kg or about 0.514 mg / kg, wherein the administration is preferably via intrathecal route. In an embodiment, the dose used in humans is 0.14 mg / kg or about 0.14 mg / kg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the dose used in humans is 0.91 mg / kg or about 0.91 mg / kg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the dose used in humans is 0.32 mg / kg or about 0.32 mg / kg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the dose used in humans is 0.65 mg / kg or about 0.65 mg / kg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the dose used in humans is 2.59 mg / kg or about 2.59 mg / kg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the dose used in humans is 2.80 mg / kg or about 2.80mg / kg per dose per person wherein the administration is preferably via intrathecal route.

[0224] Preferably, the use comprises administering the oligonucleotide as defined in the first aspect or any of its embodiment, or a composition, preferably a pharmaceutical composition, as defined in the second aspect or any of its embodiments at a dose of between 0.142 mg per kg of body weight per day of administration (mg / kg / day) and 16,07 mg / kg / day, preferably between 0.142 mg / kg / day and 4.285 mg / kg / day, more preferably between 0.214 mg / kg / day and 4.142 mg / kg / day, even more preferably between 0.257 mg / kg / day and 4.114 mg / kg / day, most preferably between 0. 4878 mg / kg / day and 2.057 mg / kg / day, and wherein, preferably, the oligonucleotide and / or oligonucleotide analogue or the composition is administered intravenously. Preferably, the use involves administering to a human, preferably intravenously, a dose of the oligonucleotide and / or analogue thereof selected from the list consisting of 0.257 mg / kg / day, 0.514 mg / kg / day, 1.028 mg / kg / day, 2.057 mg / kg / day, 4.114 mg / kg / day and 8.228 mg / kg / day of administration. Preferably, the use involves administering to a human, preferably intravenously, a dose of the oligonucleotide and / or analogue thereof selected from the list consisting of 0.514 mg / kg / day, 1 .028 mg / kg / day and 2.057 mg / kg / day of administration. In an embodiment, the dose used in humans is 2.68 mg / kg / day, or less than 2.68 mg / kg / day, wherein the administration is preferably via intravenous route. In an embodiment, the dose used in humans is 0.257 mg / kg / day or more than 0.257mg / kg / day, wherein the administration is preferably via intravenous route. In an embodiment, the dose used in humans is 0.51 mg / kg / day or about 0.51 mg / kg / day, wherein the administration is preferably via intravenous route. In an embodiment, the dose used in humans is 0.14 mg / kg / day or about 0.14 mg / kg / day wherein the administration is preferably via intravenous route. In an embodiment, the dose used in humans is 0.91 mg / kg / day or about 0.91 mg / kg / day herein the administration is preferably via intravenous route.

[0225] Preferably, the use comprises administering the oligonucleotide as defined in the first aspect or any of its embodiment, or a composition, preferably a pharmaceutical composition, as defined in the second aspect or any of its embodiments at a dose of between 0.14 and 5.71 mg per kg of body weight per day of administration (mg / kg / day of administration), or 0.142 mg mg / kg / day and 3.28 mg / kg / day of administration, preferably between 0.214 mg / kg / day of administration and 3 mg / kg / day of administration, more preferably between 0.25 mg / kg / day of administration and 2.85 mg / kg / day of administration, even more preferably between 0.31 mg / kg / day of administration and 2.85 mg / kg / day of administration, most preferably between 0.325 mg / kg / day of administration and 2.808 mg / kg / day of administration or between 0.65 mg / kg / day and 2.59 mg / kg / day of administration, and wherein, preferably, the oligonucleotide and / or oligonucleotide analogue is administered intrathecal ly. In an embodiment, the dose in humans is between 0.32 mg / kg / day and 5.91 mg / kg / day, wherein the administration is preferably via intrathecal route. Preferably, the dose in humans is selected from the list consisting of 0.142 mg / kg / day, 0.214 mg / kg / day, 0.25 mg / kg / day, 0.28 mg / kg / day, 0.31 mg / kg / day, 0.325 mg / kg / day, 0.65 mg / kg / day, 2.59 mg / kg / day, 2.80 mg / kg / day and 2.85 mg / kg / day wherein the administration is preferably via intrathecal route. Preferably, the dose in humans is selected from the list consisting of 3.28 mg / kg / day, 3 mg / kg / day and 2.85 mg / kg / day of administration, wherein the administration is preferably via intrathecal route. Most preferably, the dose in humans is selected from the list consisting of 0.32 mg / kg / day, 0.65 mg / kg / day, 2.59 mg / kg / day and 2.80 mg / kg / day of administration, wherein the administration is preferably via intrathecal route.

[0226] In an embodiment, the dose used in humans is 2.85 mg / kg / day, or less than 2.85 mg / kg / day, wherein the administration is preferably via intrathecal route. In an embodiment, the dose used in humans is 0.325 mg / kg / day or more than 0.325 mg / kg / day, wherein the administration is preferably via intrathecal route. In an embodiment, the dose used in humans is 0.65 mg / kg / day or more than 0.65 mg / kg / day, wherein the administration is preferably via intrathecal route. In an embodiment, the dose used in humans is 0.514 mg / kg / day or about 0.514 mg / kg / day, wherein the administration is preferably via intrathecal route. In an embodiment, the dose used in humans is 0.14 mg / kg / day or about 0.14 mg / kg / day wherein the administration is preferably via intrathecal route. In an embodiment, the dose used in humans is 0.91 mg / kg / day or about 0.91 mg / kg / day herein the administration is preferably via intrathecal route. In an embodiment, the dose used in humans is 0.32 mg / kg / day or about 0.32 mg / kg / day herein the administration is preferably via intrathecal route. In an embodiment, the dose used in humans is 0.65 mg / kg / day or about 0.65 mg / kg / day herein the administration is preferably via intrathecal route. In an embodiment, the dose used in humans is 2.59 mg / kg / day or about 2.59 mg / kg / day herein the administration is preferably via intrathecal route. In an embodiment, the dose used in humans is 2.80mg / kg / day or about 2.80 mg / kg / day herein the administration is preferably via intrathecal route.

[0227] Administration of a dose can be accomplished by a single administration, such as by bolus injection, or in several administrations over a period of time, or by continuous infusion over an appropriate period of time. Preferably, the use involves administering the dose in a single administration step, preferably intravenously or intrathecally. Preferably, the use involves administering the dose once every 2 weeks, once a month, or once every eight weeks. Preferably, the use involves administering the dose every two weeks or every month.

[0228] A further aspect provides a method of treating DM, preferably DM1 , in a subject in need thereof, the method comprising administering the oligonucleotides or pharmaceutical compositions of the present invention to a patient in need thereof. In some embodiments, the oligonucleotides will be present at a concentration that allows the administration of a therapeutically effective dose. Preferably, said method of treatment includes the use of the at least one oleic acid molecule as a vehicle when conjugated to an oligonucleotide molecule and / or analogue thereof to deliver said oligonucleotide molecule and / or analogue thereof to the relevant tissue, such as muscle, CSF and / or to CNS.

[0229] As explained above, the Examples provide evidence on how the oleic acid is capable of increasing the delivery to target issues such as muscle and brain. This lead to the conclusion that oleic acid is capable of not only reducing the toxicity when a higher amount of PS with respect to PO is included in the molecule, but also oleic acid is an efficient vehicle to transport the oligonucleotide molecule and / or analogue thereof to target tissues, such as muscle, CSF and / or CNS (particularly to the hindbrain, more particularly to cerebellum). In view of this, a fifth aspect of the present invention relates to the use of at least one oleic acid molecule as a pharmaceutically acceptable vehicle or carrier when said oleic acid is conjugated to a oligonucleotide molecule and / or analogue thereof, preferably conjugated to the 3’ or the 5’ of said oligonucleotide molecule and / or analogue. Importantly, the use of at least one oleic acid molecule as a pharmaceutically acceptable vehicle or carrier refers to a use in which the oleic acid molecule is responsible of the transport, delivery, carriage, of the oligonucleotide molecule and / or analogue thereof to which it is conjugated, to a specific target tissue, preferably muscle, CSF and / or CNS tissue (particularly to the hindbrain, more particularly to cerebellum). In this context, “vehicle” and “carrier” are considered synonymous and thus are used interchangeably. Preferably, the oleic acid is responsible of the transport, delivery, carriage, of a oligonucleotide molecule and / or analogue thereof to which is conjugated in its 3’ and / or 5’ end, when the oligonucleotide molecule and / or analogue (conjugated to oleic acid) is administrated intrathecally or intravenously. All of the dosages disclosed in the first aspect apply to the fifth aspects.

[0230] The skilled person in the art knows how to test whether oleic acid is acting as a vehicle for the oligonucleotide molecule and / or analogue thereof to which it is conjugated to. For example, a way of evaluating whether the at least one oleic acid is being used a vehicle is by measuring the amount of the oligonucleotide molecule and / or analogue thereof that arrives at a target tissue (preferably CNS, CSF and / or muscle tissue) after intravenous, intrathecal, intraarterial or subcutaneous administration, and comparing said amount to the amount present in said tissue when the oligonucleotide molecule and / or analogue thereof is administrated not conjugated to the at least one oleic acid.

[0231] Preferably, the oligonucleotide molecule and / or analogue thereof to which the oleic acid is conjugated is the oligonucleotide molecule and / or analogue thereof defined in the first aspect of the present invention, or any of its embodiments. Hence, a preferred embodiment of the fifth aspect refers to the use of at least one oleic acid molecule as a pharmaceutically acceptable vehicle or carrier when said oleic acid conjugated to the 3’ end or the 5’ end of the oligonucleotide molecule and / or analogue thereof defined in the first aspect, preferably wherein said oligonucleotide molecule and / or analogue thereof is the active ingredient of a method of treatment by therapy as defined in the third or fourth aspects of the present invention or any of their embodiments. It is noted that the conjugation between the oligonucleotide molecule and / or analogue thereof may be a direct conjugation or a conjugation throughout a spacer molecule, as described in under the first aspect of the present invention. Preferably, the oleic acid used as a vehicle is conjugated to the oligonucleotide molecule and / or analogue thereof via a spacer molecule selected from the group consisting of NHC3, NHC5, NHC6, threoninol, and a derivative thereof. In an embodiment of the fifth aspect, only one oleic acid molecule is conjugated to the 5’ end or 3’ end of the oligonucleotide molecule and / or analogue thereof of the first aspect or any of its embodiments, so that the single oleic acid molecule acts as a vehicle of said oligonucleotide molecule and / or analogue thereof. In an embodiment of the fifth aspect, only one oleic acid molecule is conjugated to the oligonucleotide molecule and / or analogue thereof of the first aspect or any of its embodiments, so that the single oleic acid molecule acts as a vehicle of said oligonucleotide molecule and / or analogue thereof, and the oligonucleotide molecule o and / or analogue thereof defined in the first aspect acts as an active ingredient in a method of treatment by therapy as defined in the third or fourth aspects. Preferably, the treatment is of hindbrain disorders, more preferably cerebellum disorders, as described above.

[0232] In a preferred embodiment, the at least one oleic acid molecule conjugated to the oligonucleotide molecule and / or analogue thereof as defined in the first aspect of the present invention, or any of its embodiments, is capable of transporting said oligonucleotide molecule and / or analogue thereof to tissues of interest (or target tissue), such as muscle, CSF and / or CNS, with more efficiency that when the oligonucleotide molecule and / or analogue thereof is not conjugated to oleic acid, as shown in Example 9 or 10. Hence, the oleic acid molecule is used as an active ingredient delivery vehicle, wherein the active ingredient component is the oligonucleotide molecule and / or analogue thereof, preferably the oligonucleotide or analogue thereof as defined in the first aspect or any of its embodiments. As shown in Examples 22-24, the oleic acid delivers the oligonucleotide, preferably the oligonucleotide of the first aspect, to deep brain regions, particularly hindbrain, more particularly cerebellum, when administered intravenous. Preferably, the oleic acid is conjugated to the 3’ end of the oligonucleotide, preferably the oligonucleotide of the first aspect, and is administered intravenous to treat hindbrain disorders, preferably cerebellum disorders.

[0233] In an embodiment, the at least one oleic acid molecule is used as a pharmaceutically acceptable vehicle or carrier when conjugated to the 3’ end or the 5’ end of an oligonucleotide or analogue thereof, preferably the oligonucleotide molecule and / or analogue of the first aspect or any of its embodiments, wherein the oligonucleotide molecule and / or analogue thereof comprises a mixture of phosphorothioate and phosphodiester linkages chemically linking the nucleotides, preferably wherein the number of nucleotides that are chemically linked by a phosphorothioate linkage is greater than the number of nucleotides that are chemically linked by a phosphodiester linkage.

[0234] In an embodiment, the at least one oleic acid molecule is used as a pharmaceutically acceptable vehicle or carrier when conjugated to the 3’ end or the 5’ end of the oligonucleotide molecule and / or analogue of the first aspect or any of its embodiments, wherein said oligonucleotide molecule and / or analogue thereof is an antagonist of a microRNA, preferably an antagonist of the human has-miR-23b-3p or the humhashsa-miR-218-5p.

[0235] In an embodiment, the at least one oleic acid molecule is used as a pharmaceutically acceptable vehicle or carrier when conjugated to the 3’ end or the 5’ end of an oligonucleotide or analogue thereof, preferably the oligonucleotide molecule and / or analogue of the first aspect or any of its embodiments, wherein the oleic acid used as a vehicle delivers said oligonucleotide molecule and / or analogue thereof to muscular, CSF and / or CNS (particularly to the hindbrain, more particularly to cerebellum) cells in a subject in need thereof when said oligonucleotide molecule and / or analogue thereof is administrated via intravenous, intrathecal, intraarterial or subcutaneous route. Preferably, the route is intravenous.

[0236] In an embodiment, at least one oleic acid molecule is used as a pharmaceutically acceptable vehicle or carrier when conjugated to the 3’ end or the 5’ end of an oligonucleotide or analogue thereof, preferably the oligonucleotide molecule and / or analogue thereof as defined in the first aspect or any of its embodiments, wherein said oligonucleotide molecule and / or analogue thereof is the active ingredient of a method of treatment by therapy that comprises the prevention or treatment of muscular diseases, nervous system diseases, and / or RNAopathies.

[0237] In an embodiment, the at least one oleic acid molecule is used as a pharmaceutically acceptable vehicle or carrier when conjugated to the 3’ end or the 5’ end of an oligonucleotide or analogue thereof, preferably the oligonucleotide molecule or analogue thereof as defined in the first aspect or any of its embodiments, wherein said oligonucleotide molecule and / or analogue thereof is the active ingredient of a method of treatment by therapy that comprises the prevention or treatment of myotonic dystrophy, preferably myotonic dystrophy is of type 1.

[0238] In an embodiment of the fifth aspect, the one oleic acid molecule used as a pharmaceutically acceptable vehicle or carrier when said oleic acid is conjugated to an oligonucleotide molecule and / or analogue thereof is administrated at any of the doses disclosed above, and at any of the routed disclosed above.

[0239] Preferably, the oleic acid is for use as a vehicle or carrier to deliver an oligonucleotide molecule or analogue thereof to a target tissue in a human, wherein the oleic acid molecule is conjugated to the 3’ and / or 5’ end of said oligonucleotide molecule or analogue thereof, wherein the oligonucleotide molecule or analogue thereof is the active ingredient of a method of treatment by therapy, and wherein said oligonucleotide molecule or analogue thereof is administered in humans at a dose of between 18 mg and 288 mg per person, and wherein the administration is intravenous or intrathecal.

[0240] Preferably, the oleic acid is for use as a vehicle or carrier to deliver an oligonucleotide molecule or analogue thereof to a target tissue in a human, wherein the wherein the dose is between 33 mg and 144 mg per person, and the administration is intravenous. Preferably, the oleic acid is for use as a vehicle or carrier to deliver an oligonucleotide molecule or analogue thereof to a target tissue in a human, wherein the dose is between 22.75 mg and 196.46 mg per person, and the administration is intrathecal. Preferably, the target tissue is central nervous system (CNS), muscular tissue, and / or cerebrospinal fluid (CSF). More preferably, the target tissue is hindbrain, preferably cerebellum. Preferably, the oligonucleotide molecule or analogue thereof is the active ingredient in a method of treatment or prevention of muscular and / or nervous system diseases, preferably diseases affecting the hindbrain, particularly the cerebellum, as defined above.

[0241] Preferably, the oleic acid molecule is for use as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, preferably the oligonucleotide molecule and / or analogue thereof of the first aspect or any of it embodiments, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of between 10 mg to 1125 mg per dose per person, preferably between 10 mg and 300 mg, more preferably between 15 mg and 290 mg, even more preferably between 18 mg and 288 mg, most preferably between 33 mg and 144 mg per dose per person and wherein, preferably, the oligonucleotide and / or oligonucleotide analogue is administered intravenously. Preferably, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of about 10 to about 1125 mg per dose per person, preferably about 10 to about 300 mg, more preferably about 15 to about 290 mg, even more preferably about 18 to about 288 mg, most preferably about 34 to about 144 mg per dose per person, wherein preferably the administration is intravenously. Preferably, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose selected from the list consisting of 18 mg, 36 mg, 72 mg, 144 mg, 288 mg and 576 mg per dose per person, wherein the administration is preferably via intravenous route. Most preferably, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose selected from the list consisting of 36 mg, 72 mg and 144 mg per dose per person, wherein the administration is preferably via intravenous route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 188 mg per dose per person, or less than 188 mg, wherein the administration is preferably via intravenous route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 18 mg per dose per person, or more than 18 mg, wherein the administration is preferably via intravenous route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 36 mg or about 36 mg per dose per person wherein the administration is preferably via intravenous route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 10 mg or about 10 mg per dose per person wherein the administration is preferably via intravenous route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 64 mg or about 64 mg per dose per person wherein the administration is preferably via intravenous route.

[0242] In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of between 0.142 mg to 16.07 mg per kg of body weight (mg / kg), preferably between 0.142 mg / kg and 4.285 mg / kg, more preferably between 0.214 mg / kg and 4.142 mg / kg, even more preferably between 0.257 mg / kg and 4.114 mg / kg, most preferably between 0.4878 mg / kg and 2.057 mg / kg, and wherein, preferably, the oligonucleotide and / or oligonucleotide analogue conjugated to the oleic acid is administered intravenously. Preferably, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated, preferably intravenously, at a dose of about 0.142 mg to about 16,07 mg per kg of body weight (mg / kg), preferably about 0.142 mg / kg to about 4.285 mg / kg, more preferably about 0.214 mg / kg to about 4.142 mg / kg, even more preferably about 0.257 mg / kg to about 4.114 mg / kg, most preferably about 0.4878 mg / kg to about 2.057 mg / kg. Preferably, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose selected from the list consisting of 0.257 mg / kg, 0.514 mg / kg, 1.028 mg / kg, 2.057 mg / kg, 4.114 mg / kg and 8.228 mg / kg, wherein the administration is preferably via intravenous route. Most preferably, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose selected from the list consisting of 0.514 mg / kg, 1.028 mg / kg and 2.057 mg / kg, wherein the administration is preferably via intravenous route.

[0243] In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 2.68 mg / kg, or less than 2.68 mg / kg, wherein the administration is preferably via intravenous route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 0.257 mg / kg or more than 0.257 mg / kg, wherein the administration is preferably via intravenous route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 0.51 mg / kg or about 0.51 mg / kg, wherein the administration is preferably via intravenous route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 0.14 mg / kg or about 0.14 mg / kg per dose per person wherein the administration is preferably via intravenous route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 0.91 mg / kg or about 0.91 mg / kg per dose per person wherein the administration is preferably via intravenous route.

[0244] In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of between 0.142 mg per kg of body weight per day of administration (mg / kg / day of administration) and 16,07 mg / kg / day of administration, preferably between 0.142 mg / kg / day of administration and 4.285 mg / kg / day of administration, more preferably between 0.214 mg / kg / day of administration and 4.142 mg / kg / day of administration, even more preferably between 0.257 mg / kg / day of administration and 4.114 mg / kg / day of administration, most preferably between 0. 4878 mg / kg / day of administration and 2.057 mg / kg / day of administration, and wherein, preferably, the oligonucleotide and / or oligonucleotide analogue is administered intravenously. Preferably, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose selected from the list consisting of 0.257 mg / kg / day, 0.514 mg / kg / day, 1.028 mg / kg / day, 2.057 mg / kg / day, 4.114 mg / kg / day and 8.228 mg / kg / day of administration, wherein the administration is preferably via intravenous route. Most preferably, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 0.514 mg / kg / day, 1.028 mg / kg / day and 2.057 mg / kg / day of administration, wherein the administration is preferably via intravenous route.

[0245] In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 2.68 mg / kg / day, or less than 2.68 mg / kg / day, wherein the administration is preferably via intravenous route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 0.257 mg / kg / day or more than 0.257 mg / kg / day, wherein the administration is preferably via intravenous route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 0.51 mg / kg / day or about 0.51 mg / kg / day, wherein the administration is preferably via intravenous route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 0.14 mg / kg / day or about 0.14 mg / kg / day wherein the administration is preferably via intravenous route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 0.91 mg / kg / day or about 0.91 mg / kg / day herein the administration is preferably via intravenous route.

[0246] In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of between 10 to 400 mg per dose per person, or 10 mg to 230 mg per dose per person, preferably between 15 mg and 210 mg, more preferably between 18 mg and 200 mg, even more preferably between 22 mg and 200 mg, most preferably between 22.75 mg and 196.46 mg per dose per person or between 45.50 mg and 181.51 mg per dose per person and wherein, preferably, the oligonucleotide and / or oligonucleotide analogue is administered intrathecally. Preferably, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated, preferably intrathecally, at a dose of about 10 to about 230 mg per dose per person, preferably about 15 to about 210 mg, more preferably about 18 to about 200 mg, even more preferably about 22 to about 200 mg, most preferably about 22.75 to about 196.46 mg per dose per person or between 45.50 mg and 181.51 mg per dose per person. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of between 22.5 and 392.92 mg per dose per person, wherein the administration is preferably via intrathecal route.

[0247] Preferably, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose elected from the list consisting of 10 mg, 15 mg, 18 mg, 20 mg, 22 mg, 22.75 mg, 45.50 mg, 181.51 mg, 196.46 and 200 mg per dose per person, wherein the administration is preferably via intrathecal route. Most preferably, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose selected from the list consisting of 22.75 mg, 45.50 mg, 181.51 mg and 196.46 mg per dose per person, wherein the administration is preferably via intrathecal route.

[0248] In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 200 mg per dose per person, or less than 200 mg, wherein the administration is preferably via intrathecal route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 18 mg per dose per person, or more than 18 mg, wherein the administration is preferably via intrathecal route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 36 mg or about 36 mg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 10 mg or about 10 mg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 64 mg or about 64 mg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 22.75 mg or about 22.75 mg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 45.50 mg or about 45.50 mg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 181.51 mg or about 181.51 mg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 196.46 mg or about 196.46 mg per dose per person wherein the administration is preferably via intrathecal route.

[0249] In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of between 0.14 and 5.71 mg per kg of body weight (mg / kg), or between 0.142 mg to 3. 28 mg / kg, preferably between 0.214 mg / kg and 3 mg / kg, more preferably between 0.25 mg / kg and 2.85 mg / kg, even more preferably between 0.31 mg / kg and 2.85 mg / kg, most preferably between 0.325 mg / kg and 2.808 mg / kg or between 0.65 mg / kg and 2.59 mg / kg and wherein, preferably, the oligonucleotide and / or oligonucleotide analogue is administered intrathecally. Preferably, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated, preferably intrathecally, at a dose of about 0.142 mg to about 3.28 mg per kg of body weight (mg / kg), preferably about 0.214 mg / kg to about 3 mg / kg, more preferably about 0.25 mg / kg to about 2.85 mg / kg, even more preferably about 0.31 mg / kg to about 2.85 mg / kg, most preferably about 0.325 mg / kg to about 2.8087 mg / kg or about 0.65 mg / kg to about 2.59 mg / kg.

[0250] In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of between 0.32 mg / kg / and 5.91 mg / kg, wherein the administration is preferably via intrathecal route. Preferably, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose selected from the list consisting of 0.14 mg / kg, 0.21 mg / kg, 0.25 mg / kg, 0.28 mg / kg, 0.31 mg / kg, 0.32 mg / kg, 0.65 mg / kg, 2.59 mg / kg, 2.80 mg / kg and 2.85 mg / kg , wherein the administration is preferably via intrathecal route. Most preferably, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose selected from the list consisting of 0.32 mg / kg, 0.65 mg / kg, 2.59 mg / kg and 2.80 mg / kg , wherein the administration is preferably via intrathecal route.

[0251] In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 2.85 mg / kg, or less than 2.85 mg / kg, wherein the administration is preferably via intrathecal route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 0.325 mg / kg or more than 0.325mg / kg, wherein the administration is preferably via intrathecal route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 0.65 mg / kg or more than 0.65mg / kg, wherein the administration is preferably via intrathecal route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 0.514 mg / kg or about 0.514 mg / kg, wherein the administration is preferably via intrathecal route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 0.14 mg / kg or about 0.14 mg / kg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 0.91 mg / kg or about 0.91 mg / kg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 0.32 mg / kg or about 0.32 mg / kg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 0.65 mg / kg or about 0.65 mg / kg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 2.59 mg / kg or about 2.59 mg / kg per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 2.80 mg / kg or about 2.80 mg / kg per dose per person wherein the administration is preferably via intrathecal route.

[0252] In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of between 0.14 and 5.71 mg per kg of body weight per day of administration (mg / kg / day), or 0.142 mg / kg / day of administration and 3.28 mg / kg / day of administration, preferably between 0.214 mg / kg / day of administration and 3 mg / kg / day of administration, more preferably between 0.25 mg / kg / day of administration and 2.85 mg / kg / day of administration, even more preferably between 0.31 mg / kg / day of administration and 2.85 mg / kg / day of administration, most preferably between 0.325 mg / kg / day of administration and 2.808 mg / kg / day of administration or between 0.65 mg / kg / day and 2.59 mg / kg / day of administration, and wherein, preferably, the oligonucleotide and / or oligonucleotide analogue is administered intrathecally. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of between 0.32 mg / kg / day and 5.91 mg / kg / day, wherein the administration is preferably via intrathecal route.

[0253] Preferably, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose is selected from the list consisting of 0.14 mg / kg / day, 0.21 mg / kg / day, 0.25 mg / kg / day, 0.28 mg / kg / day, 0.31 mg / kg / day, 0.32 mg / kg / day, 0.65 mg / kg / day, 2.59 mg / kg / day, 2.80 mg / kg / day and 2.85 mg / kg / day, wherein the administration is preferably via intrathecal route. Most preferably, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose selected from the list consisting of 0.32 mg / kg / day, 0.65 mg / kg / day, 2.59 mg / kg / day and 2.80 mg / kg / day , wherein the administration is preferably via intrathecal route.

[0254] In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 2.85 mg / kg / day, or less than 2.85 mg / kg / day, wherein the administration is preferably via intrathecal route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 0.325 mg / kg / day or more than 0.325 mg / kg / day, wherein the administration is preferably via intrathecal route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 0.65 mg / kg / day or more than 0.56 mg / kg / day, wherein the administration is preferably via intrathecal route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 0.514 mg / kg / day or about 0.514 mg / kg / day, wherein the administration is preferably via intrathecal route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 0.14 mg / kg / day or about 0.14 mg / kg / day wherein the administration is preferably via intrathecal route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 0.91 mg / kg / day or about 0.91 mg / kg / day herein the administration is preferably via intrathecal route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 0.32 mg / kg / day or about 0.32 mg / kg / day per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 0.65 mg / kg / day or about 0.65 mg / kg / day per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 2.59 mg / kg / day or about 2.59 mg / kg / day per dose per person wherein the administration is preferably via intrathecal route. In an embodiment, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is administrated at a dose of 2.80 mg / kg / day or about 2.80 mg / kg / day per dose per person wherein the administration is preferably via intrathecal route.

[0255] In an embodiment of the fifth aspect, the oleic acid molecule is used as a vehicle to deliver an oligonucleotide molecule and / or analogue thereof, wherein said oligonucleotide molecule and / or analogue thereof is selected from the list consisting SEQ ID NOs: 22 (MD23b-2 V2 3' Ol), 23 (MD23b-2-PS / PO 3'01), or 25 (218 MOE Oleic 3'), and wherein the spacer molecule defined in said SEQ ID NOs: 22, 23 or 25 is selected from the group consisting of NHC3, NHC5, NHC6, and threoninol, and wherein the oligonucleotide molecule is formulated to be administered in humans at a dose of between 18 mg and 288 mg per person. Preferably, the oleic acid for use as a vehicle is conjugated to the 5’ and / or 3’ of an oligonucleotide molecule and / or analogue thereof selected from the list consisting of SEQ ID NOs: 3, 4 or 7, wherein the oligonucleotide molecule is formulated to be administered in humans at a dose of between 18 mg and 288 mg per person.

[0256] Preferably, the oleic acid for use as a vehicle is conjugated to the 5’ and / or 3’ of an oligonucleotide molecule and / or analogue thereof selected from the list consisting of SEQ ID NOs: 22, 23, m 24, 3, 4 or 7, wherein the oligonucleotide molecule is formulated to be administered in humans at a dose of between 33 mg and 144 mg per person (assuming an average of 70kg of body weight), and wherein the administration is preferably intravenous.

[0257] Preferably, the oleic acid for use as a vehicle is conjugated to the 5’ and / or 3’ of an oligonucleotide molecule and / or analogue thereof selected from the list consisting of SEQ ID NOs: 22, 23, m 24, 3, 4 or 7, wherein the oligonucleotide molecule is formulated to be administered in humans at a dose of between 22.5 mg and 196.46 mg per person (assuming an average of 70kg of body weight), and wherein the administration is preferably intrathecally.

[0258] Preferably, the oleic acid for use as a vehicle according to the fifth aspect, is for delivering to muscular, CSF and / or CNS cells in a subject in need thereof when said oligonucleotide molecule and / or analogue thereof, preferably when administrated via intravenous or intrathecal.

[0259] In a sixth aspect, the invention also provides a conjugate, wherein the conjugate consists of at least one oleic acid conjugated to the 3’ end or 5’ end of the oligonucleotide molecule or analogue thereof as defined in the first aspect or any of its embodiments, wherein said oligonucleotide molecule or analogue thereof is used as an active ingredient in a method of treatment by therapy as defined in the third or fourth aspects or any of their embodiments, and wherein the at least one oleic acid is used as a pharmaceutically acceptable vehicle for delivering said oligonucleotide molecule or analogue thereof to the target tissues, such as CNS, CSF and / or muscle tissue, as explained in the fifth aspect or any of its embodiments.

[0260] In an embodiment, the conjugate only comprises one oligonucleotide molecule, to which an oleic acid is conjugated, either directly or indirectly (i.e., by means of a linker), wherein said oligonucleotide molecule is the active ingredient, and the oleic acid is the carrier. The dosages, uses, and features of the oligonucleotide molecule and oleic acid describe above, also apply to the conjugate.

[0261] This aspect includes the uses as defined in the third and fourth aspects. The dosages explained above also apply to this aspect.

[0262] The following clauses are also included in the present invention:

[0263] 1. An oligonucleotide molecule, or a mixture of two or more of said molecules, wherein said oligonucleotide molecule comprises between 10 to 30 nucleotides in length, wherein said oligonucleotide molecule comprises at least two nucleotides chemically linked by a phosphoroth ioate linkage, and wherein said oligonucleotide molecule is conjugated at its 3' and / or 5' ends to at least one oleic acid molecule.

[0264] 2. The oligonucleotide molecule of clause 1 , wherein the molecule is an antagonist of a microRNA.

[0265] 3. The oligonucleotide molecule of clause 2, wherein the microRNA is the human hsa- miR-23b-3p or the human hsa-miR-218-5p.

[0266] 4. The oligonucleotide molecule according to any of clauses 1 to 3, wherein said oligonucleotide molecule comprises between 15 to 30 nucleotides in length, wherein at least two nucleotides of said molecule are linked by a phosphodiester linkage and wherein the number of nucleotides that are chemically linked by a phosphoroth ioate linkage is greater than the number of nucleotides that are chemically linked by a phosphodiester linkage.

[0267] 5. The oligonucleotide molecule according to of any of clauses 1 to 4, wherein said oligonucleotide molecule comprises between 15 to 30 nucleotides in length, and wherein said oligonucleotide molecule comprises a fragment composed of a succession of at least 15 consecutive nitrogen bases of nucleotides that are identical in at least 80% to the sequence of a region present in SEQ ID NO: 1 (antimiR-218-5p) or 2 (antimiR-23b-3p), or SEQ ID NO: 52-110.

[0268] 6. The oligonucleotide molecule according to any of clauses 1 to 5, wherein said oligonucleotide molecule comprises between 15 to 30 nucleotides in length, and wherein said oligonucleotide molecule comprises a fragment composed of a succession of at least 15 consecutive nitrogen bases of nucleotides that are identical to the sequence of a region present in SEQ ID NO: 1 (antimiR-218-5p) or 2 (antimiR- 23b-3p).

[0269] 7. The oligonucleotide molecule according to any of clauses 1 to 6, comprising at least one chemical modification, wherein the chemical modification is selected from the group of: i) 2'-O-methyl (2'OMe), ii) 2'-O-Methoxyethyl (2' MOE), and / or iii) an extra bridge connecting the 2' oxygen and 4' carbon (LN A).

[0270] 8. The oligonucleotide molecule according to any of clauses 1 to 7, wherein said oligonucleotide molecule comprises between 15 to 30 nucleotides in length, and wherein said oligonucleotide molecule comprises a fragment composed of a succession of at least 15 consecutive nitrogen bases of nucleotide that are identical in at least 80% to the sequence of a region present in SEQ ID NOs: 3, 4, 5, 22, 23, 24, 49, 50 or 51 (antagonists of hsa-miR-23b) or SEQ ID NOs: 7, 8, 9, 14, 25, 26, 27, or 28 (antagonists of hsa-miR-218-5p).

[0271] 9. The oligonucleotide molecule according to any of clauses 1 to 8, wherein said oligonucleotide molecule comprises between 15 to 30 nucleotides in length, and wherein the nucleotide sequence of said oligonucleotide consists of SEQ ID NOs: 3, 4, 5, 22, 23, 24, 49, 50 or 51 (antagonists of hsa-miR-23b) or SEQ ID NOs: 7, 8, 9, 14, 25, 26, 27, or 28 (antagonists of hsa-miR-218-5p).

[0272] 10. A composition, preferably a pharmaceutical composition, comprising at least an oligonucleotide molecule as defined in any of clauses 1 to 9, or a mixture of two or more of them, optionally further comprising a carrier and / or one or more pharmaceutically acceptable excipients.

[0273] 11. A composition, preferably a pharmaceutical composition, comprising at least an oligonucleotide molecule as defined in any of clauses 1 to 9, or a mixture of two or more of them, optionally further comprising a carrier and / or one or more pharmaceutically acceptable excipients, for use in therapy.

[0274] 12. A composition, preferably a pharmaceutical composition, comprising at least an oligonucleotide as defined in any of clauses 1 to 9, or a mixture of two or more of them, optionally further comprising a carrier and / or one or more pharmaceutically acceptable excipients, for use in targeting muscular cells in a subject in need thereof.

[0275] 13. A composition, preferably a pharmaceutical composition, comprising at least an oligonucleotide as defined in any of clauses 1 to 9, or a mixture of two or more of them, optionally further comprising a carrier and / or one or more pharmaceutically acceptable excipients, for use in the prevention or treatment of muscular diseases or in the prevention or treatment of RNAopathies.

[0276] 14. The composition, preferably a pharmaceutical composition, for use according to clause

[0277] 13, wherein the disease is myotonic dystrophy.

[0278] 15. The composition, preferably a pharmaceutical composition, for use according to clause

[0279] 14, wherein the myotonic dystrophy is of type 1.

[0280] ITEMS OF THE INVENTION

[0281] 1. An oligonucleotide molecule consisting of SEQ ID NOs: 22 (MD23b-2 V2 3' Ol), 23 (MD23b-2-PS / PO 3'01), or 25 (218 MOE Oleic 3'), wherein said oligonucleotide molecule is conjugated at its 3' end to at least an oleic acid, and wherein the spacer molecule defined in said SEQ ID NOs: 22, 23 or 25 is selected from the group consisting of NHC3, NHC5, NHC6, and threoninol, and wherein the oligonucleotide molecule is formulated to be administered in humans at a dose of between 18 mg and 288 mg per person.

[0282] 2. The oligonucleotide molecule according to item 1 , wherein the oligonucleotide molecule is formulated to be administered in humans at a dose of between 33 mg and 144 mg per person.

[0283] 3. The oligonucleotide molecule according to any one of items 1 or 2, wherein the oligonucleotide molecule is formulated to be administered in humans intravenously.

[0284] 4. The oligonucleotide molecule according to any one of items 1 to 3, consisting of SEQ ID NO: 3 (MD23b-2 V2 3' Ol). 5. The oligonucleotide molecule according to any one of items 1 to 3, consisting of SEQ ID NO: 4 (MD23b-2-PS / PO 3'01).

[0285] 6. The oligonucleotide molecule according to any one of items 1 to 3, consisting of SEQ ID NO: 7 (218 MOE Oleic 3').

[0286] 7. A composition, preferably a pharmaceutical composition, comprising at least an oligonucleotide molecule as defined in any of items 1 to 6, or a mixture of two or more of them, optionally further comprising a carrier and / or one or more pharmaceutically acceptable excipients.

[0287] 8. An oligonucleotide molecule according to any one of items 1 to 6, or a composition as defined in item 7, for use in therapy.

[0288] 9. An oligonucleotide molecule according to any one of items 1 to 6, or a composition as defined in item 7, for use in the prevention or treatment of RNAopathies.

[0289] 10. An oligonucleotide molecule according to any one of items 1 to 6, or a composition as defined in item 7, for use in the prevention or treatment of muscular diseases and / or nervous system diseases.

[0290] 11. An oligonucleotide or a composition for use according to item 10, wherein the disease is myotonic dystrophy.

[0291] 12. An oligonucleotide or a composition for use according to item 11 , wherein the myotonic dystrophy is type 1 .

[0292] 13. An oligonucleotide or a composition for use according to any one of items 9 to 13, wherein the use comprises administering said oligonucleotide or composition at a dose of between 18 mg and 288 mg per person.

[0293] 14. An oligonucleotide or a composition for use according to item 13, wherein the use comprises administering said oligonucleotide or composition at a dose of between 36 mg and 144 mg per person. 15. An oligonucleotide or a composition for use according to any one of items 9 to 14, wherein the use comprises administering said oligonucleotide or composition intravenously.

[0294] MORE ITEMS OF THE INVENTION

[0295] The invention also refers to:

[0296] 1. An oleic acid molecule for use as a vehicle or carrier to deliver an oligonucleotide molecule or analogue thereof to a target tissue in a human, wherein the oleic acid molecule is conjugated to the 3’ and / or 5’ end of said oligonucleotide molecule or analogue thereof, wherein the oligonucleotide molecule or analogue thereof is the active ingredient of a method of treatment by therapy, and wherein said oligonucleotide molecule or analogue thereof is administered in humans at a dose of between 18 mg and 288 mg per person.

[0297] 2. The oleic acid molecule for use according to item 1 , wherein the administration is intravenous or intrathecal.

[0298] 3. The oleic acid molecule for use according to items 1 or 2, wherein the dose is between 33 mg and 144 mg per person, and the administration is intravenous.

[0299] 4. The oleic acid molecule for use according to item 3, wherein the target tissue is central nervous system (CNS), muscular tissue, and / or cerebrospinal fluid (CSF), preferably muscular tissue.

[0300] 5. The oleic acid molecule for use according to item 1 or 2, wherein the dose is between 22.75 mg and 196.46 mg per person, and the administration is intrathecal.

[0301] 6. The oleic acid molecule for use according to item 5, wherein the target tissue is central nervous system (CNS), muscular tissue, and / or cerebrospinal fluid (CSF), preferably CSF.

[0302] 7. The oleic acid molecule for use according to any one of items 1 to 6, wherein the oligonucleotide molecule or analogue thereof comprises a mixture of phosphorothioate and phosphodiester linkages chemically linking the nucleotides. 8. The oleic acid molecule for use according to item 7, wherein the number of nucleotides that are chemically linked by a phosphorothioate linkage is greater than the number of nucleotides that are chemically linked by a phosphodiester linkage.

[0303] 9. The oleic acid molecule for use according to any one of items 1 to 8, wherein the oligonucleotide molecule or analogue thereof is the active ingredient in a method of treatment or prevention of muscular and / or nervous system diseases.

[0304] 10. An oleic acid molecule conjugated to the 3’ and / or 5’ end of an oligonucleotide molecule or analogue thereof for use in the prevention or treatment of central nervous system (CNS) diseases, wherein the oleic acid molecule is a pharmaceutically acceptable vehicle or carrier that delivers the oligonucleotide molecule or analogue thereof to the CNS, wherein the oligonucleotide molecule or analogue thereof is the active ingredient and comprises a mixture of phosphorothioate and phosphodiester linkages chemically linking the nucleotides, wherein the oligonucleotide molecule or analogue thereof is administered in humans at a dose of between 18 mg and 288 mg per person, using the intrathecal route.

[0305] 11 . The oleic acid for use according to item 10, wherein the dose is between 22 and 200, preferably 22.75 and 196.46, mg per dose per person.

[0306] 12. The oleic acid for use according to any one of items 1 to 11 , wherein the oligonucleotide molecule or analogue thereof is an antagonist of a microRNA, preferably human hsa- miR-23b-3p or the human hsa-miR-218-5p.

[0307] 13. The oleic acid for use according to any one of items 1 to 12, wherein the oligonucleotide molecule or analogue thereof is an antagonist of the human hsa-miR-23b-3p or the human hsa-miR-218-5p and comprises between 10 to 30 nucleotides in length and a fragment composed of a succession of at least 15 consecutive nitrogen bases of nucleotides that are identical in at least 80% to the sequence of a region present in SEQ ID NO: 1 (antimiR-218-5p) or 2 (antimiR-23b-3p), or SEQ ID NO: 52-110.

[0308] 14. The oleic acid for use according to any one of items 1 to 13, wherein the oligonucleotide molecule or analogue thereof is at least 80% identical to SEQ ID NOs: 22, 23 or 25, and wherein the spacer molecule defined in said SEQ ID NOs: 22, 23 or 25 is preferably selected from the group consisting of NHC3, NHC5, NHC6, threoninol, and a derivative thereof.

[0309] 15. The oleic acid for use according to any one of items 1 to 14, wherein the oligonucleotide molecule or analogue thereof is at least 80% identical to SEQ ID NOs: 22, 23 or 25, wherein the spacer molecule defined in said SEQ ID NOs: 22, 23 or 25 is preferably selected from the group consisting of NHC3, NHC5, NHC6, threoninol, and a derivative thereof, and wherein said oligonucleotide molecule is capable of increasing the endogenous levels of MBNL1 and / or MBNL2 proteins.

[0310] 16. The oleic acid for use according to any one of items 1 to 15, wherein the oligonucleotide molecule or analogue thereof consists of SEQ ID NOs: 3, 4, or 7.

[0311] MORE ITEMS OF THE INVENTION

[0312] The invention also refers to:

[0313] 1. An oleic acid molecule for use as a vehicle or carrier to deliver an oligonucleotide molecule or analogue thereof to a target tissue in a human, wherein the oleic acid molecule is conjugated to the 3’ and / or 5’ end of said oligonucleotide molecule or analogue thereof, wherein the oligonucleotide molecule or analogue thereof is the active ingredient of a method of treatment by therapy, and wherein the administration is intravenous or intrathecal.

[0314] 2. The oleic acid molecule for use according to item 1 , wherein the target tissue is central nervous system (CNS), muscular tissue, and / or cerebrospinal fluid (CSF), preferably muscular tissue.

[0315] 3. The oleic acid molecule for use according to item 1 or 2, wherein the dose is between 22.75 mg and 196.46 mg per person.

[0316] 4. The oleic acid molecule for use according to any one of items 1 to 3, wherein the oligonucleotide molecule or analogue thereof comprises a mixture of phosphorothioate and phosphodiester linkages chemically linking the nucleotides. 5. The oleic acid molecule for use according to item 4, wherein the number of nucleotides that are chemically linked by a phosphorothioate linkage is greater than the number of nucleotides that are chemically linked by a phosphodiester linkage.

[0317] 6. The oleic acid molecule for use according to any one of items 1 to 5, wherein the oligonucleotide molecule or analogue thereof is the active ingredient in a method of treatment or prevention of muscular and / or nervous system diseases.

[0318] 7. An oleic acid molecule conjugated to the 3’ and / or 5’ end of an oligonucleotide molecule or analogue thereof for use in the prevention or treatment of central nervous system (CNS) diseases, wherein the oleic acid molecule is a pharmaceutically acceptable vehicle or carrier that delivers the oligonucleotide molecule or analogue thereof to the CNS, wherein the oligonucleotide molecule or analogue thereof is the active ingredient and comprises a mixture of phosphorothioate and phosphodiester linkages chemically linking the nucleotides, wherein the oligonucleotide molecule or analogue thereof is administered in humans at a dose of between 18 mg and 288 mg per person, using the intrathecal route.

[0319] 8. The oleic acid for use according to item 7, wherein the dose is between 22 and 200, preferably 22.75 and 196.46, mg per dose per person.

[0320] 9. The oleic acid for use according to any one of items 1 to 8, wherein the oligonucleotide molecule or analogue thereof is an antagonist of a microRNA, preferably human hsa- miR-23b-3p or the human hsa-miR-218-5p.

[0321] 10. The oleic acid for use according to any one of items 1 to 9, wherein the oligonucleotide molecule or analogue thereof is an antagonist of the human hsa-miR-23b-3p or the human hsa-miR-218-5p and comprises between 10 to 30 nucleotides in length and a fragment composed of a succession of at least 15 consecutive nitrogen bases of nucleotides that are identical in at least 80% to the sequence of a region present in SEQ ID NO: 1 (antimiR-218-5p) or 2 (antimiR-23b-3p), or SEQ ID NO: 52-110.

[0322] 11 . The oleic acid for use according to any one of items 1 to 10, wherein the oligonucleotide molecule or analogue thereof is at least 80% identical to SEQ ID NOs: 22, 23 or 25, and wherein the spacer molecule defined in said SEQ ID NOs: 22, 23 or 25 is preferably selected from the group consisting of NHC3, NHC5, NHC6, threoninol, and a derivative thereof.

[0323] 12. The oleic acid for use according to any one of items 1 to 11 , wherein the oligonucleotide molecule or analogue thereof is at least 80% identical to SEQ ID NOs: 22, 23 or 25, wherein the spacer molecule defined in said SEQ ID NOs: 22, 23 or 25 is preferably selected from the group consisting of NHC3, NHC5, NHC6, threoninol, and a derivative thereof, and wherein said oligonucleotide molecule is capable of increasing the endogenous levels of MBNL1 and / or MBNL2 proteins.

[0324] 13. The oleic acid for use according to any one of items 1 to 12, wherein the oligonucleotide molecule or analogue thereof consists of SEQ ID NOs: 3, 4, or 7.

[0325] MORE ITEMS OF THE INVENTION

[0326] 1. An oleic acid molecule for use as a vehicle or carrier to deliver an oligonucleotide molecule or analogue thereof to a target tissue in a human, wherein the oleic acid molecule is conjugated to the 3’ and / or 5’ end of said oligonucleotide molecule or analogue thereof, wherein the oligonucleotide molecule or analogue thereof is the active ingredient of a method of treatment by therapy, and wherein the administration of the oligonucleotide molecule or analogue thereof conjugated to the oleic acid molecule is intrathecal.

[0327] 2. The oleic acid molecule for use according to item 1 , wherein the target tissue is central nervous system (CNS), muscular tissue, and / or cerebrospinal fluid (CSF), preferably muscular tissue.

[0328] 3. The oleic acid molecule for use according to item 1 or 2, wherein the dose is between 22.75 mg and 196.46 mg per person.

[0329] 4. The oleic acid molecule for use according to any one of items 1 to 3, wherein the oligonucleotide molecule or analogue thereof comprises a mixture of phosphorothioate and phosphodiester linkages chemically linking the nucleotides. 5. The oleic acid molecule for use according to item 4, wherein the number of nucleotides that are chemically linked by a phosphorothioate linkage is greater than the number of nucleotides that are chemically linked by a phosphodiester linkage.

[0330] 6. The oleic acid molecule for use according to any one of items 1 to 5, wherein the oligonucleotide molecule or analogue thereof is the active ingredient in a method of treatment or prevention of muscular and / or nervous system diseases.

[0331] 7. An oleic acid molecule conjugated to the 3’ and / or 5’ end of an oligonucleotide molecule or analogue thereof for use in the prevention or treatment of central nervous system (CNS) diseases, wherein the oleic acid molecule is a pharmaceutically acceptable vehicle or carrier that delivers the oligonucleotide molecule or analogue thereof to the CNS, wherein the oligonucleotide molecule or analogue thereof is the active ingredient and comprises a mixture of phosphorothioate and phosphodiester linkages chemically linking the nucleotides, and wherein the administration of the oligonucleotide molecule or analogue thereof conjugated to the oleic acid molecule is intrathecal.

[0332] 8. The oleic acid for use according to item 7, wherein the dose is between 22 and 200, preferably 22.75 and 196.46, mg per dose per person.

[0333] 9. The oleic acid for use according to any one of items 1 to 8, wherein the oligonucleotide molecule or analogue thereof is an antagonist of a microRNA, preferably human hsa- miR-23b-3p or the human hsa-miR-218-5p.

[0334] 10. The oleic acid for use according to any one of items 1 to 9, wherein the oligonucleotide molecule or analogue thereof is an antagonist of the human hsa-miR-23b-3p or the human hsa-miR-218-5p and comprises between 10 to 30 nucleotides in length and a fragment composed of a succession of at least 15 consecutive nitrogen bases of nucleotides that are identical in at least 80% to the sequence of a region present in SEQ ID NO: 1 (antimiR-218-5p) or 2 (antimiR-23b-3p), or SEQ ID NO: 52-110.

[0335] 11 . The oleic acid for use according to any one of items 1 to 10, wherein the oligonucleotide molecule or analogue thereof is at least 80% identical to SEQ ID NOs: 22, 23 or 25, and wherein the spacer molecule defined in said SEQ ID NOs: 22, 23 or 25 is preferably selected from the group consisting of NHC3, NHC5, NHC6, threoninol, and a derivative thereof. The oleic acid for use according to any one of items 1 to 11 , wherein the oligonucleotide molecule or analogue thereof is at least 80% identical to SEQ ID NOs: 22, 23 or 25, wherein the spacer molecule defined in said SEQ ID NOs: 22, 23 or 25 is preferably selected from the group consisting of NHC3, NHC5, NHC6, threoninol, and a derivative thereof, and wherein said oligonucleotide molecule is capable of increasing the endogenous levels of MBNL1 and / or MBNL2 proteins. The oleic acid for use according to any one of items 1 to 12, wherein the oligonucleotide molecule or analogue thereof consists of SEQ ID NOs: 3, 4, or 7.

[0336] SEQUENCE LISTING (5’ to 3’ direction)

[0337] As mentioned above, the SEQ ID NOs listed below and as referred throughout the application comprise a nucleobase sequence and, for those of the oligonucleotides that depart from their natural chemistry, also their chemical modifications and / or fatty acid conjugation. The following nomenclature has been used throughout the entire specification to define the chemical modifications included in the SEQ ID NOs disclosed herein:

[0338] LNA nucleotides are indicated by the combinations of a capital letter and a small letter: Ab, Gb, Tb, Cb,

[0339] Phosphorothioate linkages are indicated by small “s” letters,

[0340] 2'-O-MOE RNA nucleotides are indicated by a combination of a capital letter and a small letter: Am, Cm, Gm, Tm,

[0341] 2’-O-Methyl-nucleotides are represented by the small letters: a, g, c, u,

[0342] 2'-Fluoro RNA nucleotides are indicated by a combination of a capital letter and a small letter: Af, Cf, Gf, Tf,

[0343] 2'-O-Methyl-2,6-diaminopurine modification is indicated with the expression (dap), deoxynucleotides are indicated by the combination of small letter and capital letter: dA, dC, dG, dT,

[0344] 2’-OMe-5-methyluridine or 2’-OMe-ribothymidine is represented by small “t” letter, 5-Methyl-2'-O-Methyl cytidine are represented by the expression (5Mc), the expression (OleicAcid) means that the oligonucleotide is conjugated to Oleic Acid, the expression (PalmiticAcid) means that the oligonucleotide is conjugated to Palmitic Acid, the (spacer molecule) is preferably selected from the group consisting of NHC3, NHC5, NHC6, threoninol, or a derivative thereof. Preferably, the spacer molecule is NHC6 or NHC3,

[0345] “Y” is used for any pyrimidine (C or U / T)

[0346] "I" is used for hypoxanthine because hypoxanthine is the nucleobase of inosine.

[0347] SEQ ID NO 1 : Antagonist of the human hsa-miR-218-5p: TTAGATCAAGCACAA

[0348] SEQ ID NO 2: Antagonist of the human hsa-miR-23b-3p: ATCCCTGGCAATGTGA SEQ ID NO 3: MD23b-2 V2 3'01 (X82108):

[0349] AbsTbs(5Mc)s(5Mc)sCmTbGmsgsCmsAbAmTbGbTmsGbsAb(NHC6)(OleicAcid)

[0350] SEQ ID NO 4: MD23b-2-PS / PO 3'01:

[0351] AbsTms(5Mc)s(5Mc)(5Mc)Tbgsgs(5Mc)sAbAmTbGbsTmsGbsAb(NHC6)(OleicAcid)

[0352] SEQ ID NO 5: MD23b-2-PS / PO 5'01:

[0353] (OleicAcid)(NHC6)AbsTms(5Mc)s(5Mc)(5Mc)Tbgsgs(5Mc)sAbAmTbGbsTmsGbsAb

[0354] SEQ ID NO: 6: MD23b-2-PS / PO:

[0355] AbsTms(5Mc)s(5Mc)(5Mc)Tbgsgs(5Mc)sAbAmTbGbsTmsGbsAb

[0356] SEQ ID NO 7: 218 MOE Oleic 3':

[0357] TbsTbsAmsGbsAmsTmsCbAmsAmGbCmAbsCmsAbsAb(NHC6)(0leicAcid)

[0358] SEQ ID NO: 8: 218 MOE DD Oleic 3':

[0359] TbsTbsAmsGbsAmsTmsCbAmsAmsGbCmAbsCms(dap)s(dap)(NHC6)(0leicAcid)

[0360] SEQ ID NO: 9: 218 OME / MOE oleic 3':

[0361] TbsTmsasGbsastsCbAmsAmGbCmAbsCmsAmsAb(NHC6)(0leicAcid)

[0362] SEQ ID NO: 10: hsa-miR-218-5p: UUGUGCUUGAUCUAACCAUGU

[0363] SEQ ID NO: 11 : hsa-miR-23b-3p: AUCACAUUGCCAGGGAUUACCAC

[0364] SEQ ID NO: 12: seed region of hsa-miR-218-5p: UGUGCU

[0365] SEQ ID NO: 13: seed region of hsa-miR-23b-3p: UCACAll

[0366] SEQ ID NO: 14: 218 OME / MOE oleic 3'2:

[0367] TbsTbsasGbsastsCbAmsAmGbCmAbsCmsAmsAb(NHC6)(0leicAcid)

[0368] SEQ ID NO: 15: 218 MOE:

[0369] TbsTbsAmsGbsAmsTmsCbAmsAmGbCmAbsCmsAbsAb

[0370] SEQ ID NO: 16 MD23b-2 V2 3’Pal (X85204):

[0371] AbsTbs(5Mc)s(5Mc)sCmTbGmsgsCmsAbAmTbGbTmsGbsAb(NHC6)(PalmiticAcid) SEQ ID NO: 17: MD23b-2 V2:

[0372] AbsTbs(5Mc)s(5Mc)sCmTbGmsgsCmsAbAmTbGbTmsGbsAb

[0373] SEQ ID NO: 18: MD23 MOE: AbsTbsCmsCmCmsTmsGmGmsCmAmAmsTbGmsTmGbsAb

[0374] SEQ ID NO: 19: The microRNA precursor (pre-microRNA) of hsa-miR-23b-3p: CUCAGGUGCUCUGGCUGCUUGGGUUCCUGGCAUGCUGAUUUGUGACUUAAGAUUAA AAUCACAUUGCCAGGGAUUACCACGCAACCACGACCUUGGC

[0375] SEQ ID NO: 20: Pre-hsa-miR-218-5p-1(chr4:20529898-20530007):

[0376] GUGAUAAUGUAGCGAGAUUUUCUGUUGUGCUUGAUCUAACCAUGUGGUUGCGAGGU AUGAGUAAAACAUGGUUCCGUCAAGCACCAUGGAACGUCACGCAGCUUUCUACA

[0377] SEQ ID NO: 21 : Pre-miR-218-2 (chr5:1681951 SI- 168195260): GACCAGUCGCUGCGGGGCUUUCCUUUGUGCUUGAUCUAACCAUGUGGUGGAACGAU GGAAACGGAACAUGGUUCUGUCAAGCACCGCGGAAAGCACCGUGCUCUCCUGCA

[0378] SEQ ID NO 22: MD23b-2 V2 3’01 without specific spacer molecule: AbsTbs(5Mc)s(5Mc)sCmTbGmsgsCmsAbAmTbGbTmsGbsAb(Spacer molecule)(OleicAcid), wherein the spacer molecule is preferably selected from the group consisting of NHC3, NHC5, NHC6, threoninol, or a derivative thereof.

[0379] SEQ ID NO 23: MD23b-2-PS / PO 3’01 without specific spacer molecule: AbsTms(5Mc)s(5Mc)(5Mc)Tbgsgs(5Mc)sAbAmTbGbsTmsGbsAb(Spacer molecule)(OleicAcid), wherein the spacer molecule is preferably selected from the group consisting of NHC3, NHC5, NHC6, threoninol, or a derivative thereof.

[0380] SEQ ID NO 24: MD23b-2-PS / PO 5’01 without specific spacer molecule: (OleicAcid)(Spacer molecule)AbsTms(5Mc)s(5Mc)(5Mc)Tbgsgs(5Mc)sAbAmTbGbsT msGbsAb, wherein the spacer molecule is preferably selected from the group consisting of NHC3, NHC5, NHC6, threoninol, or a derivative thereof.

[0381] SEQ ID NO 25: 218 MOE Oleic 3’ without specific spacer molecule: TbsTbsAmsGbsAmsTmsCbAmsAmGbCmAbsCmsAbsAb(Spacer molecule)(OleicAcid), wherein the spacer molecule is preferably selected from the group consisting of NHC3, NHC5, NHC6, threoninol, or a derivative thereof. SEQ ID NO: 26: 218 MOE DD Oleic 3’ without specific spacer molecule: TbsTbsAmsGbsAmsTmsCbAmsAmsGbCmAbsCms(dap)s(dap)(Spacer molecule)(OleicAcid), wherein the spacer molecule is preferably selected from the group consisting of NHC3, NHC5, NHC6, threoninol, or a derivative thereof.

[0382] SEQ ID NO: 27: 218 OME / MOE oleic 3’ without specific spacer molecule:

[0383] TbsT msasGbsastsCbAmsAmGbCmAbsCmsAmsAb(Spacer molecule)(OleicAcid), wherein the spacer molecule is preferably selected from the group consisting of NHC3, NHC5, NHC6, threoninol, or a derivative thereof.

[0384] SEQ ID NO: 28: 218 OME / MOE oleic 3’2 without specific spacer molecule: TbsTbsasGbsastsCbAmsAmGbCmAbsCmsAmsAb(Spacer molecule)(OleicAcid), wherein the spacer molecule is preferably selected from the group consisting of NHC3, NHC5, NHC6, threoninol, or a derivative thereof.

[0385] SEQ ID NO: 29: MD23b-2 V2 3’Pal without specific spacer molecule: AbsTbs(5Mc)s(5Mc)sCmTbGmsgsCmsAbAmTbGbTmsGbsAb(Spacer molecule)(PalmiticAcid), wherein the spacer molecule is preferably selected from the group consisting of NHC3, NHC5, NHC6, threoninol, or a derivative thereof.

[0386] SEQ ID NO 49: MD23b-2 V2 3’01 with C6SSC6 and NHC6

[0387] AbsTbs(5Mc)s(5Mc)sCmTbGmsgsCmsAbAmTbGbTmsGbsAb(C6SSC6)(NHC6)(OleicAcid)

[0388] SEQ ID NO: 50: MD23b-2 V2 3’ 01 with C6SSC6 and NHC3

[0389] AbsTbs(5Mc)s(5Mc)sCmTbGmsgsCmsAbAmTbGbTmsGbsAb(C6SSC6)(NHC3)(OleicAcid)

[0390] SEQ ID NO 51: MD23b-2-PS / PO 5’01 without spacer molecule: (OleicAcid)AbsTms(5Mc)s(5Mc)(5Mc)Tbgsgs(5Mc)sAbAmTbGbsTmsGbsAb.

[0391] SEQ ID NO 52: functional equivalent sequence of antimiR-23b-3p: YTCCCTGGCAATGTGA

[0392] SEQ ID NO 53: functional equivalent sequence of antimiR-23b-3p:

[0393] ATCCCTYGCAATGTGA

[0394] SEQ ID NO 54: functional equivalent sequence of antimiR-23b-3p: ATCCCTGYCAATGTGA

[0395] SEQ ID NO 55: functional equivalent sequence of antimiR-23b-3p: ATCCCTGGCYATGTGA

[0396] SEQ ID NO 56: functional equivalent sequence of antimiR-23b-3p: ATCCCTGGCAYTGTGA

[0397] SEQ ID NO 57: functional equivalent sequence of antimiR-23b-3p: ATCCCTGGCAATYTGA

[0398] SEQ ID NO 58: functional equivalent sequence of antimiR-23b-3p: ATCCCTGGCAATGTYA

[0399] SEQ ID NO 59: functional equivalent sequence of antimiR-23b-3p: ATCCCTGGCAATGTGY

[0400] SEQ ID NO 60: functional equivalent sequence of antimiR-23b-3p: GTCCCTGGCAATGTGA

[0401] SEQ ID NO 61: functional equivalent sequence of antimiR-23b-3p: ATUCCTGGCAATGTGA

[0402] SEQ ID NO 62: functional equivalent sequence of antimiR-23b-3p: ATCUCTGGCAATGTGA

[0403] SEQ ID NO 63 functional equivalent sequence of antimiR-23b-3p: ATCCUTGGCAATGTGA

[0404] SEQ ID NO 64: functional equivalent sequence of antimiR-23b-3p: ATCCCTGG U AATGTGA

[0405] SEQ ID NO 65: functional equivalent sequence of antimiR-23b-3p:

[0406] ATCCCTGGCGATGTGA

[0407] SEQ ID NO 66: functional equivalent sequence of antimiR-23b-3p:

[0408] ATCCCTGGCAGTGTGA SEQ ID NO 67: functional equivalent sequence of antimiR-23b-3p:

[0409] ATCCCTGGCAATGTGG

[0410] SEQ ID NO 68: functional equivalent sequence of antimiR-23b-3p: ITCCCTGGCAATGTGA

[0411] SEQ ID NO 69: functional equivalent sequence of antimiR-23b-3p: ATCCCTGGCIATGTGA

[0412] SEQ ID NO 70: functional equivalent sequence of antimiR-23b-3p: ATCCCTGGCAITGTGA

[0413] SEQ ID NO 71: functional equivalent sequence of antimiR-23b-3p: ATCCCTGGCAATGTGI

[0414] SEQ ID NO 72: functional equivalent sequence of antimiR-23b-3p: AICCCTGGCAATGTGA

[0415] SEQ ID NO 73: functional equivalent sequence of antimiR-23b-3p: ATCCCIGGCAATGTGA

[0416] SEQ ID NO 74: functional equivalent sequence of antimiR-23b-3p: ATCCCTGGCAAIGTGA

[0417] SEQ ID NO 75: functional equivalent sequence of antimiR-23b-3p: ATCCCTGGCAATGIGA

[0418] SEQ ID NO 76: functional equivalent sequence of antimiR-23b-3p: ATCCCTIGCAATGTGA

[0419] SEQ ID NO 77: functional equivalent sequence of antimiR-23b-3p: ATCCCTGICAATGTGA

[0420] SEQ ID NO 78: functional equivalent sequence of antimiR-23b-3p:

[0421] ATCCCTGGCAATITGA SEQ ID NO 79: functional equivalent sequence of antimiR-23b-3p:

[0422] ATCCCTGGCAATGTIA

[0423] SEQ ID NO 80: functional equivalent sequence of antimiR-218-5p:

[0424] TTYGATCAAGCACAA

[0425] SEQ ID NO 81: functional equivalent sequence of antimiR-218-5p:

[0426] TTAYATCAAGCACAA

[0427] SEQ ID NO 82: functional equivalent sequence of antimiR-218-5p:

[0428] TTAGYTCAAGCACAA

[0429] SEQ ID NO 83: functional equivalent sequence of antimiR-218-5p:

[0430] TTAGATCYAGCACAA

[0431] SEQ ID NO 84: functional equivalent sequence of antimiR-218-5p:

[0432] TTAGATCAYGCACAA

[0433] SEQ ID NO 85: functional equivalent sequence of antimiR-218-5p:

[0434] TTAGATCAAYCACAA

[0435] SEQ ID NO 86: functional equivalent sequence of antimiR-218-5p:

[0436] TTAGATCAAGCYCAA

[0437] SEQ ID NO 87: functional equivalent sequence of antimiR-218-5p:

[0438] TTAGATCAAGCACYA

[0439] SEQ ID NO 88: functional equivalent sequence of antimiR-218-5p:

[0440] TTAGATCAAGCACAY

[0441] SEQ ID NO 89: functional equivalent sequence of antimiR-218-5p:

[0442] TTGGATCAAGCACAA

[0443] SEQ ID NO 90: functional equivalent sequence of antimiR-218-5p:

[0444] TTAGGTCAAGCACAA

[0445] SEQ ID NO 91: functional equivalent sequence of antimiR-218-5p: TTAGATUAAGCACAA

[0446] SEQ ID NO 92: functional equivalent sequence of antimiR-218-5p: TTAGATCGAGCACAA

[0447] SEQ ID NO 93: functional equivalent sequence of antimiR-218-5p: TTAGATCAGGCACAA

[0448] SEQ ID NO 94: functional equivalent sequence of antimiR-218-5p: TTAGATCAAGUACAA

[0449] SEQ ID NO 95: functional equivalent sequence of antimiR-218-5p: TTAGATCAAGCGCAA

[0450] SEQ ID NO 96: functional equivalent sequence of antimiR-218-5p: TTAGATCAAGCAUAA

[0451] SEQ ID NO 97: functional equivalent sequence of antimiR-218-5p: TTAGATCAAGCACGA

[0452] SEQ ID NO 98: functional equivalent sequence of antimiR-218-5p: TTAGATCAAGCACAG

[0453] SEQ ID NO 99: functional equivalent sequence of antimiR-218-5p: TTIGATCAAGCACAA

[0454] SEQ ID NO 100: functional equivalent sequence of antimiR-218-5p: TTAGITCAAGCACAA

[0455] SEQ ID NO 101: functional equivalent sequence of antimiR-218-5p: TTAGATCIAGCACAA

[0456] SEQ ID NO 102: functional equivalent sequence of antimiR-218-5p:

[0457] TTAGATCAIGCACAA

[0458] SEQ ID NO 103: functional equivalent sequence of antimiR-218-5p:

[0459] TTAGATCAAGCICAA SEQ ID NO 104: functional equivalent sequence of antimiR-218-5p:

[0460] TTAGATCAAGCACIA

[0461] SEQ ID NO 105: functional equivalent sequence of antimiR-218-5p: TTAGATCAAGCACAI

[0462] SEQ ID NO 106: functional equivalent sequence of antimiR-218-5p: ITAGATCAAGCACAA

[0463] SEQ ID NO 107: functional equivalent sequence of antimiR-218-5p:

[0464] TIAGATCAAGCACAA

[0465] SEQ ID NO 108: functional equivalent sequence of antimiR-218-5p:

[0466] TTAGAICAAGCACAA

[0467] SEQ ID NO 109: functional equivalent sequence of antimiR-218-5p:

[0468] TTAIATCAAGCACAA

[0469] SEQ ID NO 110: functional equivalent sequence of antimiR-218-5p: TTAGATCAAICACAA

[0470] SEQ ID NO 111 : TbsCsAsCbsAsTsTbsGsCsCbsAsGsGbsGsAsTb-Digoxigenin NHS ester

[0471] SEQ ID NO 161 : MD23b-2 V2 (X82102):

[0472] AbsTbs(5Mc)s(5Mc)sCmTbGmsgsCmsAbAmTbGbTmsGbsAb(NH2C6).

[0473] The following examples merely illustrate the present invention.

[0474] EXAMPLES

[0475] Materials and Methods

[0476] Cell culture experimentation

[0477] Immortalized MyoD-inducible (doxycycline) DM1 and control fibroblasts (Arandel L., et al. (2017). "Immortalized human myotonic dystrophy muscle cell lines to assess therapeutic compounds" Dis Model Meeh 10(4): 487-497.) were grown in DMEM with 4.5 g / L glucose, 1% P / S, and 10% FBS (Sigma, Saint Louis, Misuri). Fibroblast transdifferentiation into myotubes was according to (Cerro-Herreros et al. (2018). “miR-23b and miR-218 silencing increase Muscleblind-like expression and alleviate myotonic dystrophy phenotypes in mammalian models". Nat. Commun. 9, 2482). Transdifferentiation was induced at day 0, and test compounds were added to the cell culture medium at different concentrations (for MD23b-2, MD23b-8, MD23b-4, MD23b-13, MD23b-7, MD23b-14, MD-23b-1 , 23-LNA4, MD23b-10, MD23b-3, AntimiR-23b, MD23b-6, , MD23b-12, MD23b-9, MD23b-5, MD23b-11 , 23-LNA6, non-conjugated-23b, 5’-23b-Oleic, 5’-23b-Linoleic, 5’-23b-MeToc, 5’-23b-MeChol, 5’-23b- MePal, 5’-23b-Elaidic, 5’-23b-Estearic, OL-MD23b-2, MD23b-2- PS / PO, MD23b-2- PS / PO 5'01, non-conjugated-218, Ax-218, 5’-218-Oleic, 5’-218-MeChol, 5'-218-Linoleic, 5'-218- MePal, 5'-218-MeToc, Sc-Oleic, MD218-12, MD218-6, MD218-11 , non-conjugated-218, MD218-13, MD218-5, MD218-4, MD218-15, MD218-10, MD218-3: 10 nM, 50 nM, 200 nM, 1 pM and 5 pM; for 23-LNA8, AX-23b , MD23b-2 V2 3’01, MD23b-2 V2 3’01 (C6SSC6) (NHC6), MD23b-2 V2 3’01 (C6SSC6) (NHC3), and MD23b-2 V2 3’01 (threoninol): 2 nM, 10 nM, 50 nM, 200 nM and 1 pM; 23-D / LNA1 , 23-D / LNA2 and 218-2F / LNA1 : 0.4 nM, 2 nM, 10 nM, 50 nM and 200 nM); and for 218-D / LNA2, 218-2F / MOE: 0.08 nM, 0.4 nM, 2 nM, 10 nM and 50 nM) by lipofection with X-tremeGENE™ HP (Roche, Basel, Switzerland) and were replaced with fresh differentiation medium 4 h afterward. Cells were collected on day 4 in the differentiation medium and processed for protein extraction.

[0478] Cell proliferation assay

[0479] Cells seeded at 105cells / ml in 96-well plates were transfected 24 h later with antimiRs, as previously explained; after 96 h, cell proliferation was measured using the CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay (Promega, Madison, Wisconsin). The TC50 was calculated using non-linear least-squares regression, and absorbance levels were determined using an Infinite M200 PRO plate reader (Tecan, Mannedorf, Switzerland).

[0480] Quantitative Dot Blot (QDB) assay

[0481] For the activity assay, cells were seeded in 6-well plates at a density of 8x104cells per well and transfected 24 h later with antimiRs, as previously explained. For total protein extraction, human muscle cells were sonicated while mouse muscles (gastrocnemius and quadriceps) were homogenized in Pierce® RIPA buffer (Thermo Scientific, Waltham, Massachusetts) supplemented with protease and phosphatase inhibitor cocktails (Roche Applied Science, Penzberg, Germany). Quantification of total protein was performed with a Pierce® BCA protein assay kit (Thermo Scientific, Waltham, Massachusetts) using bovine serum albumin as standard. For the immunodetection assay, 1 pg / well of cell samples and 2 pg / well of mice samples were denatured (100°C for 5 min) and loaded in QDB plates (Quanticision Diagnostics Inc, Research Triangle Park, North Carolina). Each cell sample was loaded in quadruplicate on two different plates; one was used to detect MBNL1 and the other for GAPDH, which was used here as an endogenous control. In the case of mouse samples, each sample was loaded in quadruplicate on three different plates, one for detection of MBNL1 , one for Tubulin, which was used as endogenous control, and the other for anti-mouse IgG secondary antibody as a negative control to subtract background. For the QDB protocol, the protein is prepared at 2 pg / well. Each sample is loaded in quadruplicate on two different plates, one is used for the detection of MBNL1 and the other for GAPDH, which is used here as an endogenous control. For the preparation of the sample mix (enough for 10 samples, to account for pipetting errors) put the protein extract at the indicated concentration, add 10.4 pl of loading buffer 4X and finally complete to 50 pl of ddH2O. Once the sample is prepared, boil it for 5 min in water and after protein denaturation, leave it on ice. To load the samples, place the QDB plates (Quanticision Diagnostics, Inc) upside down. On each membrane circle, put 5 pl of the protein mix previously prepared. The loaded QDB plates are allowed to dry at room temperature for 30 minutes in a well-ventilated space to dry the membrane completely. After the dry, dip the QDB plate in the transfer buffer (0.039 M Glycine, 0.048 M Tris, 0.37% SDS, 20% methyl alcohol) and gently shake the plate for 1 min. The plate was rinsed with TBST (137 mM NaCI, 2.7mM KCI, 20 mM Tris, pH7.4, plus 0.1 % Tween-20) for 3 times, and blotted with blocking buffer (5% non-fat milk in TBST) in one container. The plate was incubated with primary mouse anti-MBNL1 (1 :1000, ab77017, Abeam) or mouse anti-GAPDH (1 :500, clone G-9, Santa Cruz) overnight at 4°C into a 96 well plate. The plate was washed three times with TBST and incubated again with the secondary antibody anti-mouse-POD (1 :200, Sigma-Aldrich) for 2 hours before the plate was washed again for three times with TBST. The plate was inserted into a 96 well plate loaded with 100 pL / well ECL substrate (Pierce) solution for 1 minute before it was inserted into a white 96 well plate for chemiluminescence signal quantification using a Tecan Infiniti 200 pro microplate reader with the option “plate with cover” chosen in the user interface.

[0482] Plates were incubated at 4 °C overnight with primary mouse anti-MBNL1 (1 :200, MB1a(4A8), (DSHB, Iowa City, Iowa) and rabbit anti-a-tubulin (1 :1000, PA5-16891 , Thermo Fisher) antibodies. The primary antibodies were detected using goat horseradish peroxidase (HRP)- conjugated anti-Mouse-IgG and anti-Rabbit-IgG secondary antibodies (1 :3500, (Sigma- Aldrich, Saint Louis, Missouri), respectively. Immunoreaction was detected using PierceTM ECL Western reagent (Thermo Scientific, Waltham, Massachusetts), and luminescence was acquired using an Infinite M200 PRO plate reader (Tecan, Mannedorf, Switzerland). RNA extraction, Reverse Transcription PCR (RT-PCR) and Real-Time Quantitative Reverse Transcription PCR (qRT-PCR)

[0483] Total RNA from murine gastrocnemius and quadriceps muscle was isolated using the miRNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. One microgram of RNA was digested with DNase I (Invitrogen, Carlsbad, California) and reverse-transcribed with SuperScript II (Invitrogen, Carlsbad, California) using random hexanucleotides. For subsequent PCR reactions, 20 ng of cDNA was used with GoTaq polymerase (Promega, Madison, Wisconsin). Specific primers were used to analyze the alternative splicing of Atp2a1, Nfix, MbnH and Clcnl in mouse samples (both muscles). Gapdh levels established the endogenous reference levels using 0.2 ng of cDNA. PCR products were separated on a 2% agarose gel and quantified using Imaged software (NIH, Bethesda, Maryland). Percentage splice recovery index (PSR) was defined as value %Siminus X%DSI, divided by X%DSI minus X%HSI (SI: splicing inclusion of each sample; DSI: disease splicing inclusion; HSI: healthy splicing inclusion; in all cases splicing refers to the inclusion of the indicated alternative exon). This ratio was calculated for ATP2A1, NFIX, MBNL1 and CLCN1. The primer sequences and exons analyzed are available in (Cerro- Herreros et al. 2018 2018 Jun 26;9(1):2482. doi: 10.1038 / s41467-018-04892-4.) and are reproduced below:

[0484] SEQ ID NO: 30: Gapdh Fwd: ATCAACGGGAAGCCCATCAC

[0485] SEQ ID NO: 31 : Gapdh Rv: CTTCCACAATGCCAAAGTTGT

[0486] SEQ ID NO: 32: Atp2a Fwd: GCTCATGGTCCTCAAGATCTCAC

[0487] SEQ ID NO: 33: Atp2a Rv: GGGTCAGTGCCTCAGCTTTG

[0488] SEQ ID NO: 34: Clcnl Fwd: GTCCTCAGCAAGTTTATGTCC

[0489] SEQ ID NO: 35: Clcnl Rv: GAATCCTCGCCAGTAATTCC

[0490] SEQ ID NO: 36: Nfix Fwd: TCGACGACAGTGAGATGGAG

[0491] SEQ ID NO: 37: Nfix Rv: CAAACTCCTTCAGCGAGTCC

[0492] SEQ ID NO: 38: MbnH ex5 F:

[0493] AGGGGAGATGCTCTCGGGAAAAGTG

[0494] SEQ ID NO: 39: MbnH ex5 R:

[0495] GTTGGCTAGAGCCTGTTGGTATTGGAAAATAC

[0496] We used 1 ng of mouse tissue cDNA as a template for multiplex qRT-PCR using the QuantiFast Probe PCR Kit reagent. Commercial TaqMan probes (Qiagen, Hilden, Germany) were used for mouse (MBNL1 and MBNL2', FAM-labeled probes) and reference (GAPDH', MAX-labeled probe) genes. Results were normalized to Gapdh endogenous gene expression. The primers used are the following: SEQ ID NO: 40: Probe Mbnll / 56-

[0497] FAM / TCGCAAATCAGCTGTGAGGAGATTCCCT / 3IAbRQSp /

[0498] SEQ ID NO: 41 : Mbnll F: TACCGATTGCACCACCAAAC

[0499] SEQ ID NO: 42: Mbnll R: GCTGCTTTCAGCAAAGTTGTC

[0500] SEQ ID NO: 43: Mbnl2 probe: / 56-FAM / CCCGGCAGACAGCACCATGATCGA / 3IAbRQSp / SEQ ID NO: 44: Mbnl2 F:GAGACAGACTGCCGCTTTG

[0501] SEQ ID NO: 45: Mbnl2 R: GGTTACGGTGTTGTCGTTTGT

[0502] SEQ ID NO: 46: Gapdh probe: / 5MAXN / -CGCCTGGTCACCAGGGCTGCT- / 3BHQ_1 / SEQ ID NO: 47: Gapdh _F or: CAACGGATTTGGTCGTATTGG

[0503] SEQ ID NO: 48: Gapdh _Rev: TGATGGCAACAATATCCACTTTACC

[0504] MiRNA expression in muscle tissues was quantified using specific miRCURY™-locked nucleic acid microRNA PCR primers (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Relative gene expression was normalized to U1 (YP00203909) and U6 (YP00203907) snRNAs.

[0505] Expression levels were measured using a QuantStudio 5 Real-Time PCR System (Applied Biosystems, Foster City, California). Expression relative to the endogenous gene and control group was calculated using the 2"AACtmethod. Pairs of samples were compared using two- tailed t-tests (a = 0.05), applying Welch's correction when necessary. The statistical differences were estimated by the Student's t-tests (p < 0.05) on normalized data.

[0506] Animal experimentation and oligonucleotides administration

[0507] Mouse handling and experimental procedures followed the European law regarding laboratory animal care and experimentation (2003 / 65 / C. E.) and were approved by Conselleria de Agricultura, Generalitat Valenciana. Homozygous transgenic HSALR (line 20 b) mice (Mankodi et al. 2000 Science: 289(5485): 1769-73. doi: 10.1126 / science.289.5485.1769 ) were provided by Prof. C. Thornton (University of Rochester Medical Center, Rochester, NY, USA). Experimental groups were FVB as normal control and HSALR treated with PBS as a negative control, in addition to HSALR mice treated with all experimental oligonucleotides. The sample size was four mice per treatment group, twelve mice for PBS, and eighteen mice for the FVB group. All the groups were injected intravenously (tail vein) with 150 pl of 1 * PBS (vehicle) or the specific oligonucleotides (see Fig 2-5) with a single dose of 3 mg / kg. Four days after injection, the mice were sacrificed, and the tissues of interest were frozen in liquid nitrogen for the molecular assays. Electromyography studies

[0508] Electromyography was performed before the treatment and at the time of sacrifice under general anaesthesia, as previously described (Kanadia et al. 2006 Proc Natl Acad Sci II S A . 2006 Aug 1 ;103(31):11748-53. doi: 10.1073 / pnas.0604970103). The determination was performed blindly to eliminate bias. Five needle insertions were performed in each quadriceps muscle of both hind limbs, and myotonic discharges were graded on a five-point scale: 0, no myotonia; 1 , occasional myotonic discharge in <50% of the needle insertions; 2, myotonic discharge in >50% of the insertions; 3, Myotonic discharge in nearly all of the insertions; and 4, myotonic discharge in all insertions.

[0509] Forelimb grip strength test

[0510] The forelimb grip strength was measured with a Grip Strength Meter (BIO-GS3; Bioseb, Pinellas Park, Florida). The peak pull force (measured in grams) was recorded on a digital force transducer when the mouse grasped the bar. The gauge of the force transducer was reset to 0 g after each measurement. Tension was recorded by the gauge at the time the mouse released its forepaws from the bar. We performed three consecutive measurements at 30 s intervals. The bodyweight measurement was performed in parallel. The final value is obtained by dividing the average value of the grip force by the bodyweight of each mouse. The bodyweight measurement was performed in parallel, and the experiment was performed with animals identified by a code to eliminate experimental bias.

[0511] Radar charts

[0512] The values obtained are represented as the recovery index (Rl), and it measures how close the different parameter values obtained with treated HSALRmice are from those of FVB controls. This Rl is obtained for the different parameters (Mbnll protein, Mbnl1 / 2 expression level, Splicing recovery, Mbnll ex5 inclusion recovery, and functional recovery) of each mouse after treatment according to this formula: value % MT minus X% MNT, divided by X% MH minus X% MNT (where MT is the value of each mice treated (PBS or oligonucleotide), MNT is HSALRmice treated with PBS (PBS), and MH is healthy mice value (FVB)). These values range from 0 to 1 , where 0 are untreated mice (HSALR-PBS) and 1 are healthy mice (FVB).

[0513] Mbnll protein refers to the average of the values obtained by Quantitative dot blot of both muscles (quadriceps and gastrocnemius) of each treatment group.

[0514] Mbnl1 / 2 expression level refers to the average of the mRNA values of genes Mbnll and Mbnl2 obtained by real-time PCR in both muscles (quadriceps and gastrocnemius) and of each group of treatment applying the previous formula. Splicing recovery refers to the average percentage of inclusion for Nfix exon 7, Atp2a1 exon 22 and Clcnl exon 7a of both muscles of each group treatment.

[0515] MbnH ex5 inclusion recovery refers to the percentage of inclusion for Mbnll exon 5 of both muscles of each group treatment.

[0516] Functional recovery refers to the average of the values obtained by force / weight of each mouse after treatment and the grade of myotonic discharges of each group treatment. The Forelimb grip strength test was used to obtain the force and the electromyography was used to obtain the grade of myotonic discharges.

[0517] EXAMPLE 1

[0518] We have previously shown that inhibiting miR-23b-3p or miR-218-5p could be therapeutic in Myotonic Dystrophy (Cerro-Herreros et al. 2018 Nat. Commun. 26;9(1):2482. doi: 10.1038 / s41467-018-04892-4.) by using commercially available antimiRs with antagomiR structure against miR-23b-3p (Ax-23b) or miR-218-5p (Ax-218). Transfection of human DM1 cells with these antagomiRs and their injection in a mouse model of the disease produced a downregulation of the target miRNA expression and concomitant upregulation of MBNL1, which was their direct target. The antagomiRs used were long (22 nt), contained almost the entire complementary sequence to the miRNA, and were all composed of 2'OME nucleotides. They carried phosphorothioate linkages between the nucleotides in the 3' and 5' ends to improve stability of the nucleotidic part of the molecule and were bound to cholesterol in 3' as a carrier to enhance the pharmacokinetic behavior and cellular internalization. Looking for the most effective and safe carrier, we combined the polynucleotidic part of Ax-23b (sequence name: non-conjugated-23b in table 1) with different lipidic carriers either in 3' or 5' end of the molecule, including; the sterols cholesterol and tocopherol; and the fatty acids palmitoyl acid, stearic acid, elaidic acid, linoleic acid and oleic acid (List of molecules in Table 1). We performed a screen on human DM1 cells (Arandel L., et al. (2017). Dis Model Meeh 10(4): 487- 497.). "Immortalized human myotonic dystrophy muscle cell lines to assess therapeutic compounds " Dis Model Meeh 10(4): 487-497.) transfected with these conjugated antagomiRs, looking for their effects on toxicity (cell viability study), and MBNL1 protein levels.

[0519] Each of these molecules was transfected into DM1 human myotubes in a range of 5 different concentrations and the percentage of cell viability and the levels of MBNL1 protein were quantified. We ranked the antimiRs according to their therapeutic index (Tl), defined as: Tl= (TC50 / EC50)*Emax

[0520] Where:

[0521] TC50 is the concentration of compound that reduces the cell viability to 50% of the mock EC50 is the concentration of compound that produces 50% of Emax

[0522] Emax is the maximum fold change of MBNL1 protein obtained after transfection with a specific antimiR compared to the mock (transfected with the vehicle).

[0523] From these experiments, we concluded that:

[0524] - The conjugation with oleic acid (cis-monounsaturated fatty acid with 18 carbon atoms) was the one producing the highest Tindex (see table 1). The curves of toxicity and efficacy (levels of MBNL1 protein) of the molecules named “non-conjugated-23b” and “5'-23b-Oleic” are shown in Fig. 1 C and B for a direct comparison. Importantly, the low Tindex of the scramble oligo conjugated to oleic acid (“Sc-Oleic) shows that oleic acid itself has no impact on the Tindex

[0525] -Linoleic acid (cis-polyunsaturated fatty acid with 18 carbon atoms) was the second most effective carrier. Surprisingly, the Tindex results obtained with elaidic acid (a trans isomer of oleic acid), palmitic acid (a saturated non-esterified fatty acid with 16 carbon atoms), and stearic acid (saturated fatty acid having a carbon chain with 18 carbon atoms) were significantly lower. Therefore, our data show that cis-unsaturated fatty acids are better carriers for antimiRs in our DM1 cells.

[0526] -Cholesterol was the only of the carriers that we tested conjugated in two different positions; 3'and 5'. According to our data, it seemed that the conjugation in 3' worked more efficiently than in 5'. The use of cholesterol derivatives as the tocopherol did not improve the Tindex.

[0527] We carried out the same experiments conjugating the nucleotidic part of Ax-218 (sequence name: non-conjugated-218 in table 1) with different lipidic carriers (Table 1). Oleic acid was confirmed as the best carrier among all the fatty acids tested and cholesterol worked better in 3’ than 5’. However, it is noted that cholesterol has been associated with toxicity in the liver in mice, even though the hepatic changes may become reversible after a recovery period (see Cholesterol Registration Dossier ECHA, April 4, 2017, available on https: / / echa.europa.eu / es / registration-dossier / - / registered-dossier / 11031 / 7 / 6 / 1#). However, as the therapeutic posology for the oligonucleotide is intended to be a chronic treatment, cholesterol as a linker may increase the risk of toxicity in the liver. On the contrary, oleic acid has a good safety profile and has been used as a food additive with beneficial effects in humans (see FDA Response Letter to the Health Item Petition Concerning Oleic Acid, November 19, 2018 available at https: / / www.fda.gov / food / cfsan-constituent-updates / fda- completes-review-qualified-health-item-petition-oleic-acid-and- risk-coronary-heart-disease).

[0528] Once we had found an appropriate carrier, our next step was to optimize the sequence and chemical modifications contained in the antimiR molecule that would be conjugated to the carrier. Therefore, we also performed the same in vitro screening, looking for the most effective sequence and chemical modifications that improve the Tindex of non-conjugated (unconjugated) antimiRs in DM1 cells. We generated a group of different single-stranded molecules (lengths ranging between 16 and 22 nucleotides) that were complementary to different parts of human miR-23b-3p or miR-218-5p. The molecules included in this screening carried different chemical modifications, including LNA, 2'OME and 2'MOE oligonucleotide, and all the linkages between nucleotides were phosphorothioate (PS) (list of molecules tested in Tables 2 and 3).

[0529] The molecule with a better Tindex score against miR-23b-3p was MD23b-2, and in the case of the antimiR molecules designed to inhibit miR-218-5p, the best scoring molecule was 218- D / LNA2 (see Tables 2 and 3). Importantly, MD23b-2 showed significantly higher effects on MBNL1 levels (Emax), and Tindex, than 218-D / LNA2. The curves of toxicity and efficacy (levels of MBNL1 protein) of these molecules are shown in Fig. 1 A and D.

[0530] Next, we tested the effects of conjugation of oleic acid on the best scoring antimiR sequence MD23b-2 (Table 4). Surprisingly, the conjugated molecule (OI-MD23b-2) exhibited a reduced Tindex compared to the MD23b-2. On the other hand, we have observed that oleic acid conjugation to oligonucleotides that had a mix of PS / PO increased their Tindex (Table 4). This data confirms that the effects of oleic acid in the Tindex are surprisingly remarkable in mixed PS / PO oligonucleotides.

[0531] TABLE 1

[0532] Note: (Pro)(Chol) stands for hydroxyprolinol C5-alkyl cholesterol. (Teg)(Chol) stands for 15 atom triethyleneglycol cholesterol depending on the spacer used.

[0533]

[0534]

[0535] EXAMPLE 2

[0536] Next, we took the best performing oligo against miR-23b-3p (MD23b-2), and against miR-218- 5p (218-D / LNA2) in vitro, and applied several modifications to these molecules to improve their ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) properties, in order to assess their in vivo therapeutic potential in the mouse model of DM1 (HSALR). The rationale behind the modifications introduced was the following:

[0537] (1) Methylation of Cytosines is a well-known method of inhibiting immune system activation by in vivo treatment with antisense oligos (Joseph J. Senn, et al. Non-CpG- Containing Antisense 2'-Methoxyethyl Oligonucleotides Activate a Proinflammatory Response Independent of Toll-Like Receptor 9 or Myeloid Differentiation Factor 88. Journal of Pharmacology and Experimental Therapeutics September 1 , 2005, 314 (3) 972-979; DOI: https: / / doi.org / 10.1124 / jpet.105.084004).

[0538] (2) Chemically modified nucleotides of LNA and 2'MOE-modified type are known to be more stable than standard RNA, DNA or 2'OME modified oligos (W. Brad Wan and Punit P. Seth. 2016. The Medicinal Chemistry of Therapeutic Oligonucleotides).

[0539] (3) In all the molecules tested in vitro, phosphodiester (PO) linkages between nucleotides have been substituted by phosphoroth ioate (PS) linkages in order to increase their stability and efficacy. Fully modified PS oligos are widely used in in vitro studies. However, some toxicity in vivo associated with an excess of PS linkages in a single molecule has been previously reported (e.g., Smith and Zain. 2019. Therapeutic oligonucleotides: State of the Art. Annual Review of Pharmacology and T oxicology, and Hu et al. 2020. Therapeutic siRNA: state of the art. Signal transduction and targeted therapy), and mixed oligos PS / PO have proven to be more stable in vivo (Zhang, et al. In vivo stability, disposition and metabolism of a “hybrid” oligonucleotide phosphorothioate in rats. Biochemical Pharmacology. Volume 50, Issue 4, 1995, Pages 545-556, ISSN 0006-2952, https: / / doi.org / 10.1016 / 0006-2952(95)00159-W. Therefore, in order to design antisense oligos that could be tested in in vivo models, we decided to reduce the amount of PS linkages in subsequent in vivo studies.

[0540] Taking into account these 3 criteria, we generated 4 antisense oligos:

[0541] -MD23b-2 PS / PO, which conserves the same chemical modifications found in MD23b- 2 but with lower PS content and all cytosines methylated. -MD23b-2 V2, with the same sequence as MD23b-2 but with some OME modifications in 2' substituted by MOE, lower PS content, and all cytosines methylated.

[0542] -218 MOE, with the sequence of 218-D / LNA2, all-natural DNA nucleotides substituted by 2 'MOE, all cytosines methylated, and lower PS content.

[0543] -218 OME / MOE, with the sequence of 218-D / LNA2, all-natural DNA nucleotides substituted by 2'MOE or 2'MOE,all cytosines methylated, and lower PS content.

[0544] These molecules were used non-conjugated (with the exception of 218 OME / MOE) and conjugated with oleic acid in order to assess their therapeutic potential in HSALRmice (model of DM1 , see Mankodi, A., et al. (2000). "Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat." Science 289(5485): 1769-1773.). Specifically; MD23b-2 PS / PO was used non-conjugated, conjugated with oleic acid in 3'(MD23b 2 PS / PO 3'01 ) and conjugated with oleic acid in 5'(MD23b-2 PS / PO 5'01) in order to assess the effect of the conjugation site with the oleic acid on the therapeutic effect. MD23b-2 V2 was used non-conjugated, conjugated to Oleic acid in 3' (MD23b-2 V2 3’01), and conjugated with palmitic acid in 3'(MD23b-2 V2 3’Palm) to confirm whether the conjugation with oleic acid produced stronger effects of the antimiRs than the conjugation with palmitic acid, also in vivo. The two antimiRs against miR-218-5p, were both conjugated with oleic acid in 3'.

[0545] All these molecules were injected intravenously at a concentration of 3 mg / Kg in the tail vein of 3-5 months old HSALRmice. The strength and myotonia of these mice were evaluated just before the injection and also before their sacrifice 5 days after the single injection. Figure 2 shows the results of the grip strength normalized to weight (A) and the myotonia (B) levels measured just before the sacrifice of the mice. In all the mice treated with antimiRs, the strength was improved in comparison to the PBS-injected mice, but this difference was statistically significant only for some of the antimiRs. Similarly, myotonia was reduced in the antimi R-treated mice. The most important reductions in myotonia were achieved by the molecules MD23b-2 V2 3'01 and 218 MOE Oleic 3'. For both molecules, the oleic acid conjugated molecules produced stronger rescue than the non-conjugated versions, and it produces stronger effects when conjugated at 3’.

[0546] EXAMPLE 3

[0547] At the moment of sacrifice, we dissected the quadriceps and gastrocnemius muscles of the hind limbs of the mice and processed them for protein and RNA extraction. qPCR after retrotranscription of extracted RNA, with specific probes to detect the levels of miR-23b-3p (Fig. 3A) or miR-218-5p (Fig. 3B) showed that all antimiRs reduced the levels of its corresponding miRNA efficiently. Importantly, non-conjugated versions of the antimiRs tended to be less efficient than the conjugated ones. In the case of the antimiRs against miR-218-5p, 218 MOE was the least effective one.

[0548] EXAMPLE 4 qRT-PCR was used to quantify the levels of expression of MbnH (Fig. 4A) and Mbnl2 (Fig. 4B) transcripts in quadriceps and gastrocnemius, and the total protein extracted from these muscles was processed for protein MbnH detection by quantitative dot blot analysis (Fig. 4C). Although small differences were detected between antimiR-23b-3p and antimiR-218-5p regarding the level of MbnH transcripts, miR-23b-3b antimiRs had a stronger effect on Mbnl protein. Importantly, we observed no difference between placing the oleic acid carrier either in 3' or 5' in the molecule MD23b-2 PS / PO, and in the case of the molecules MD23b-2 V2, the non-conjugated version was clearly less efficient than the conjugated versions with oleic or palmitoyl acids, and the oleic acid had a stronger effect, particularly on Mbnl2 transcript and MbnH protein levels.

[0549] EXAMPLE 5

[0550] Total RNA was also used to analyse the missplicing of transcripts regulated by MbnH protein, such as Atp2a1 exon 22, Nfix exon 7, MbnH exon 5, and Chloride channel (Clcnl) exon 7a (Fig. 5 and 6).

[0551] Nfix, Clcnl, Atp2a1 and Mbn transcripts showed abnormally increased inclusion of exon 7, 7a, 22, and 5, respectively, in HSALRmice, but they recovered between 30%-50% of normal values in muscles after being treated with 3 mg / kg with MD23-b V2 3’01 and other similar molecules.

[0552] EXAMPLE 6.

[0553] To analyze all the DM1 -related functional and molecular phenotypes that we have measured in the model mice, we generated spider graphs (Figure 7) calculating a recovery index for each individual mouse (Rim) for the different parameters (MbnH protein, Mbnl1 / 2 expression level, Splicing recovery, MbnH ex5 inclusion recovery, and functional recovery) of each mouse after treatment according to this formula: where ValueMT is the individual value of each treated (PBS or oligonucleotide injected) mouse, XMNT is the mean value of the non-treated disease mice (PBS injected), and XMH is the mean value of the healthy mice group (FVB). Next individual Rl values (Rim) were averaged to generate the global Rl values represented in Fig 7.

[0554] These values range from 0 to 1 , where 0 are untreated mice (HSALR-PBS) and 1 are healthy mice (FVB). Mbnll protein refers to the average of the values obtained by Quantitative dot blot of both muscles (quadriceps and gastrocnemius) of each group treatment. Mbnl1 / 2 expression level refers to the average of the values obtained by real-time PCR of both muscles (quadriceps and gastrocnemius) and genes (Mbnll and Mbnl2) of each group treatment applying the previous formula. Splicing recovery refers to the average percentage of inclusion for Nfix exon 7, Atp2a1 exon 22 and Clcnl exon 7a of both muscles of each group treatment. Mbnll ex5 inclusion recovery refers to the percentage of inclusion for Mbnll exon 5 of both muscles of each group treatment. Functional recovery refers to the average of the values obtained by force / weight of each mouse after treatment and the grade of myotonic discharges of each treatment group.

[0555] The representation of these graphs in Figure 7 and Tables 5 and 6 shows that MD23b-2 V2 3’01 was the antimiR molecule that produced the strongest rescue of all the phenotypes studied. Of note, the difference in efficacy when this same antimiR sequence was nonconjugated or conjugated with palmitic acid supports our surprising results in the in vitro studies and confirms a clear stronger therapeutic effect for the molecule when conjugated with the oleic acid. The second-best performing molecule was MD23b-2 PS / PO 3'01, which was slightly better than MD23b-2 PS / PO 5’01. These data also support the results obtained in vitro with the conjugation of cholesterol, confirming that the conjugation of the carrier in 3' is beneficial. As observed in vitro, the antimiRs against miR-218-5p produced lower phenotype rescue. The data supports a stronger therapeutic effect of the inhibition of miR-23b-3p (Figure 7B and Table 5) compared to the inhibition of miR-218-5p (Figure 7B and Table 6). In the case of the molecule 218 MOE (Figure 7B), also the conjugation with the oleic acid improves its activity in vivo. Thus, it confirms that the effects of oleic acid conjugation on the therapeutic effects in vivo are not limited to a specific nitrogenous base sequence but are of more general application. Table 5

[0556] Table 6

[0557] EXAMPLE 7 In all the antimiRs tested, we have always conjugated oleic acid either in 3' or 5' using a spacer that contains an amino group to form an amide linkage between the oleic acid and the oligonucleotide. The first spacer was the 6-aminohexyl group (NHC6 spacer) that was introduced both at the 3’ and the 5’-ends. Next, we tested whether other types of spacer (NHC6, NHC3 or threoninol) and the addition of spacers of different sizes (either 3 or 6 carbon atoms) between the oligo sequence MD23b-2 V2 and the oleic acid (Figure 8), could improve the effects of the conjugated resulting molecule on the levels of MBNL1 protein. We observed that all the antimiRs generated (4 in total in Table 7, Table 8 and Figure 9), were able to produce upregulation of MBNL1 protein. Of note, the molecule conjugated using the threoninol was the most active as it reached the EC50 at the lowest concentration, but the molecule with the 6 carbons spacer (NHC6) was the one producing the most robust maximum upregulation of the protein. This data demonstrates that modifications in the spacer can further modulate the efficacy and pharmacodynamics of the oleic acid-conjugated antimiRs of the invention. Table 7

[0558] Table 8

[0559] EXAMPLE 8

[0560] Although synthesis methods of oligonucleotides are widely known in the art, we provide herein an example of the synthesis of MD23b-2 V2 3’01, MD23b-2 V2 3’01 is a 16 nt long oligonucleotide consisting of LNA, 2’-O-MOE and 2’-0-Me modified building blocks that are linked by phosphodiester or phosphorothioate linkages. Its 3’ end is modified with an oleic acid moiety (Figure 10). This oleic acid is introduced by coupling the activated carboxylic acid to a hexyl amino spacer at the 3’-end of a precursor oligonucleotide. The synthesis of the MD23b- 2 V2 3’01 is based on solid-phase synthesis using building blocks and spacers-GPG. This process consists of two main steps.

[0561] First, the synthesis of the unconjugated oligonucleotide (precursor) with sequence AbsTbs(5Mc)s(5Mc)sCmTbGmsgsCmsAbAmTbGbT msGbsAb(NH2C6). The first phosphoramidite considered as a building block in the chain is attached to the solid surface with a catalyzed condensation reaction. This step will be repeated as many times as the length of nucleotides of the final sequence. In this case, 16 times. Upon completion of the solid phase synthesis, the manufacture involves the following steps: cleavage and deprotection, purification, desalting

[0562] Secondly, the oleic acid is conjugated. Once the desalted unconjugated oligonucleotide from the last step is conjugated with the oleic acid, it is purified, desalted and lyophilized.

[0563] EXAMPLE 9

[0564] 1.1 Quantification of MD23b-2 V2 3’01 by ELISA

[0565] MD23b-2 V2 and MD23b-2 V2 3'01 were used. A dose of 12 mg / kg of the compounds was administered intravenously to the HSALRmice. After 14 days, all mice were euthanized, and their brain, kidney, liver, gastrocnemius, and quadriceps muscles were removed, weighed, and frozen for further processing. The experiments were conducted in a blinded manner by the investigator, who was unaware of the group assignment. Samples from brain, muscle (quadriceps and gastrocnemius), kidney and liver were collected during the necropsy procedure from all the experimental groups. Samples were weighed upon collection in gram units to a minimum of 3 decimal places. Each piece was placed in RNase-free tubes and snap frozen (e.g., 2 ml Eppendorf tube RNase-free).

[0566] 1.1.1 Sample Preparation

[0567] 1) Remove the tissues and wash them in phosphate-buffered saline.

[0568] 2) Dry the tissues on absorbent paper and weigh them (20 mg per tissue; in the case of the brain take 30 mg per tissue).

[0569] 3) Add the 100 pL of RIPA buffer supplemented with PhosSTOP EASYpack and Complete ULTRA Tablets, Mini, EASYpack (1 tablet of each per 10 mL of RIPA buffer) per each 10 mg of tissue.

[0570] 4) Homogenize the tissues using a tissuelyser in 2 ml Eppendorf tubes for 20 s, 4 times at 5000 RPMs, or until the tissues are fully homogenized.

[0571] 5) Incubate the homogenate at 55 °C overnight.

[0572] 6) Centrifuge the homogenate at 15000 rpm for 15 min, aliquot the supernatant, and store it at -20 °C ready for analysis.

[0573] For the muscle lysate, 1 / 10 of the actual homogenate in oligonucleotide diluting buffer was used. If the samples were above the limit of quantification, then a dilution of 1 :40 was applied. For the brain, 1 / 5 dilution was used, and for the liver and kidney a dilution of 1 :400 was used. 1.1.2 Stock Preparation for standard curve

[0574] In the case of stock preparation for the standard curve. First, a stock of 20 pM of the MD23b- 2 V2 3’01 was made. For standard curve preparation, 1 pM concentration was used. So, the 20 pM stock was diluted in water for the final volume of 1 pM and stored in different aliquots. For each experiment, make the standard curve fresh, and for this it is necessary to heat the 1 pM stock each time at 65 °C for 15 minutes. On the other hand, after preparing the tissue homogenate, 55 pL of the homogenate was added in 5445 pL of compound diluting buffer to have the control tissue homogenate. 1.1.3 Standard curve preparation

[0575] For this, a control tissue homogenate is needed to prepare the standard dilution. Then, to prepare the serial dilution, 1 pM of the desired compound was denatured at 65°C for 15 min and vortexed for 30 s at least. Then 32 pL of this denatured compound was diluted in 968 pL of control homogenate. This is the first point of the standard curve (32000 pM). Then for the next point, 500 pL of 32000 pM was diluted in 500 pL of compound diluting buffer (16000 pM).

[0576] By this similar fashion 8000 pM, 4000 pM, 2000 p...

Claims

CLAIMS1 . A conjugate for use in the treatment of a subject having a hindbrain disorder, wherein the conjugate comprises:(i) an oligonucleotide molecule or analogue thereof, which functions as an active ingredient for the treatment of the disorder, and(ii) an oleic acid molecule, which functions as a pharmaceutically acceptable vehicle or carrier; and that is conjugated to the 3’ and / or 5’ end of the oligonucleotide molecule or analogue thereof, and wherein the conjugate is administered intravenously.

2. The conjugate for use according to claim 1 , wherein the hindbrain disorder is a pons, medulla oblongata, or cerebellum disorder.

3. The conjugate for use according to claims 1 or 2, wherein the disorder is a cerebellum disorder, preferably selected from the list consisting of autosomal dominant spinocerebellar ataxias SCA1 , SCA2, SCA3 (Machado-Joseph disease), SCA6, SCA7, SCA8, SCA10, SCA12, SCA17, SCA27B and SCA4, CANVAS syndrome, Friedreich ataxia, ataxia with vitamin E deficiency, ataxia-telangiectasia, AOA1 , AOA2, ARSACS, and mitochondrial ataxias.

4. The conjugate for use according to claims 1 to 3, wherein the conjugate is administrated to the subject intravenously at a dose of between 18 mg and 288, preferably between 22.75 mg and 196.46, mg per person.

5. The conjugate for use according to claims 1 to 4, wherein the oligonucleotide molecule or analogue thereof is the active ingredient and comprises a mixture of phosphorothioate and phosphodiester linkages chemically linking the nucleotides.

6. The conjugate for use according to claims 1 to 5, wherein the oleic acid is conjugated to the 3’ end of the oligonucleotide molecule or analogue thereof.

Images